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EXECUTIVE SUMMARY

Despite the success of anti-mycobacterial drugs over the past 70
years, mycobacterial disease, particularly tuberculosis is still responsible for
millions of deaths worldwide. Additionally, the emergence of Multidrug
Resistant

(MDR-TB)

and

Extensively

Drug

Resistant

(XDR-TB)

Tuberculosis throughout the world has motivated calls by the World Health
Organization for novel mycobacterial drugs, vaccines and diagnostic tests.
Consequently, this study sought to identify and evaluate the efficacy of a
range of anti-mycobacterial compounds against a representative cohort of
pathogenic mycobacterial species. The development and employment of the
rapid,

robust

and

inexpensive

microtitre

alamarBlue

assay

(MABA)

facilitated the assessment of a vast array of anti-mycobacterial compounds
including chemically and biologically derived drug analogues of pre-existing
anti-mycobacterial agents.
While

existing

anti-mycobacterial

drugs

are

effective

when

administered a cocktail, continuous research and development of novel
classes of anti-mycobacterial is of paramount importance. In particular,
there is significant scope for the implementation of gene-encoded anti
microbials for therapeutic application. Bio-engineering of these peptides
such as nisin and lacticin 3147 facilitates the identification of more active
variants of the natural peptide. In this regard, three nisin clones (nisin S,
nisin

T

and

mycobacterial

nisin

V)

activity.

were

identified

Mycobacterial

as

possessing

drug

resistance

enhanced

anti-

to

anti-

such

mycobacterial drugs was also investigated. Using in silico analysis the role
xii

of

drug

efflux

pumps

as

a

mechanism

of

intrinsic

resistance

was

investigated, resulting in the identification of novel drug efflux pumps in M.

avium subsp. paratuberculosis.
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CHAPTER 1

LITERATURE REVIEW

“TB is too often a death sentence. It does not have to be this way,”

(Nelson Mandela)

1.1

FACTS AND FIGURES ABOUT TUBERCULOSIS:

More than 2 billion people, equal to one-third of the worlds
population, are infected with TB bacilli, the microbes that cause
TB. 1 in 10 people infected with TB bacilli will become sick with
active TB in their lifetime.
1.8 million people died from TB in 2008, including 500,000
people with HIV - equal to 4500 deaths a day.
There were 9.4 million new TB eases in 2008 (3.6 million of
whom are women), including 1.4 million cases among people
living with HIV.
There were 5.7 million TB case notifications in 2008. TB is
contagious and spreads through the air. If not treated, each
person with active TB infects on average 10 to 15 people every
year.
IB is a leading killer of people with HIV. People who are HIV
positive and infected with TB are 20 to 40 times more likely to
develop active TB than people not infected with HIV living in the
same country.
5% of all TB cases have Multi Drug Resistant-TB (MDR-TB),
based on data from more than 100 countries collected during the
last decade.
There were an estimated 500,000 new MDR-TB cases in 2007.
In 2008, WHO reported the highest rates of MDR-TB ever
recorded, with peaks of up to 22% in the former Soviet Union.

History

1.2

Mycobacteria are not only some of the most robust and resistant
bacteria known to man, they are also amongst the oldest, infecting
humans since antiquity.

'y

Tuberculosis (TB) in particular, has been the

cause of the majority of mycobacterial-related deaths and has been
known by many names such as Consumption, Phthisis, Potts disease and
Scrofula, with nomenclature attributed to varying dissemination patterns
of TB in the body.^
Recent studies suggest that tuberculosis plagued populations as
far back as ancient Egypt, resulting in widespread mortality.'^ More than
a third of mummies recently studied proved positive for tuberculosis
DNA

using

PCR

detection,

including

‘Dr.

Granville’s

mummy’

(Irtyersenu) (600B.C) who was diagnosed with tuberculosis in January
2010, 2,411 years after her death in Egypt.

Systematic investigation of

this mummy indicated advanced infection of tuberculosis in both the
lungs and bones. In 2008, researchers also isolated and characterized
tuberculosis

DNA

from

9,000

year

old

Settlement in the Eastern Mediterranean.

fossils

from

a

Neolithic

This not only highlights that

tubereulosis has been around since antiquity but also demonstrates the
sensitivity of molecular detection methods used today.
Tuberculosis may date back to the first domestication of animals,
(Middle Pleistoeene 490-510,000 years before present) indicated by
morphologieal changes consistent with tuberculosis in a fossil Homo
erectus from Turkey.^ M. tuberculosis DNA has also been identified in a
17,000 year old extinct bison originating from North America suggesting

that bovids were the likely vector and reservoir for transmission of
tuberculosis, as they are today.^

1.3

Clinical disease

The success of mycobacteria as pathogens can be attributed to a
number of factors such as their unique cell wall and especially their
ability to co-exist with their host.

n

There are now over 130 established
o

and validated

species of mycobacteria,

Identification

of mycobacteria

and

as well

their

as

11

subspecies

subspecies.

has

increased

dramatically since the genomic era,^ consequently implicating many
non-tuberculosis mycobacteria (NTM) as causative agents in serious
infections.

Here

the

leading

pathogenic

species

and

subspecies of

mycobacteria are discussed.

1.3.1 M. tuberculosis
Tuberculosis is a contagious disease which predominantly affects the
lungs and kills nearly two million people annually.'^ It is caused by the

Mycobacterium tuberculosis complex, which includes four species, M.
tuberculosis, M. bovis, M. africanum, and M. microti.'‘ M. tuberculosis
is spread in airborne droplets through coughing and sneezing

and

causes

and

both

cutaneous

and

pulmonary

tuberculosis

in

humans

animals (Fig. 1.1). Generally, tuberculosis is a curable disease provided
the correct prescription of anti-mycobacterial drugs are taken for the
duration of the course. However, the success of these treatments has

been ehallenged with the emergence of Multidrug Resistant (MDR-TB)
and Extensively Drug Resistant (XDR-TB) Tuberculosis.'^''^
Most people infected with M. tuberculosis do not become ill as
their immune system contains the infection.

However, the bacteria

remain dormant within the body and can cause tuberculosis years later if
immunity declines because of, for example, infection with HIV. The
unique ability of mycobacteria, in particular M. tuberculosis, to not only
overcome the front line defence of the human immune system, but to use
it as a means of protection illustrates how adaptive and successful these
pathogens are.

This front line defence is part of the innate immune

response and involves endocytosis of bacteria, whereby white blood
cells engulf bacteria and subsequently destroy them via phagocytosis.'^
However, mycobacteria are not destroyed following endocytosis and
remain viable within the white blood cell.'^ Reports suggest many
reasons for this but the production of ammonia is thought to play a large
role.'^

In this latent state, they may lay dormant but can reactivate at

any point which facilitates the spread of tuberculosis between their
hosts.

1.3.2 M. leprae
Many other species of mycobacteria are responsible for disease and
deformities worldwide (Fig.

leprae,

1.1). One such species, Mycobacterium

was identified by Armauer Hansen in 1 873 as the bacterium

known to cause leprosy.

This bacterium causes a granulomatous

disease affecting the skin, mucous membrane, peripheral nerves and

bones.The diagnosis and treatment of leprosy is easy and most
countries where this is endemic are striving to fully integrate leprosy
services into existing general health services.'^ However, according to
official report of 118 countries and territories (2008)

by the WHO, the

prevalence of leprosy at the beginning of 2008 stood at 212,802 cases,
while the number of new cases detected during 2007 was 254,525
(excluding the small number of cases in Europe). The number of new
cases detected globally has fallen by 11,100 cases (a 4% decrease)
during 2007 compared with 2006.

19

1.3.3 M. ulcerans

Another bacterium which infects the skin is Mycobacterium ulcerans.
This species of mycobacteria causes painful and disfiguring Buruli
ulcers (Fig.

1.1).

'

The prevalence of Buruli ulcer is increasing,

particularly in West Africa.

Buruli

ulcers often start as painless

nodules, usually on the arms or legs. These then develop into large
ulcers, with a whitish-yellowish base. Although most ulcers eventually
heal, poorly managed patients may develop severe scars and local
deformities, including disabling contractures, the shortening of a muscle
or joint.Notwithstanding, TB and Leprosy, Buruli ulcer is the most
common mycobacterial infection in immunocompromised individuals.
Ulcers

and

bone

lesions

usually

form

following

the

9A

accidental

introduction of the bacterium into a wound following skin trauma.The
pathogenesis

is

immunosuppressant

directly
toxin

related

to

the

necrotizing

produced

by

M.

ulcerans

and
called

mycolactone.^^ The disease occurs most frequently in children living in
rural tropical environments, near wetlands^^

which supports recent

studies which suggest transmission may be caused by the bites of
infected aquatic insects such as mosquitos

Cutaneous Tuberculosis

27

Pulmonary Tuberculosis

/
Leprosy cause by M. leprae

Buruli ulcer caused by M. ulcerans

Fig. 1.1: Clinical manifestations following infection with M. tuberculosis (top), M.
leprae (bottom left) and M. ulcerans (bottom right).

1.3.4 The Non-Tuberculosis Mycobacteria (NTMs, MOTT)

The non-tuberculosis mycobacteria are the mycobacterial species
that are not members of the Mycobacterium tuberculosis complex. These
came to attention as the numbers of tuberculosis cases declined,
predominantly due to the introduction of the Bacille Calmette Guerin
vaccine

and

anti-TB

drugs.

Non-tuberculosis

mycobacteria

are

infections.

28 3 1

'

In most cases, infections are prevalent in immuno

compromised

individuals,^' commonly AIDS patients, and are regarded

as secondary “opportunistic infections'’.

Due to the ever emerging numbers of new species and subsp. of
mycobacteria, Runyon's classification system was implemented which
involved the NTM being grouped into 4 categories.^'' Groups I to III are
slow-growing NTM, and group IV are fast growers. The slow-growing
NTM (SGM), which take longer than 7 days to grow to stationary phase,
are subdivided into group I photochromogens (pigment producers in the
presence of light), group II scotochromogen (pigment producers in the
absence of light), and group 111 nonchromogens.More recently growth
conditions of NTMs have been shown to have a major influence on their
virulence. For example, in vitro growth of M. marinum was observed at
33°C but not at 37°C^^ and culture and infection of MAP has recently
been shown to be enhanced at 39°C.

Therefore, growth temperature

may be an additional characteristic to include in the classification
system.

1.3.4.1

Mycobacterium avium complex (MAC)

Mycobacterium avium complex (MAC) are classified as acid-fast,
slow growing bacilli that may produce a yellow pigment in the absence
of light.

The

MAC

intracellulare and all

are

composed

of opportunistic

subspecies of M. avium.

pathogens,

M.

These species are

capable of causing disease in both animals and humans.While M.

gordonae is the most frequent NTM species isolated from human
specimens, MAC is most frequently associated with human disease (38.2
to 73.3% of all pathogenic isolates).

^9

1.3.4.2 Mycobacterium avium subsp. paratuberculosis (MAP)

Mycobacterium avium paratuberculosis (MAP) is a subspecies of
the Mycobacterium avium complex (MAC) and is a known animal
pathogen which takes approximately 6-8 weeks to grow. MAP is an
opportunistic pathogen which will cause disease if introduced into a host
inadvertently. Interestingly, MAP also infect mammalian white blood
cells and is therefore a good model to study when combating M.

tuberculosis. Unlike M. tuberculosis however, MAP has evolved to
target the gastrointestinal tract of ruminants causing an inflammatory
disease called Johne’s disease.

1.3.4.2.1 Johne’s disease
Paratuberculosis (Johne’s disease; JD) is a chronic, granulomatous
enteritis

of

ruminants

caused

by

Mycobacterium

avium

subsp.

paratuberculosis (MAP). The disease is characterised by persistent
diarrhoea,

weight

loss

and

protein-losing

enteropathy

(Fig.

1.2).

Different strains of the bacteria usually affect different animals. For
example. Ovine Johne’s disease (OJD), is caused by ovine strains of M.

paratuberculosis and affects mainly sheep and goats. Bovine Johne’s
Disease (BJD), caused by bovine strains of M. paratuberculosis, affects
mainly cattle, goats, deer and alpaca.

40

Disease (BJD), caused by bovine strains of M. paratuberculosis, affects
mainly cattle, goats, deer and alpaca. 40

A Sheep with Ovine Paratuberculosis

A Cow with Bovine Paratuberculosis

Fig. 1.2: Clinical manifestations of OJD (left) and BJD (right) following infection
with M. avium subsp. paratuberculosis

Paratuberculosis can cause significant economic loss in affected
herds, as a result of reduced milk yield, increased incidence of mastitis,
altered milk constituents, increased somatic cell counts, poor feed
conversion,

increased susceptibility to disease

reproductive

efficiency,

premature

culling

in general, reduced

and

reduced

cull

cow

values."^' Despite the fact that this disease develops slowly, it can be
fatal in a high percentage of cases. This is of major concern to global
dairy industry due to economic and production losses, with the USA
alone suffering losses of $1.5 billion a year.'^^

In Ireland, which is an economy largely dependent on agriculture,
the

predicted

effect

of disease

on

a

100-cow

dairy

herd

using

international effects of disease on production, was to lower farm net
10

of paratuberculosis in Ireland has increased since the introduction of the
Single

European

Market.

Faecal-oral

transmission

is

the primary

mechanism for transfer of MAP from one generation of animals to the
next. Shedding of MAP from contaminated teats also causes transfer of
MAP to offspring and commercial milk before pasteurization. Reports
have also identified the ability of MAP to survive standard milk
pasteurization processes.Additionally, MAP has been identified in
off-the-shelf milk in retail grocery stores in the U.S. and the European
Union (E.U.)."^^ MAP has also been implicated as a causative agent of
Crohn’s disease in humans.’

1.3.4.2.2 Crohn’s disease

Crohn’s disease is a devastating illness in humans, characterized
by severe inflammation of the intestine resulting in abdominal pain,
diarrhoea, bleeding, and obstruction of the bowel which can impede day
to day life of a patient (Fig 1.3). There is widespread debate about the
zoonotic potential of MAP, with substantial scientific evidence to both
support and refute this hypothesis.As there is increasing evidence
that MAP can also be found in water,

as well as dairy products and

meat, some researchers hypothesize that these are modes of transmission
which may play a role in human infection.
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Fig. 1.3: Inflamed intestine ofpatient with Crohn’s disease

1.4 Treatment of mycobacterial disease

The advent of the BCG vaccination and anti-mycobacterial drugs over
the last 90 years have for the first time in history facilitated the control
of mycobacterial disease, namely tuberculosis. The impact of these
discoveries may be under-appreciated in modern times but the fact still
remains that active tuberculosis will kill about two of every three people
affected if left untreated, whereas treated tuberculosis has a mortality
rate of less than 5%.

1.4.1 Vaccination
The introduction of vaccination programmes, pioneered by Edward
Jenner, has led to the eradication of smallpox and the control of many
modern day diseases such as tuberculosis. The first human trials of a
tuberculosis vaccine (BGC), developed by Albert Calmette and Camile
Guerin, began in 1920. This overwhelming success of this attenuated
12

vaccine, derived from M. bovis, only became evident in the 1950s
following the routine introduetion of the vaccine into sehools across
Europe (100 million vaccinations). This resulted in an 80% decrease in
infection rates^'* and it is estimated that its implementation saved the
lives of over 40,000 children.However, subsequent overconfidence in
the battle against tuberculosis led to a decrease in research studies and
ultimately treatments. As a result, the BCG vaccine, the only licensed
vaccine for TB disease, is almost 90 years old and offers little to no
protection from pulmonary TB. Moreover, no new class of TB drugs
have been approved in over 40 years and some of the most powerful
current drugs cannot be

used

with certain

anti-HIV

treatments.

Additionally, evidence also suggests that the BCG provides little or no
protection for HIV-infected infants.
However, three novel vaccines are currently in phase H clinical
trials (Table 1.1), while other vaccine constructs will be entering phase
11 studies in the coming year.

Agent

Strategy
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Status
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Pbxe il

Prre xoj

yr:! ve±r

Cnxeil fy.';'Aerx

Phase ilp

Prre xo:!

Vra: ve^cr

ymvef:itycfC)iDr(j/

Phase ilb

Table 1.1; TB Vaccine Constructs in Phase II Clinical Trials (201 Of

1.4.2 Drug treatment of mycobacteria
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activity.

Since then, a plethora of anti-mycobaeterial drugs have been

identified, the most effective being the first line drugs rifampicin and
isonazid. Isonazid was introduced as an anti-mycobacterial drug in 1951
while rifampicin was first introduced in 1967. Although both initially
exhibited potent activity, the emergence of drug resistant mycobacteria
has prompted these drugs to be administered in combination and in some
cases as a cocktail with other first line drugs including pyrazimamide
and ethambutol.
In 2006, a meeting between the World Health Organization
(WHO) and the US Centers for Disease Control and Prevention (CDC)
resulted in concern over the emergence of virulent drug-resistant strains
of tuberculosis (TB), namely MDR-TB (Multidrug Resistant TB), and
XDR-TB strains (Extensive Drug Resistant TB).^^ MDR-TB are resistant
to at least the two main first-line TB drugs - isoniazid and rifampicin,
and XDR-TB, or Extensive Drug Resistant TB (also referred to as
Extreme Drug Resistance) is MDR-TB that is also resistant to three or
more of the six classes of second-line drugs. This resistance to anti-TB
drugs occurs primarily due to poorly managed TB care. Problems
include incorrect drug prescribing practices by providers, poor quality
drugs, erratic supply of drugs, and patient non-compliance.

Z *7

This meeting was prompted by data reported from 2000-2004
which found that XDR-TB has been identified in all regions of the world
but is most frequent in the former Soviet Union and in Asia. For
example, of 544 patients studied, 221 had MDR-TB. Of the 221 MDRTB cases, 53 were defined as XDR-TB. Of the 53 patients, 44 had been
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tested for HIV and all were HIV-positive. 52 of 53 patients died, on
average, within 25 days including those benefiting from antiretroviral
drugs.

67

Therefore, the development of novel vaccines, anti-mycobacterial
drugs and diagnostic tests is crucial in the continuing fight against
mycobacterial disease, especially tuberculosis. The current TB drug
pipeline is the most full and promising it has been in 50 years, with 10
drug candidates currently in clinical trials, a level unprecedented since
the 1960s (Table 1.2).

65

One approach used for the identification of novel treatments has
seen the modification of existing anti-mycobacterial drugs such as
Quinolones which has led to the development of active novel analogues
of these drugs. This approach has lead to the implementation of clinical
drugs including sparfloxacin, and the identification of moxifloxacin and
gatifloxacin, two fluoroquinolone drugs which are undergoing clinical
trials (Table 1.2). The most recent success of this approach has been the
identification of the class of diarylquinoline compounds. These are the
most

promising

(TMC207)
specifically

has

class
a

causes

of novel

very
proton

compounds

specific
pump

and

mechanism
inhibition

one

of

of the

in

action.

M.

particular
TMC207

tuberculosis

adenosine triphosphate ATP synthase which is the main source of fuel
for M. tuberculosis.

A complete list of potential TB drugs currently in

clinical trials is tabulated in Table 1.2.
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for M. tuberculosis.^^ A complete list of potential TB drugs currently in
clinical trials is tabulated in Table 1.2.
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Table 1.2: The TB Treatment Pipeline—Drugs in Clinical Trials (July 20l0f^

Despite the overwhelming success of the BCG vaccine and anti-TB
drugs, tuberculosis is still responsible for millions of deaths worldwide.
Thus, the implementation of campaigns such as ‘Stop TB’ is crucial for
controlling its resurgence. This campaign has set itself three ambitious
goals: (1) to detect at least 70% of infectious TB cases and to treat
successfully at least 85% of these cases; (2) to have halted and begun to
reverse incidence of TB by 2015; and (3) to have halved TB prevalence
and death rates by 2015 compared with 1990 levels. 69
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1.4.3 Diagnostic test for mycobacteria
Since its introduction, the BACTEC 460 TB system (Becton Dickinson,
Sparks, Maryland) has been widely accepted as the “gold standard” for
detection of mycobacterial growth.

However, this system has several

drawbacks, such as the use of radioactive materials, a labour-intensive
workflow, the lack of an on-board incubation facility and the potential
risk of cross-contamination.^' More recently, the BACTEC MGIT 960
system (Becton Dickinson) has been developed to overcome the pitfalls
of the BACTEC 460. The BACTEC 960 instrument is an automated
system that exploits the fluorescence of an oxygen sensor to detect
growth

of mycobacteria

on

Mycobacteria

Growth

Indicator

Tubes

7?

(MGIT). *■ An average detection time tor Bactec 460 TB system was
found to be 13.3 days as compared to the traditional culture methods
which may require up to six weeks for detection alone.

73

7'here have been a number of other useful mycobacterial drug
susceptibility assays described such as bioluminescence assays, phage
amplification assays and the Microtitre alamarBlue Assay (MABA)

74-76

The colorimetric alamarBlue assay is rapid, inexpensive and
lends itself to a high-throughput screening format. It has also been
shown to be applicable to a wide range of mycobacterial species.

77 78

’

Furthermore, its correlation with other more expensive methods for
determining mycobacterial viability is high, between 93% and 100%.^^’^''
These methods include the Mycobacteria Growth Indicator Tube, the
Bactec460, radiometric method, and lueiferase reporter systems.
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determining mycobacterial viability is high, between 93% and 100%/^'**^
These methods include the Mycobacteria Growth Indicator Tube, the
Bactec460, radiometric method, and luciferase reporter systems.
The Stop TB Partnership has aimed to harness new scientific tools
and approaches to accelerate the discovery, development, approval, and
distribution of new diagnostic technologies that could make diagnosing
TB more accurate, faster, reliable, affordable and easy to use at the
point of care. Currently, there are 5 novel diagnostic tools in the
pipeline which are pending review by the WHO (Table 1.3).

Sponsor/Developer

Technique

Measures

Estimated Date
of WHO Review

Manual loop-mediated
isothermal a'^plificaticn
process iLAMP'

Eiken Chemical and
FIND

Man^,al nucleic acid

MTB DNA

2011

Cled'vie.v
Lipoarabinomannin ■.LAM'
antigen en:>'me-ln«.ed
im^-unoahso^tient assay
; ELISA:

n»emess Medical
nn^ovations

ELISA to detect LAM antigen
in -r^ne

MTB LAM antraen

2012

Name of Test or Process
Peripheral Laboratories

Reference Laboratories
Ge'e'iped KB 'R

Ceoheid. FIND and
UMDNJ*

Automated nucleic acid
amplification test

KB DNA. '■i^"i3ion
'csistance seouericec

201!

QuansiFERON-TB Gold Test

Cellestis

lnte'^e''on-'gamma 'elease assa','

Immune cell 'esponse to
latent B in‘ec*tcn

2011

T-SP0"’B

Oxford 1:—unofec

Inte'^emn-ga’^ma 'elease
assay

Immune cell 'esponse to
latent TB in'ecion

2011

Table 1.3: TB Diagnostic Test or Processes in the Pipeline, 2010.^^

1.5 Potential alternative anti-mycobacterial treatments
The widespread resistance of bacterial pathogens to conventional
antibiotics has prompted renewed interest in the use of alternative
natural

microbial

Antimicrobial

inhibitors

peptides (AMPs)

such
are
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as

antimicrobial

peptides.

small

evolutionarily

conserved

intestine.

Those

bacteriocins.

derived

from

bacterial

sources

are

known

as

Bacteriocins, in particular Class 1 bacteriocins called

Lantibiotics, exhibit potent antibacterial activity.

1.5.1 Bacteriocins
Bacteriocins have been identified in a wide range of species, with
tens of bacteriocins in some species. They are stable, non toxic and
active against a plethora of bacterial species.

They are the focus of

much work as possible alternatives to current antibiotics, so much so
that a recent database platform for Bacteriocins characterisation has
been developed.However, they differ from antibiotics in two key
ways.

Unlike antibiotics, they are ribosomally synthesized and have a

relatively narrow killing spectrum.
Bacteriocins
peptides

of

smaller

Gram-positive
than

6KD

bacteria

and

are

resemble

usually

peptides

heat

stable

produced

by

eukaryotes such as defensins, some of which are in clinical trials for
application as therapeutics.

81

The bacteriocins of the lactic acid bacteria (LAB) have been an
important focus of research interest over the past two decades as they
are considered to

be generally regarded as safe (GRAS), and are

consequently widely accepted as food additives.
1.5.2 Classes of bacteriocins
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There have been many attempts to classify bacteriocins due to their ever
expanding

numbers,

structures

and

mechanisms

of

actions.

Most

schemes agree on two main classes which are class I (lanthionine
containing peptides i.e. lantibiotics) and class 2 (unmodified peptides).
A

more

novel

alignments

scheme

proposes

of unmodified

classification

structural

peptides.

based

on

This

sequence

approach

is

advantageous in that it highlights a number of conserved amino acid
stretches that are present within and across subclasses of bacteriocins.
These

conserved

domains may represent crucial

functional

regions

within the peptides.

Class

1

bacteriocins, also

known

as

lantibiotics

(Fig.

1.4)

undergo modifications resulting in the presence of unusual amino acid
residues lanthionine (Lan) and B-methyllanthionine (Me-Lan). Therefore
these

peptides

are

termed

Lantibiotics

(Lanthionine

containing

antibiotics). These lanthionine containing residues are a result of a two
step process which involves the initial enzymatic dehydration of serine
and threonine residues to form the respective unsaturated amino acids
2,3-didehydroalanine (Dha) or 2,3-didehydrobutyrine (Dhb) followed by
the attack of the double bond within Dha and Dhb by thiol groups (S-H)
from nearby cysteine residues. These modifications are responsible for
the formation of internal ring structures and consequent active peptides.
The resulting lanthionine residue is D-alanine (derived from a serine
residue) and L-alanine (derived from a cysteine residue).
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Class II bacteriocins (Fig. 1.4) are also small (<10kDa) nonlanthionine, heat stable peptides. However they differ from class I
bacteriocins in one main respect. Class II peptides do not undergo
extensive post-translational modifications. Both class I and class II
bacteriocins are positively charged (cationic), possess both hydrophobic
and

hydrophilic

residues

(amphophillic)

and

are

membrane

permeabilizing. Although both classes resemble the AMPS produced by
eukaryotes,

their

activities

seem

to

be

more

potent,

resulting

in

inhibition at the nano-molar range rather than the micro-molar range
eukaryotic AMPs.

Bacteriolysins
bacteriocins)

are

(Fig.

1.4)

heat-labile

(formerly

proteins

classified

larger

than

as
15kDa

class
with

Ill
a

mechanism of action that hydrolyse the specific peptide bonds in the
peptidoglycan of the cell walls of sensitive cells. For the purpose this
review, only class 1 and class II bacteriocins, particularly class I
lantibiotics, will be discussed.

21

Cork Institiile oi Teclinology

Class
iNiLSr i|

Cla33 II

Oacteriolysina
l'Lv;iOC»tup* :II0

^ « t # ^

■: ;rii '.vT I

K

I I'
i I

I

:-

< V

c >

> >

•

<. V

-

»

^ ^

I § I I I I I g

i r
‘ f t TTj^^

\t^

I'l '
■ »-■’
I I I I
. >; :< ,-: •*. > <>
T.;:- ; >
6 8 i S i e 8
til fill

l'“ i^‘
i % ^I>
3
11

■'••. “^5
el' rt'GTTiDrni’©

’4V
Pi .; 'll - h fij'rr

I

,S‘ it u IJijT

Fig 1.4; Modes of action of lactic acid bacteria bacteriocins.

82

1.5.3 Bacteriocins - Mode of action
Bacteriocins

have

three

modes

of action

which

are

pore

formation, cell wall interference and nuclease activity.Moreover nisin
has also been shown to reduce the thermo stability of spores.*^ Class 1
lantibiotics such as nisin generally have two of these modes of action.
They can target the membrane bound cell wall precursor Lipid II,
preventing peptidoglycan synthesis and Lipid 11 is also a key component
in the second mode of action, pore formation (Fig. 1.4). In this situation
several nisin/lipid 11 complexes bind to generate transient pores in the
cell membrane. Besides having the distinct advantage of having dual

22

modes of action, lantibiotics also have the advantage of attacking
bacterial cell walls from the outside negating the need for transport
across the cell membrane, a requirement for most anti-mycobacterials.
A two-peptide lantibiotic, such as lacticin 3147, can have these
dual activities distributed across two peptides. In general, the class II
peptides have an amphiphilic helical structure, which allows them to
insert into the membrane of the target cell, leading to depolarisation and
death (Fig. 1.4). Larger bacteriolysins, such as lysostaphin, can function
directly on the cell wall of Gram-positive targets, leading to death and
lysis of the target cell (Fig. 1.4).^"

1.5.4 Lipid ll/bacteriocin complex
Lipid 11, the precursor molecule of peptidoglycan, consists of two
amino sugars, N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid
(MurNAc), and a pentapeptide, often L-Ala-D-Glu-L-Lys-D-Ala-D-Ala,
which is attached to the carboxyl group of MurNAc. These subunits are
assembled in the cytosol on a membrane-anchoring carrier, undecaprenyl
phosphate, (undecaprenyl-Pyrophosphoryl-MurNAc-(pentapeptide)GlcNAc) giving rise to lipid II (Fig. 1.5).

’

This acts as a docking

molecule for many bacteriocins such as nisin, epidermin, mutacin and
lactic 3147 as well as conventional antibiotics such as vancomycin.

23

Pyrophosphate binding region of nisin

Fig. 1.5: Chemical structure of a lipid II (a) and primary structure of nisin (b). The
pyrophosphate region of lipid II, to which nisin binds, is highlighted in red. The Nterminal

region

of nisin

(residues

I-I2)

(blue),

specifically

binds

to

this

pyrophosphate region of lipid II.^^

Bacteriocins compromise bacterial cell wall stability via attachment to
the pyrophosphate region of lipid II. This leads to the formation of a
pyrophosphate cage structure preventing peptidoglycan assembly and
subsequent cell wall formation (Fig. 1.6).

24

Lipid II

Fig. 1.6 : Solution structure of nisin-lipid 11 complex and the pyrophosphate cage
formation.

The N-terminal part of nisin (residues 1-12) encages the pyrophosphate

moiety of Lipid 11 (left).

Carbon, nitrogen, oxygen and phosphorus atoms of lipid 11

are coloured in white, blue, red and cyan, respectively.

Hydrogen bonds indicated

by yellow dashed lines and the corresponding residues are labelled (pyrophosphate
group in spheres) (right)

Additionally

92

this attachment to

lipid

II

may also

facilitate

pore

formation of the plasma membrane causing rapid efflux of metabolites
and

eventual

cell

death.

Once

the

N-terminal

of nisin

forms

a

pyrophosphate cage structure with lipid II, the C-terminal of nisin
inserts into the plasma membrane. The central hinge region of nisin
(amino acids 20, 21 and 22), allows the N-terminal and C-terminal
domains to move relative to one another (Fig. 1.7).
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Fig. 1.7: Model of the nisin-lipid II complex in a membrane bi-layer. The
backbone of three representative structures of nisin are shown and coloured from
blue to red from N- to C-termini. Each conformation, taken from the ensemble of
structures of the nisin-3LII complex, corresponds to a possible orientation of the Cterminal part of nisin outside, on the surface, or inserted into the membrane bi
layer, respectively.'^^

Importantly, the pyrophosphate moiety of lipid II cannot be
altered or replaced by simple genetic mutations, thereby reducing the
probability of resistance occurring. In contrast, the development of
vancomycin resistance is due to alteration of the pentapeptide on
another region of the lipid II moiety (Fig.

1.5).^^ Several studies

investigating lipid II and its relationship with nisin have confirmed its
role in pore formation.
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1.5.4.1 Mycobacterial lipid II
Natural alterations in the mycobacterial lipid II cause it to differ from
Q O

all other bacterial lipid II moieties investigated to date (Fig. 1.10).
However, the binding of mycobacterial lipid II by bacteriocins, such as
nisin,

is

not

compromised

despite

extensive

lipid

II

structural

modifications, an alternative lipid II synthesis pathway and an unusual
prenyl chain attachment (Fig. 1.6).
used for all

bacterial

The polyprenyl phosphate (Pol-P)

species during the synthesis of lipid

I and

subsequently lipid II is undecaprenyl phosphate. Flowever, mycobacteria
do not synthesize undecaprenyl phosphate (11 isoprene units) and recent
studies

have

revealed

that

tuberculosis

M.

contains

decaprenyl

phosphate (10 isoprene units),while M. smegmatis produces a mixture
of hepta-, octa-, and decaprenyl phosphate.

98

However, an alternative prenyl phosphate is unlikely to directly
affect binding of nisin as previous reports have suggested that the
majority of isoprene units of the poly-isoprenoid carrier (decaprenyl
phosphate in M. tuberculosis) are not required for recognition of nisin,
and only the first unit may be directly involved in lantibiotic binding.^'
The isoprene repeats of the decaprenyl phosphate are however important
in the stability of the nisin-lipid 11 complex and for enhanced efficacy.^'
As mycobacteria naturally contain
bacteria contain

11

isoprene

units,

10 isoprene units and all other
the

efficacy

of nisin

may

be

somewhat greater as the number of isoprene repeats is closer to the
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optimum number of isoprene units (seven) required for maximum nisin
efficiency.^'
Additionally, the mycobacterial

lipid

II

is unique in that it

contains a complex mixture of muramyl residues and pentapeptides
which are modified singly and in combination (Fig. 1.8).

These natural

deviations from the standard lipid II structure may provide a crucial
insight into the possible conserved and variable structures of the lipid in
general and its binding by nisin and other lipid II targeted lantibiotics.
Most modifications appear on the pcntapeptide side chain, and as
binding of nisin is not impeded, it supports previous observations which
suggest the pcntapeptide may not be necessary for formation of the
pyrophosphate cage of lipid II and nisin.
Nevertheless, modifications of this side chain are the primary
cause of resistance of a wide range of bacteria to vancomycin. Therefore
the natural structure of the M. tuberculosis pcntapeptide may confer
resistance to vancomycin due to alteration on the terminal residue
alanine, as previously demonstrated."''' However, the modification which
confers vancomycin resistance is specifically on the amide group rather
than

the

carboxyl

Nevertheless,

group

which

is

modified

a modification of the carboxyl

in

M.

group

tuberculosis.
may alter the

terminal alanine residue on the side chain and may explain resistance to
vancomycin by mycobacteria (Fig LS).'""
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NM

Hf-

O

Ri

O

Ri = H. COCH3 (./v-acetyl) or COCHjOH (^-glycolyl)

2

‘2

^2

'^'- •*3

R4 = OH, NHj or OCH3

Fig. 1.8 ; Observed variations in the structure of mycobacterial lipid II. The various
substituents found at the R positions (indicated on the figure) can occur in
essentially any combination.'^*

Importantly one natural modification is naturally present on the
N-Aceytlmuramic

acid which is

part

of the

complex

of MurNAc,

pyrophosphate and the first isoprene, essential for formation of the
pyrophosphate cage (Fig. 1.8).

However, the activity of nisin against

mycobacteria’^' suggests this region of the NAM structure does not play
an essential role during the formation the lipid Il-nisin complex. This
observation may provide an insight into both the mycobacterial lipid II
structure

and

a

deeper

understanding

of

the

lipid

11-1 antibiotic

interaction. Additionally, it supports the understanding that resistance to
such lantibiotics is rare, not only because of the dual modes of action of
lantibiotics but because the pyrophosphate of bacteria cannot simply be
29

altered or replaced by mutations as opposed to protein target sites such
as the pentapeptide side chain of lipid II.
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1.6 Nisin
The lantibiotic nisin is produced by Lactococcus lactis subsp.

lactis.

It

has

antibacterial

activity

against

various

Gram-positive

bacteria and is the “prototype” bacteriocin. Initial studies on nisin in the
1940s led to it being called an antibiotic as it killed a broad range of
pathogenic bacteria.

At this time however, the authors also noted

cytotoxic effects of nisin and this was most likely due to impurities
during preparation as only 2-4% of the preparation was nisin. Nisin is
the only bacteriocin that is approved for use in biotechnology and food
applications. Its role as a preservative (E234) has seen it approved in
over 40 countries worldwide. 103

The safety of bacteriocins in the body is paramount and several
studies have highlighted how often nisin-producing bacteria come into
contact with humans. For example, everyday foods such as cheese as
well as fermented foods such as sauerkraut'^"^ and fermented sausage'^^
contain nisin-producing species of bacteria. Nisin producers have also
been isolated from river water*^^ and most interestingly in human breast
milk.
age

Therefore, humans are safely exposed to nisin at a very early
and

possibly

have

been

throughout

the

ages.

Nisin-producing

bacteria have also been isolated from human and animal faeces and from
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human throat swabs indicating that nisin-producing bacteria are part of
the natural baeterial flora of our bodies.

The stability and solubility

of nisin is paramount to its aetivity. Although extremely soluble and
thus active at pH 3, nisin A becomes gradually insoluble at increasing
pH levels leading to significant loss of activity.
natural

nisin

peptide

identified

and

has

Nisin A was the first

been

followed

by

the

identification of other naturally produced nisins including nisin Z, nisin
Q and nisin U wdiich have an identical structure but differ by the
presence of substituted amino acids at certain locations. For example,
nisin Z has an asparagine instead of a histidine at position 27 of the
nisin protein. This phenomenon has been exploited in recent years
through the laboratory manipulation of nisin A and nisin Z for the
purpose of generating more soluble, stable and active compounds.

Nisin has received much renewed attention in recent years with
some studies suggesting its application as a therapeutic compound. 8 2
This interest is justified by the potent activity of nisin at nanomolar
concentrations and its ability to inhibit antibiotic resistant bacteria
including MRSA and VRE.'*' Moreover, nisin has also been shown to be
active against Streptococcus pneumoniae, Staphylococcus epidermidis
and Clostridium difficileIn this regard, nisin has recently been
applied therapeutically in the form of an anti-mastitis product called
‘Wipe-out’.

Another advantage is its dual mode of action, which

involves binding to lipid 11, an essential intermediate in peptidoglycan
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biosynthesis, followed by insertion into the membrane of the target cell
to form a pore."' The dual mode of action of nisin A is seen in Fig. 1.9.

Fig. 1.9: Illustration of the dual modes of action used by nisin. Nisin initially binds
to lipid II, an essential intermediate to cell wall synthesis (left), which is followed
by insertion of the C-terminal into the plasma membrane causing subsequent pore
formation (right). Pore formation causes a release of small molecules such as amino
acids and ATP ultimately leading to cell instability and death.

1.7 Lacticin 3147
Lacticin

3147

is

a

two-component

lantibiotic

produced

by

Lactococcus lactis subsp. lactis DPC3147, a strain isolated from an Irish
kefir grain.It has previously exhibited potent activity against a wide
range of Gram-positive pathogens including Salmonella and Listeria.^^^
To date, only nisin has been commercially used for inclusion in food but
lacticin 3147 has drawn much attention as a potential bio-preservative
due to its broad spectrum of inhibition and its stability at neutral pH. It
also exhibits specific activity against drug resistant bacteria such as

32

MRSA and VRE"’ and for this reason lacticin has become an interesting
target for structure/function analysis.'
Although
bacteriocidal

lacticin

activity,

is
its

similar to
mode

of

nisin

in

action

that

and

it

has

structure

broad
differs

considerably. Lacticin is a two component peptide which requires both
component peptidies Etna and Ltn-p for activity (Fig. 1.10).^^
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Fig 1.10; Amino acid structure of lacticin 3147 peptides Ltna (above) and Ltnfi
(below)

Ltn-a is globular in structure and has the same mode of action as nisin
in that it binds specifically to lipid II.Once Ltn-a is docked in lipid
II, it specifically binds its sister peptide Ltn-p which inserts its
elongated amphiphilic tail into the bacterial membrane causing pore
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formation and subsequent efflux of potassium ion resulting in cell lysis
(Fig. 1.11).
lacticin A2

lacticin A1

(III)

(II)

ions

in

Fig. 1.11: Illustration of the dual modes of action conferred by lacticin peptides

Ltna and Ltnf. Lacticin Ltna initially binds to lipid II (left) which is followed by
attachment of Ltnfl to the lipid II/Ltna complex, which subsequently causes pore
formation and eventual cell lysis (right).

Lacticin has also been shown to have considerable potential in
therapeutic applications, inhibiting human and animal pathogens. One
such example is the reduction of mastitis-causing pathogens by means of
a teat seal and teat dip formulation.

1.8

In vivo delivery of antimicrobial

peptides for therapeutic

application
The

main

restriction

in

using

bacteriocins

for

therapeutic

applications is that they are susceptible to proteolytic degradation in the
gut*’^ and proteolysis-resistant bacteriocins may prohibit the growth of
the natural

gut flora. Although degradation of bacteriocins is an

advantage in food applications, as there is no adverse effects on the

34

natural flora of the gut, delivery to the site of infection without
degradation of the active peptide is paramount to successful therapy. To
overcome

these

limitations,

studies

have

demonstrated

that

the

encapsulation of bacteriocins,*particularly in liposome complexes,
may offer potential for successful delivery of bacteriocins to specific
sites of infection. This strategy may also reduce or prohibit inhibition of
non-target species, eliminate undesired interactions and act as a long
term preservative in food and drugs.
demonstrated

that

a

For example, a recent study

bacteriocin-liposome

complex

could

penetrate

murine macrophages and inhibit inhabiting M. tuberculosis cells.

This

resulted in the prolonged survival of mice in an acute TB model and
I n A

MIC values were superior to the first line anti-TB drug rifampicin.

•

Another bacteriocin

1 9 1

and its producing strain L. plantarum 423

were successfully encapsulated in nano fibres.

Cells entrapped in the

nano-fibres continued to produce plantaricin 42. The method may be
used not only for the successful delivery of bacteriocins but they may
also facilitate the encapsulation of whole cells such as probiotic lactic
acid bacteria which have resistance against the delivered bacteriocin.

Although delivery systems may be required for some bacteriocins,
others naturally display in vivo antimicrobial activity in preventing
tooth decay and gingivitis.

The use of nisin for human clinical

applications has been licensed to Biosynexus Incorporated (Biosynexus
Inc., 9119 Gaither Road, Gaithersburg, MD 20877, USA)
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and ImmuCell Corporation (56 Evergreen Drive Portland, Maine) has
licensed the use of the anti-mastitic nisin-containing product “Mast Out”
to Pfizer Animal Health, (235 East 42nd Street NY, NY 10017).^^ As
mentioned, nisin is also used as an active agent in “Wipe-Out” (a teat
wipe), and lacticin-3147 has also been incorporated into Teat Seals
(Cross Vetpharm Group Ltd, Broomhill Road, Tallaght, Dublin 24)^^ and
has

demonstrated

successful

prevention

of deliberately

introduced

mastitic staphylococci and streptococci in animal challenge trials.

1 9

^

Provided a bacteriocin is active against mycobacteria, the same principle
may be applied to treat skin and subcutaneous diseases such as Buruli
ulcers.

1.9 Bioengineering of antimicrobia 1 peptides
The relatively small size of bacteriocins makes them amenable to
genetic modifications which facilitate phenotypic alterations such as
stability and activity. The enhancement of the activity, solubility and
stability of current bacteriocins at broad pH ranges has been a huge leap
forward in the realistic therapeutic application of bacteriocins. In one
report by Rollema and colleagues, a single substitution of a serine
residue

with

threonine

at the

fifth

amino

acid

(S5T)

resulted

in

resistance of nisin to acid catalyzed chemical degradation over its
wildtype.Two other nisin mutants, N27K and H31K, showed 4-7
times

higher

activity.

solubility

at

neutral

124
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pH

and

crucially

still

retained

An increase in the half life of bacteriocins is also of crucial
importance as it maintains inhibition over a longer period of time and
extends the shelf life of many products. One study on the bacteriocin
subtillin, produced by Bacillus subtillus demonstrated that a substitution
of isoleucine in the place of glutamate increased the half life from 0.8
days to 48 days,

although a reduction in activity was also seen.

Substitution of a glutamate with an alanine modification at the same
position increased the activity of the bacteriocin 3-4 fold.

Indeed, this

was the first reported enhancement of a bacteriocins activity as a result
of genetic modifications.

The hinge region of nisin has been of particular focus in recent
years as it is crucial for insertion of the C-terminal of the bacteriocin
into the cell membrane, consequently bringing about cell death via the
formation of pores. Yuan et al demonstrated the importance of the hinge
region through the mutation of a number of residues, namely the
introduction
asparagine

of

a

and

respectively.

positively

methionine

charged
at

the

lysine
20**^

and

residue
21^‘

in

place

amino

of

acids,

Interestingly, these variants were also 3-5 times more

soluble at pH 8 when compared to the wild-type. Variants which had a
neutral residue introduced into the hinge region in the form of glutamine
and glycine in place of asparaginne and methionine (N20Q and M21G
respectively) had increased stability at higher temperatures and neutral
and

alkaline

pH.

Crucially,

each

variant

retained

virtually

100%

wildtype activity. In this context, the inactivity of nisin at physiological
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pH, the main drawback of this bacteriocin, may be overcome through
subtle changes without compromising activity.

Recent work by Field et al focused on creating the largest random
collection of nisin variants through random mutagenesis.

Using this

approach, one variant which had a lysine replaced with a serine (K22S),
demonstrated

enhanced

activity.

This

variant,

(K22S)

was

also

located on the hinge region of nisin and prompted by this discovery, a
bank of hinge mutants was created using site directed and site-saturation
mutagenesis in an effort to acquire multiple enhanced variants.''"^ As a
result of this approach, three novel variants were isolated which had
enhanced

bioactivity

Staphylococcus

against

aureus.

Streptococcus

agalactiae and Listeria monocytogenes

These variants K22T (nisin T), N20P (nisin P), and M21V (nisin
V) were purified using identical procedures and their activities were
assessed. Prior to this it was unknown as to whether increased efficacy
was based on an increase in specific activity or an overproduction of the
peptide.

Subsequent

bioassays

with purified

variants

confirmed

an

increase in specific activity relative to the wild type nisin A.

Although a large number of studies have attempted to create
bacteriocin

variants

with

enhanced

activity,

it

is

somewhat

disappointing that a greater number have not been found. One of the
main reasons for this is that single modifications of the structural gene
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may more often than not abolish or reduce the activities of bacteriocins.
This may be due to a number of reasons such as lack of flexibility, as
seen in the hinge region of nisin. It may also reduce the overall charge
of the peptide thereby decreasing the ability of lantibiotics to bind to
the outer membrane of a cell.

Additionally,

the

biosynthetic

machinery

of

bacteriocin

producing bacteria may have an intolerance to process peptides with
substituted residues. Conversely, the overproduction of highly potent
bacteriocin may overwhelm a bacterias self immunity, thus killing the
producing strain.
synthesis and

As

multiple

immunity,

genes

are

required

it is therefore easier to

for

lantibiotic

use the original

bacteriocin as a template for modification rather than cloning of large
cumbersome operons.
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1.10 Mycobacteria and Bacteriocins

Although very little work has been done on investigating the
potential of bacteriocins for the treatment of mycobacterial diseases,
some recent work has highlighted their potential as anti-mycobacterial
agents. One study by Saeed and colleagues investigated the antibacterial
potential of a staphlococcin called Bacl88.

This peptide was isolated

from S. aureus AB188 (a clinical isolate from wound pus) and showed
potent activity against a wide range of Gram-positive and indeed Gram
negative pathogens including B. subfilis, S. aureus, E. faecalis, E. coli.
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S. typhi and S. dysenteriae. Interestingly, Bad 88 also showed potent
aetivity against many elinical isolates of Mycobacterium tuberculosis.

Another

recent

study

by

Stern

and

colleagues

reported

127

the

isolation of a novel bacteriocin OR-7 which decreased the numbers of C.

jejuni

in

poultry

by

one

million

fold.

The

following

year,

this

bacteriocin, along with 4 other novel peptides were investigated for
their anti-tuberculosis activity using three different models: in vitro
cultures, in vitro infection of mouse macrophages and in vivo high-dose
and infection of inbred mice. Promisingly, 4 of the 5 bacteriocins used
had superior activity to the current first line drug rifampicin. Moreover,
the bacteriocins were non toxic to mouse macrophages at O.lmg/L, a
concentration

which was greater than the

MIC

value

required

for

inhibition. Although pure bacteriocins could not inhibit mycobacteria
through penetration of murine macrophages, formation of complexes
with

liposomes

facilitated

successful

delivery

and

inhibition

of

intracellular M. tuberculosis, prolonging the survival in mice.

The relationship between bacteriocins and mycobacteria initially
investigated
peptides.

the

ability

Bacteriocins

of mycobacteria
produced

by

some

to

produce

antimicrobial

mycobacteria

which

are

inhibitory to other myeobacteria have been identified as far baek as
1 no

1958.

Since then, additional mycobacteriocins have been described. In

this regard M. tuberculosis is known to possess bacteriocin activity
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against several rapidly growing mycobacterial strains, including M.

diernhoferi.

As demonstrated above, bacteriocins have huge potential as novel
anti-mycobacterial drugs. As their specific modes of action differ from
current drugs, little, if any resistance will be seen. This is mainly due to
the dual modes of action of bacteriocins and the fact they bind lipid II at
the non-mutatable pyrophosphate region. Moreover, their potential to be
used as a template for future drug design through genetic modification is
facilitated

by

their gene-encoded nature

and

their potential

to

be

delivered to specific sites of infection. Therefore, bacteriocins may be
realistic supplements or replacements for current anti-mycobacterial
drugs.

1.11 In silico identification of bacteriocins

The genomic era has provided scientists with tools for the rapid
identification

of

genes

encoding

antibacterial

proteins

(e.g.

bacteriocins) and equally the genes responsible for resistance to these
peptides.

A

recent

study

harnessed

the

increasing

availability

of

bacterial genome sequences and identified 5 novel lantibiotics including
lichenicidin

which

demonstrated

activity

against

Listeria

monocytogenes, Methicillin-resistant Staphlococcus aureus (MRSA) and
Vancomycin-resistant

enterococcus

(VRE).

This

approach

took

advantage of the highly conserved nature of the lantibiotic biosynthetic
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enzymes,

namely

modification.

Lan

M

which

is

required

for

post

translational

1 70

Similarly, a recent study identified a number of loci which confer
resistance to bacteriocins were also identified through the in vitro
screening of a mariner transposon bank.

Subsequent in silico analysis

revealed an ABC transporter AnrAB, which contributes innate resistance
of Listeria monocytogenes to nisin, bacitracin and various beta-lactam
antibiotics. ABC transporters are the most common class of efflux
pumps which confer resistance to a wide range of solutes including
some

drugs

by

reducing

the

cytoplasmic

concentration

of

an

antimicrobial within a cell.

1.11.1 Bacteriocin/Drug efflux pumps of mycobacteria
Since the publication of the first complete mycobacterial genome in
1998 (M. tuberculosis), 14 other mycobacterial species including three
subspecies

of

M.

avium,

have

been

sequenced

and

many

more

mycobacterial genomes are currently being sequenced (Fig. 1.12). The
increase in the number of genomes sequenced each year is illustrated in
Fig. 1.13. A total of 38 genomes were sequenced between 1998 and
2009, with 6 additional genomes being published to date in 2010.
This

genomics

revolution

not

only

provides

a

detailed

understanding of mycobacterial proteins and metabolic pathways, but
also

facilitates

the

tracking

of evolutionary
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relationships

between

species. For example, it has facilitated discrimination of the subspecies
within the M. avium complex which is now known to consist of M.
avium subsp. paratuberculosis, M.

avium subsp. intracellulare,

M.

avium subsp. avium and M. avium subsp. hominissuis.

■ M. tuberculosis
■ M. bovis
■ M. Icproc
■ M. avium subsp. avium
■ M. avium subsp. paratuberculosis
■ M. smcRmatis
■ M. vanbaalenii
■ M. marinum
« M. kansasii
■ M. gilvunt
■ M. avium subsp. Intracellular
■ M. ulcerans
M. absessus
M. parascrofuloum

Fig. 1.12: Mycobacterium species sequenced over the last II years. Data was
accumulated from the National Centre for Biotechnology Information (NCBI) in July
2010
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Fig. 1.13: Number of sequenced mycobacterial genomes from 1998-2009. Data was
accumulated from the National Centre for Biotechnology Information (NCBl). There
have been an additional 6 mycobacterium genomes sequenced in the first 7 months
of 2010.

Bioinformatics has also facilitated the elucidation of many protein
domains, responsible for different roles in the regulation of solutes
travelling across the plasma membrane (efflux and influx pumps).
Although intrinsic and acquired multidrug resistance mechanisms play
an important role in the resistance of mycobacteria to drugs, the use of
efflux pumps has been highlighted as a major contributor to this
resistance. There are five large superfamilies of efflux pumps. Two of
these superfamilies are the

largest and most diverse groups with

primordial origins. The remaining superfamilies are smaller and more
recent. These are called the resistance nodulation-cell division family
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(RND), the small multidrug resistance family (SMR) and the multidrug
and toxic compounds extrusion family (MATE). 131

The two main types of transporters (i) the so-called “primary”
transporters, such as the ABC transporters which use the energy released
from ATP hydrolysis to drive ions or solutes across the membrane; (ii)
and the “secondary” transporters, which drive substrate translocation by
exploiting the free energy stored in the ion or solute gradients generated
by primary transporters (E.g. Major Facilitator Superfamily; MFS) (Fig.
1.14). 132

H+

DRUG

DRUG

!
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Ft+

DRUG

A

Outer membrane
Inner membrane

A'lP

ADP +

Pi

ABC TRANSPORTER

MFS TRANSPORTER

Fig. 1.14; The MDR transporters: the proton-motive-force dependent transporter of
the MFS (left) and the ATPase dependent ABC superfamily (right).

1.11.1.1 The ABC transporters
ABC transporters are found in all prokaryotic and eukaryotic
species. To date, there are 86 families of ABC transporters, 33 for solute
45

uptake and 53 for solute export (www.tcdb.org.). 1 3 3 Genes encoding
ABC transporters occupy about 2.5% of the M. tuberculosis genome.
They

are

considered primary transporters

which utilise

adenosine

triphosphate (ATP) as the energy donor'^^ facilitating the transport of a
wide variety of solutes across the cellular membrane. These transporters
are important virulence factors as they are involved in nutrient uptake,
secretion of toxins'^^ and antimicrobial agents and are functionally
related to the human P-glycoprotein (MDRl) and Pdr5,'^^’'^^ which are
involved in multidrug resistance shown by tumor cells.

ABC

transport

proteins

generally

exist

as

dimers,

in

total

consisting of four domains, two nucleotide-binding domains (NBD)
(A'fP-ases) and two transmembrane domains (TMD) (permeases) (Fig.
1.15). The ABC superfamily is defined on the basis of ATP-hydrolyzing
proteins which all share a common evolutionary origin.

The TMD

domains form the pathway through which the substrate crosses the
membrane and may be categorised into three topological types of ABC
porters,

(ABCl,

transmembrane

ABC2

or

alpha-helical

ABC3).*^^

ABCl

segments

(TMS),

porters
arranged

contain
as

6

three

repeating, two transmembrane structures, generated through intragenic
triplication.

ABC2 porters also contain 6 TMS which arose from

duplication of a 3 TMS-encoding genetic element. In contrast, ABC3
porters can have 4, 8 or 10 TMSs. Both ABCl and ABC2 conformations
may act as exporters (generally ABCl) while all uptake systems are
ABC2 type.

The subunits of each transporter may be expressed as
46

separate

polypeptides

or

fused

to

each

other

in

any

possible

combination. In contrast, ABC transporters in eukaryotes are often
encoded by a single gene.’"*®

Fig.

1.15:

Illustration

of an

ABC

drug-efflux

An

transporter.

ABC

drug

transporter is typically composed of two substrate-specific membrane-spanning
domains, which provide a pathway for solutes, and two substrate-binding cytosolic
nucleotide binding domains (ATPases) which provide the site for ATP hydrolysis.

In some cases, such as in ABC uptake transporters, substrate binding
proteins (SBP) are also essential for activity.In contrast, ABC efflux
systems lack this constituent. In ABC efflux systems, it is generally
accepted

that

transmembrane

domains

recognise

and

translocate

substrates whereas nucleotide binding domains (ATPases) fuel the
required

conformational

changes.

ABC

transporters

can

have

the

substrate binding subunit fused to the C-terminal of the translocator
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(TMO).'"^'
substrate

In fact,
binding

it has been proposed that two extracytoplasmic
domains

are

fused

to

the

C-terminus

of

the

translocator protein, suggesting 2 or even 4 substrate binding domains
may function as part of the ABC complex.
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As well as capturing the substrate, the substrate binding proteins
(SBP) are also proposed to transmit a signal via the transmembrane
subunit to the ATP-ase subunit(s), increasing the transporters affinity
for ATP, the energy source for the pumps. The resultant hydrolysis of
ATP leads to the opening of the translocation pore facilitating the
release of the substrate from the SBP.'"^^

1.11.1.2 The Major Facilitator (MF) Superfamily
The major facilitator superfamily (MFS) represents the largest
group of secondary active membrane transporters, and its members
transport a diverse range of substrates. Members of the MFS are single
polypeptide

seeondary earriers that

include

over

10,000

sequenced

members. Most are of 400-600 residues in length and generally possess
either 12, 14 or 24 putative trans-membrane regions.About 25% of all
known membrane transport proteins in prokaryotes belong to the major
facilitator superfamily (MFS),'"^^ with the ABC superfamily and MFS
aceounting for nearly half of the solute transporters encoded within the
genomes of mieroorganisms.
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Mechanistically, MFS transporters display three distinct kinetic
mechanisms: there are (i) uniporters, which transport only one type of
substrate and are energized solely by the substrate gradient; (ii)
symporters, which translocate two or more substrates in the same
direction simultaneously, making use of the electrochemical gradient of
one of them as the driving force; and (iii) antiporters, which transport
two

or

more

substrates,

but

in

opposite

directions

across

the

membrane.Recent work shows that the MFS antiporters, and perhaps
all members of the MFS, share the same three-dimensional structure,
consisting of two domains that surround a substrate-translocation pore
(Fig. 1.16).

Fig. 1.16: Illustration of an MFS drug-efflux transporter. An MFS drug transporter requires proton
motive force to drive the transport of metabolites.
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A detailed knowledge of a comparatively small number of protein
structural

domains

facilitates

the

identification

of

a

staggering

assortment of efflux variants which have evolved. These constitute

49

potentially valuable targets in the search
inhibitors

(EPIs)'"^^

and

restoring

the

for novel

efficacy

efflux pump

of therapeutically

ineffective antibiotics potentially suppressing the emergence of MDR
and XDR strains.
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OBJECTIVES

This study had 5 main objectives which are outlined below:

1. To identify and optimise a rapid, sensitive and inexpensive assay for the
identification of novel anti-MAP compounds. MAP is an extremely slow-growing
pathogen responsible for chronic enteropathy in animals and humans. The
identification of novel anti-MAP agents is restricted in large part by the slow-growing
nature of MAP and the identification of novel anti-MAP drugs would be best served by
a rapid viability assay.

2. The identification of active anti-mycobacterial peptides. Eukaryotic and bacterial
anti-microbial peptides have been suggested as possible alternatives to antibiotics
due to their dual modes of action, gene-encoded nature and their ability to be
delivered to the site of infection. In particular, the anti-mycobacterial activities of
lantibiotics lacticin 3147 and nisin will be investigated. The identification of novel antimycobacterial peptides with potent activity would be an exciting step forward in the
control and treatment of mycobacteria.

3. Identification of novel enhanced anti-mycobacterial peptide variants. The bio
engineering of lantibiotics has in previous years been a tool for the elucidation of
structure-activity relationships of peptides. Recently, this approach has also led to the
identification of a small number of peptide variants which exhibit enhanced activity,
stability and/or solubility. This study aims to identify novel enhanced antimycobacterial nisin variants, an approach previously not reported for the
identification of novel anti-mycobacterial drugs

4. To evaluate the activities of novel chemically modified quinoline derivatives using
alamarBlue. Quinoline drugs have previously exhibited potent anti-mycobacterial
activity with some derivatives currently in clinical trials. Here, we will evaluate the
activity of 39 novel quinoline derivatives against four species of mycobacteria.

5. Identification of the drug transporters of the Multi Facilitator Superfamily and ABC
superfamilies which confer resistance to Mycobacterium avium subsp.
paratuberculosis using in silico analysis. The advent of the genomics era has provided
scientists with a powerful tool to elucidate the structures and functions of a vast array
of proteins. Here, we aim to harness this resource to identify members of the two
largest families of transporters, specifically those involved in drug transport.
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2.1 ABSTRACT

The

microtiter alamarBlue

assay

(MABA)

is

an

inexpensive

and

established means of determining cellular viability which has already
been applied to several species of mycobacteria. MABA was initially
pre-optimized
smegmatis.

using

the

fast

growing

mycobacterial

species,

M.

Optimization results from this assay indicate that higher

concentrations of cells provide more rapid results and incubation for 6
hours is optimum for accurate detection of M. smegmatis viability.
Subsequent

to

this,

a

freshly

isolated

environmental

strain

of

Mycobacterium avium subsp. paratuherculosis (MAP) was recovered and
purified from a clinically infected cow. I'he colonies were confirmed as
MAP

using microscopic and molecular methods.

After subsequent

generation of sufficient biomass, the assay parameters for a range of
MAP dilutions (10^ - 10^ CFU/ml) were optimised, and the dye
reduction values (%) of alamarBlue were calculated over a period of 1 1
days. The minimum time required to detect viability based on percent
reduction of the dye for each dilution of cells was determined, ranging
from 30 hours for 10^ CFU/ml to 264 hours for 10^ CFU/ml.
Experimental data showed a gradual

increase in alamarBlue

utilisation on successive days, up to a maximum of 75%, and the mean
cellular incubation time required to achieve 10%, 20%, 40% and 60% for
each dilution of cells was also determined. Following the addition of
alamarBlue at each time point, it was noted that maximal dye reduction
occurred after 48 hours although substantial reduction was also observed
in as little as 6 hours for some dilutions. Finally, in order to illustrate
59

the potential applications of this technique the minimum inhibitory
concentration (MIC) of rifampicin was determined for the MAP strain,
(2pg/mi). This is the first study to highlight the potential of alamarBlue
as a means of determining the viability of MAP. This optimised, rapid,
inexpensive, and reproducible assay has many potential applications,
some of which are discussed in the text.
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2.2 INTRODUCTION
Mycobacterium
controversial,

avium

pathogenic

paratuberculosis

subsp.

subspecies

of the

(MAP)

Mycobacterium

is

a

avium

complex (MAC). It is difficult to cultivate and is reportedly resistant to
both conventional pasteurization '

and chlorination regimens.

It has

also been detected in retail milk both in Europe and the USA. MAP has
also been consistently linked with Crohn’s disease worldwide, with
substantial

scientific

evidence

to

both

support

and

refute

this

association.'^'^ MAP is however, the proven causative agent of Johne's
disease in ruminants. ’

Johne's disease is a serious wasting disease in

ruminants, and is of major concern to the dairy industry globally, with
the USA alone suffering losses of $1.5 billion a year.^ In Europe, MAP
infection rates among dairy cattle range from ~0% in Sweden and
Norway,

where new infections are actively culled, to

Netherlands and 80% in Denmark.

50% in the

Regardless of its association with

Crohn’s disease, there is little doubt as to the importance of controlling
the spread of MAP, notably through improved farming practices, stricter
controls on cattle movement, accurate detection methods, a greater
insight into its virulence properties and the development of novel antiMAP compounds.
Further studies into virulence and drug discovery for MAP would
be best served by the optimisation of a rapid viability assay. Although
there has been significant progress in isolation methodology of MAP,’^
few inexpensive methods have been developed for establishing viability.
Current

viability

methods

include

61

BACTEC,’*

MGIT,*^

phage

amplification

assays,and

luciferase

phage

reporter

assays.

Another method, MABA, previously untested for MAP, is an older but
reliable means of determining cellular viability

which is predicated

on the premise that actively growing cells reduce alamarBlue dye from
blue (oxidized) to pink (reduced).

It is cheap, fast, reproducible, non

toxic, lends itself to a high throughput screening format, and has been
shown

to

be

applicable

to

several

species

of mycobacteria.

Furthermore, its correlation with other more expensive viability methods
is appreciably high (93-100%).^^’^^

This study had a number of objectives, namely to evaluate the
potential of the MABA using a fresh environmental isolate of MAP, to
fully optimise the assay conditions for a broad range of MAP cells, and
to evaluate the application of this assay by determining the MIC for
rifampicin using MABA. The adoption of this cheap and reproducible
assay would be suitable for virulence studies, screening novel anti-MAP
compounds, antibiotic resistance profiling of MAP and determining the
viability of MAP from clinical and environmental sources.
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2.3 MATERIALS AND METHODS
2.3.1 Use of M. smegmatis to determine the impact of optimum
incubation times and cell numbers on the alamarBlue indicator
dye.

Initial mycobacteria optimization studies were performed on a fast
growing

model

enviromental

strain

(M.

determine initial assay parameters. M.

smegmatis

MC2155),

to

smegmatis was cultured in

Middlebrook broth supplemented with Oleic acid, Albumin, Dextrose
and Catalase (OADC). In a 96 well microtitre plate, 200pl of M.
smegmatis cells ranging in concentrations from 2x10
added to each appropriate row.

o

- 2x10

z

were

20pl (10% of the final volume) of a

fresh alamarBlue reagent (AbD Serotec) was added to each well with
mixing. Plates were covered, incubated at 37°C and absorbance readings
(570 and 600nm) were taken at 2, 4, 6 and 24 hours respectively.

A colour change from blue to pink indicated bacterial growth.
Percent reduction of alamarBlue was determined using the formula
below.An average of the percent reduction values of the negative
controls (containing no bacterial cells) was subtracted from the average
percent reduction values of samples in all calculations. Using the
generated data the impact of cell numbers and incubation time was
investigated.
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Percent reduction of alamarBlue=

(02 x Al) - (01 x A2)

x 100

(R1 X N2) - (R2 X Nl)
Where:
01 = (E) of oxidized alamarBlue (Blue) at 570nm
02= E of oxidized alamarBlue at 600nm
R1 = E of reduced alamarBlue (Red) at 570nm
R2= E of reduced alamarBlue at 600nm
Al = absorbance of test wells at 570nm
A2 = absorbance of test wells at 600nm
Nl = absorbance of negative control well (media plus alamarBlue but no
cells) at 570nm
N2 = absorbance of negative control well (media plus alamarBlue but no
cells) at 600nm
(E) = molar extinction coefficient

2.3.2 Isolation and characterisation of Mycobacterium avium subsp.
paratuberculosis

Mycobacterium avium subsp. paratuberculosis was isolated from a
cow in an infected cattle herd in the Munster region of Ireland using
decontamination by centrifugation protocol as previously described.

9

f\

The sample was then cultivated on HEYM agar supplemented with
mycobactin J (0.2%), amphotericin B (50pg/ml), vancomycin (50pg/ml)
and nalidixic acid (SOpg/ml) for 16 weeks at 37°C. The presumptive
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positive colonies were analysed using the acid fast stain, and evaluated
for mycobactin dependency. Subsequently, amplification and sequencing
of the 16S rRNA gene was carried out, and presence of the IS900
element was also determined by PCR using specific primers TJ 1-4.
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The confirmation of the "Cattle type" was performed by amplifying the
large sequence polymorphism LSP^20 as described by Semret et al.^^
Confirmed isolates were grown in Middlebrook 7H9GC Broth (MB),
supplemented
(10%),

with

glycerol

oleic acid,
(0.2%)

and

albumin,

dextrose,

mycobactin

J

catalase

(0.2%)

(OADC)

when

using

alamarBlue. Multiple aliquots (1ml) of the isolate were stocked at -80
degrees in 40% glycerol.

2.3.3 Determination of MAP viability using the MABA assay
Mycobacterium avium subsp. paratuberculosis was grown for 8
weeks in Middlebrook

Broth supplemented with OADC

supplement

(Becton Dickinson) and Mycobactin (Synbiotics). The 10ml culture was
centrifuged at 15,000 RPM for 20 minutes using a bench top centrifuge,
Jouan Inc, (Model CR 4-12). Following the removal of the supernatant,
the pellet was washed in fresh Middlebrook 7H9GC broth and re
suspended in 10ml of fresh supplemented MB broth containing 0.2%
mycobactin J. The turbidity was adjusted to match McFarland standard
No. 1 (3 X 10^ CFU/ml) with MB broth. As the assay was carried out in
triplicate, three sterile, transparent 96-well microtiter plates (Sarstedt)
were used to perform MABA. Sterile deionised water (300pl) was added
to all outer-perimeter wells of the plates to minimize evaporation of the
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medium in the test wells during incubation. The wells in row B2 - Bll
received

200fil

of MAP

(3x10^

CFU/ml),

re-suspended

in

fresh

supplemented broth with mycobactin J (0.2%). The wells in rows C2Cll to G2-G11 received 200pl of the serially 1:5 diluted neat sample,
(i.e. C2-C11 received the first 1:5 dilution; D2-D11 received a 1:5
dilution of this etc. Each well in each row (e.g. B2-B11) represented
each day of the assay. Fresh alamarBlue reagent (AbD Serotec) (20pl)
(10% of the final volume) was added to each column each available day,
with mixing. Plates were covered and re-sealed with parafilm and
incubated at 37°C. Absorbance readings at 570 and 600nm were taken
for that day at 6, 24 and 48 h respectively. A colour change from blue to
pink indicated bacterial growth. Percent reduction of alamarBlue was
determined using the appropriate formula. Percent reduction of the
negative controls was subtracted from percent reduction of samples in
all calculations.

2.3.4 Evaluation of the inhibitory effect of rifampicin on MAP, using
MABA

This

assay was performed to demonstrate the

application of the

optimised method. Rifampicin was obtained from Sigma and stock
solutions were prepared in dimethyl sulfoxide. Working concentrations
were

prepared

to

two

times

the

maximum

desired

final

testing

concentrations prior to their addition to microplates. Briefly, a 1:2 serial
dilution of rifampicin was carried out in triplicate using 3 independent
rows of a 96 well plate, with Middlebrook broth used as diluent. Fresh
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broth (lOOjil) containing 6 xlO”CFU/ml of MAP was then added to the
same wells containing the antibiotic. The final antibiotic concentration
ranged from 250 - 0.48gg/ml in eaeh well. The plates were sealed with
parafilm and were ineubated at 37°C for 4 days.

A 10% addition of

alamarBlue was mixed into each well and readings at 570nm and 600 nm
taken, initially as a background subtraction and subsequently after 24
hours re-incubation. The background subtraction is necessary with
coloured compounds which may interfere with interpretation of any
eolour change. In non-interfering compounds, a blue colour in the well
was interpreted as no growth, and a pink colour was scored as growth.
The

MIC

was

initially

defined

as

the

lowest

concentration

of

antimicrobial agent which prevented a visual eolour change from blue to
pink. Subsequently, the % reduction values were also determined from
the

calculation

outlined

previously,

using

the

appropriate

spectrophotometer readings and conelusive MIC values were determined.
Positive controls did not have rifampiein present in the wells and
negative controls excluded MAP cells from the wells.

2.4 RESULTS

All

statistical

analysis

was performed

using the

Microsoft Excel

programme of Microsoft Office. The means and standard deviations of
triplieate values were ealeulated in the same manner for each chapter.
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2.4.1 Identification of important parameters when using MABA

Prior to the evaluation of MAP, the fast growing indicator strain
M. smegmatis was used to optimize MABA conditions. The optimum
incubation time for a range of concentrations of M. smegmatis (2x10^ 2x10 CFU/ml) in the presence of alamarBlue was investigated. As can
be seen in Fig. 2.1, an increase in incubation time (0, 2, 4, 6 and 24
hours)

generally

correlated

with

higher

dye

reduction

values

of

alamarBlue, but this was dependent on the number of M. smegmatis cells
present in each well.

However in the presence of higher concentrations of cells (2x10^,
log 8.3), incubation of alamarBlue for 24 hours did not yield higher dye
reduction values of alamarBlue than values observed after 6 hours. In
this case, the optimum incubation time required to attain rapid dye
reduction values for 2x10

o

CFU/ml of M.

smegmatis is 6 hours,

producing a dye reduction value of 62% (Fig. 2.1).
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Fig. 2.1. Identification of the optimum number of M. smegmatis cells (2x10^) and
incubation time required for the MABA assay. Results were obtained by calculating
data from absorbance values taken at Oh, 2h, 4h, 6h and 24h.

This assay also provided an opportunity to determine the optimum cell
numbers
smegmatis

required

for

maximum

(Fig.

2.1).

Greater

reduction
dye

of alamarBlue

reduction

values

by

M.

consistently

correlated with higher cell numbers, in this case 2x10* which produced
48% dye reduction after 2 hours incubation. Therefore it is apparent that
the greater numbers of bacterial cells that are present in a sample, the
more rapid the assay proceeds. As can be seen in Fig. 2.1, there was a
substantial decrease in dye reduction values (61% to 42%) at 6 h and 24
h respectively, in the presence of 2x10* CFU/ml. The data illustrates the
necessity of knowing the optimum incubation time, (in this case 6
hours), required for alamarBlue in the presence of each bacterium. Over
incubation may lead to a marked decrease in dye reduction values with
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the

possibility

of false

negative

results

oeeurring.

This

dramatic

decrease in dye reduction values is caused the reduction of resazurin
(blue) into resorufin (pink) and then hydroresorufin (colourless).

0 'K

’

90

Once essential parameters such as number of cells and incubation
time

were

identified

using

M.

smegmatis,

it

was

decided

that

optimization of MAP in the presence of alamarBlue was required. Based
on the data generated with M. smegmatis which demonstrated higher
numbers of cells produced a more rapid result (Fig.

2.1), it was

hypothesised that higher MAP numbers would also provide a more rapid
result. However, due to the extremely slow generation time of MAP it
was decided to investigate its optimum incubation time with alamarBlue.
In an effort to more fully evaluate the assay, it was decided to optimize
assay parameters using a fresh environmental isolate of MAP.

2.4.2 Confirmation of the Mycobacterium avium subsp.
paratiiberculosis (MAP) as determined by phenotypic and
molecular analysis

A recently cultured bovine MAP strain

was used to a) optimise

the assay parameters and b) evaluate the application of the assay. The
strain was isolated and characterised as previously described.Briefly,
suspect colonies which were found to be slow growing, acid fast and
mycobactin dependent were analysed using molecular analysis of the
MAP specific IS900 element and the large sequence polymorphism
LSP'^20 (Fig. 2.2). Real-time PCR was employed to detect both targets.
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The amplified products were compared to a positive control MAP strain
(ATCC 19698). Similar results were obtained by observing the predicted
size of the amplicon (294bp of IS900 and 197bp of LSP'^20) using gel
electrophoresis (Fig. 2.2). Subsequently, definitive confirmation of the
species identity was determined by amplification and sequencing of the
16S rRNA gene. BLAST and RIDOM analysis identified the isolate as
being Mycobacterium avium subsp. paratuberculosis
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Fig.2.2. Real-time PCR melting curve analysis using SYBR green. This figure illustrates the melting
temperatures (peaks) of both products LSP20 (90°C)
strain (A TCC 19698) and LSP20 (90°C)

and IS900 (92°C)

and IS900 (92°C)

of the positive control MAP

of the environmental isolate C1T03.

Products were run on gel electrophoresis to confirm amplicons of294bp (1S900) and I97bp (LSP20).

2.4.3 Optimization of the microtitre alamarBlue assay (MABA)
The microtitre plate format used in the experimental protocol
represented a matrix for optimising this assay from 3 perspectives; the
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influence of cell numbers, the cellular incubation time prior to the
addition

of

alamarBlue

and

the

optimal

incubation

time

with

alamarBlue. All 3 had a significant impact on colour development and %
reduction of the dye. Following the requisite cellular incubation time
and addition of alamarBlue, visual recordings and colorimetric results
were taken at 6, 24 and 48 hours. For clarity purposes, only figures
representing 3x10^ CFU/ml, 2.4x 1 O^CFU/ml and 9.6x10'* are provided.

For the highest concentration of cells (3x10^ CFU/ml) (Fig. 2.3 +
Table

2.1),

strong

reduction

was

observed

after

1

day

cellular

incubation, but the values were influenced by the incubation time with
alamarBlue (as was the case for all readings).

It became apparent that at high concentrations of cells (causing
70% dye reduction),

further incubation of the cells (48

hours) or

incubation with the dye did not result in an appreciable increase in dye
reduction values. In fact, it was noticeable that at high concentrations of
cells (3x10^ CFU/ml), dye reduction readings actually decreased over
time (Fig. 2.3).

At the mid-range cellular levels, negligible reduction of the dye
occurred over the first 2 days, after which substantial increases were
observed after day 4 and day 5.
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At the lowest concentration of cells (10"^ CFU/ml), very low dye
reduction values were recorded. Cellular incubation had to proceed for
7-8 days before any noticeable change in dye reduction occurred (Fig.
2.5). A decrease in % dye reduction values did not occur at these lower
cellular levels after 6-8 days, presumably due to the fact that the
maximum threshold (~70%) had not been reached.
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Fig. 2.3: Optimization of alamarBlue conditions using 3x10^ MAP CFU/ml over 11
days. Following the addition of alamar Blue, readings were taken at 6, 24 and 48
hours.
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Fig. 2.4.' Optimization of alamarBlue conditions using 2.4x10'’ MAP CFU/ml over II
days. Following the addition of alamarBlue, readings were taken at 6, 24 and 48
hours.
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Fig. 2.5: Optimization of alamarBlue conditions using 9.6x10'' MAP CFU/ml over
11 days. Following the addition of alamarBlue, readings were taken at 6, 24 and 48
hours.
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2.4.4 Standardization of alamar blue reduction values
Visually, a change in colour from blue - purple - pink over time is
indicative of cellular viability (Fig. 2.6). Thus, wells which remain blue
in the presence of an antimicrobial compound indicate its activity
against MAP. As can be seen in Fig. 2.6, visual interpretation of
viability is sufficient for crudely determining cellular growth in the
presence of an anti-MAP agent.

••
••

•#
#9

^Ir'

HIP

• • • • '•

Fig. 2.6 : A representative minimum inhibitory concentration assay for
the detection of MAP viability assay when using the alamarBlue assay.

However, the purpose of this study was to accurately quantify and
evaluate the role of cell numbers, incubation time and dye in a
standardised format. Any wells with values below 12% after the addition
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of the dye were consistently blue indicating a lack of viability or cell
numbers below the cut off sensitivity levels of the assay. Some wells
were purple and recorded % reduction of 12-18%. These were equivocal
values that indicated presumptive viability. Any values over 20% were
pink and definitively viable.

The time taken to reach the threshold of

definitive viability (20%) varied significantly for each dilution of cells,
ranging from 1 day + 6 hours with the dye for the highest concentration
to 9 days + 48 hours with the dye for the least number of cells.
Having reviewed the overall results, the required time to reach standard
% reduction levels (10, 20, 40, and 60%) was determined for each
concentration of cells as can be seen in Table 2.1. These ranged from
30h incubation (24 h cellular incubation with 6 hours incubation with
alamarBlue) for 10^ CFU/ml (Fig. 2.3) to 264h incubation (216 cellular
incubation and 48 hours incubation with alamarBlue) for 10"^ CFU/ml
(Fig. 2.4) which only reached 20% reduction.

Determination of MAP viability can therefore be performed in as
little as one day’s growth plus 6 hours incubation with alamarBlue (Fig.
2.3) if the cell numbers are high enough. It is important to state that an
increase in cell numbers decreases the incubation time required to
confirm viability. Therefore, to attain rapid results, a considerably
higher number of MAP cells are needed than the proposed 10"^ CFU/ml
levels as recommended by the product instructions.
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However, to obtain

maximum reduction values, it is important that appropriate incubation
times be applied for each concentration of cells (Table 2.1).

.MAP cell
numbers
(CFl!/ml)

Time required to reach
10% reduction (hours)

Time required to reach
20% reduction (hours)

Cellular

alamarBlue

Cellular

24

6

24

6

24

24

3 X lO**

alamarBlue

Time required to reach
40% reduction (hours)
Cellular

alamarBlue

Time required to reach
60% reduction (hours)
Cellular

alamarBlue

24

24

24

24

48

96

24

96

24

144

48

6x10’

24

6

24

1.2 X 10’

24

24

96

24

2.4 X 10'’

96

6

96

48

120

48

N/A

N/A

4.8 X 10^

96

6

144

48

216

48

264

48

9.6 X lO-*

96

6

216

48

>264

N/A

N/A

N/A

Table 2.1: Required time (hours) taken for Mycobacterium avium subsp.
paratiiberculosis to reduce alamarBlue.

Cellular incubation (hours) refers to the

incubation time of MAP in the absence of alamarBlue.

The incubation time with

alamarBlue refers to the time taken for alamarBlue to cause a color change in the
presence of MAP cells.

N/A - Dye reduction values did not reach the threshold of
40% and 60%.

2.4.5 Detection of MAP viability in the presence of rifampicin

After optimizing the MABA assay for detection of MAP viability, the
performance of MABA was evaluated by determining the MIC90 value of
the first line anti-mycobacterial drug, rifampicin for MAP. The MIC90
was defined as the lowest concentration of rifampicin which prevented
the relative growth of MAP relative to the growth of the positive control
containing no rifampicin. The MIC90 was determined as 1.95pg/ml, (Fig.
2.7) which correlates well with other studies.
determined

using the provided calculation,

interpreted by visual analysis.
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Percent reduction was
and

results were also

Determination of the

viability of MAP

in the

presence of

rifampicin was performed in a total of 5 days, including incubation with
alamarBlue, in comparison to agar proportion methods which require
growth time of up to 8 weeks. At this concentration of cells (4 days + 24
hours with alamarBlue) maximal dye reduction was observed. However
this assay could be carried out in as little as 1 day + 24 hours with the
dye, if faster results are needed. The assay was performed in triplicate,
and all MIC results were identical. Initial background readings were
taken following the addition of alamarBlue as the color from rifampicin
at higher concentrations will interfere with subsequent calculations.
These readings subsequently replaced the negative controls in the
calculations.
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3.9

1.9

0.97

0.48

Concentration of rifampicin (pg/ml)

Fig. 2.7: Determination of the MICyo of rifampin against M. avium subsp.
paratuberculosis. Results were obtained after 5 days incubation (4 days cellular
incubation with I day incubation with alamarBlue)
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2.5 DISCUSSION
This study sought to evaluate the MABA assay as a possible
platform for detection of cellular viability of MAP and a tool for the
rapid

and

inexpensive

screening

of

anti-MAP

compounds.

Initial

optimization studies using the fast growing mycobacterial model strain

M. smegmatis were performed to investigate the important parameters
when

using

the

MABA

assay

(Fig

2.1).

Previous

work**

has

demonstrated that variables such as media and supplement addition do
not adversely affect the MABA assay. Therefore, we investigated the
role of cell numbers and incubation time on both M. smegmatis and
MAP.

From the data initially obtained

with M.

smegmatis it was

apparent that both cell numbers and length of incubation time with
alamarBlue dramatically influence dye reduction values. Higher numbers
of M

smegmatis

cells

demonstrated

higher

reduction

values

and

consequently more rapid completion of the assay. Extended incubation
times also adversely affected dye reduction values in the presence of
high cell numbers (lO^CFU/ml). H owever, at lower concentrations 24h
incubation with alamarBlue is recommended.

Based on this knowledge, we investigated the ability of MABA to
detect

cellular

paratuherculosis.

viability
We

also

Mycobacterium

of
set

out

to

optimize

avium
the

factors

subsp.
which

influence this reduction, and to evaluate the potential applications of the
assay. As traditional methods such as the BACTEC, MGIT and the agar
proportional method can be expensive and time consuming, a cheap and
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rapid

alternative

considering.

The

mycobacterial
correlation

method
use

species

with

the

of

for detection
alamarBlue

such

as

standard

M.

of MAP
is

well

viability
established

tuberculosis

methods

as

is worth

and

against

shows

mentioned

high

above.

Moreover, as few as 80 cells give a reproducible and sensitive signal,
which is in the range of radioactive methods, but without the exposure
and waste disposal issues.
In

this

study

an

environmental

MAP

strain

was

isolated,

propagated and subsequently used in the optimization of the alamarBlue
assay

for

MAP

(Fig.

2.2).

As

there

is

no

recorded

information

concerning the ability of MAP to reduce alamarBlue that we are aware
of, initial experiments set out to determine this fact, following which
extensive optimization of the assay parameters was performed (Fig. 2.3,
2.4, and 2.5). As with previous studies, interpretation of the results was
initially carried out following visual inspection of the plates. Later
however, the % reduction of the dye for each time point was calculated
to facilitate more detailed examination of the data, and to also assign
standard cut off values (20, 40, and 60%) as seen in Table 2.1. These
values serve as definitive indicators of viability and may be used in
future studies to compare the relative viability of 2 or more strains, the
influence of media composition on maximizing growth rate, or the
relative

efficacy

of

multiple

anti-mycobacterial

compounds.

The

maximum % dye reduction under these experimental conditions was
recorded as 75%. This plateau effect is often noted when measuring dye
reduction values of alamarBlue with cells generally not reaching 100%
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reduction.

For the MAP strain used in this study, higher cell numbers

gave faster % dye reduction, as did longer cellular incubation times.
Interestingly, the % dye reduction levels decreased for the higher
concentration of mycobacterial cells after reaching a critical maximal
level (70-75%) as seen in graphs 2.1 and 2.3. This phenomenon is due to
the extensive reduction of resazurin (blue) into resorufin (pink) and then
hydroresorufin (colourless). 29

As expected, the lowest concentration of MAP cells (10“^ CFU/ml)
(Fig. 2.5) caused a very slow conversion of the dye (40%) over 1 1 days.
To achieve high percent reduction value for this concentration of cells,
incubation for more than 11 days is required (Table 2.1). No visual
colour change was seen until day 6 which saw a slight colour change to
purple. This difference between days 5 (blue) and 6 (purple) was very
negligible when the percentage reduction of the dye was calculated. On
day 5 the calculated percent reduction was 11% but an overnight colour
change to purple was caused only by an increase to 13% reduction. This
is significant in that it illustrates how such a minor percent reduction of
the dye change can have such a bearing on the visual interpretation of an
assay.

Under the experimental conditions used in this study, it was
concluded that % dye reduction values of 12% and below indicate little
or no viability for MAP. Anything immediately above this value (1320%) gave equivocal results, and higher readings (21-75%) indicated
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strong viability. These correlated with the wells changing visually from
blue - purple - pink

respectively over time.

Generally,

extended

incubation with alamarBlue resulted in greater % dye reduction (i.e. 6 24 - 48 hours), although the size of this increase was largely dependent
on the cellular incubation time and the cell titre. A notable advantage of
this assay is the ability to take sequential readings once the dye has
been added. This permits an early reference point to be determined after
which comparative viability can be evaluated over time for this slow
growing pathogen. The sensitivity of this assay requires strict adherence
to specific cell numbers and their equivalent incubation time. Based on
the data the optimum cell numbers that should be used to achieve a
gradual but consistent increase of percent reduction is 10^ CFU/ml.
When using very low numbers of cells, the growth rate may be so slow
that insignificant reduction of alamarBlue will be seen. Alternatively,
rapid results may be achieved when using a high number of MAP cells
(Fig. 2.3). It is important to note that this datum only applies to freshly
grown MAP cells in log stage of growth. Preliminary cultures taken
directly from four degrees have significantly slower growth rates, and
thus lower % alamarBlue reduction values, leading to longer incubation
times (data not shown).

An

incubation

recommended

in

time

most

of 24

hours

publications

or

less

investigating

with
the

the

dye

is

potential

of

alamarBlue when using mycobacteria.Although 24 hour incubation
will give a strong indication for some dilutions, it is not always optimal
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when calculating the exact % reduction of alamarBlue. On the other
hand 72 hour incubation is not necessary as % reduction of the dye
remains the same (data not shown), consequently, it is recommended to
take multiple readings if a comprehensive picture of the viability status
is needed. Furthermore, the manufacturers generally recommend using
10"* CFU/ml when carrying out this assay.Although this may be
suitable for fast growing strains, based on the data outlined here this
number of cells is substantially lower than that required for MAP. For
the quickest results we would recommend using a titre in excess of 10
CFU/ml.

As stated above, varying levels of viability and equivalent % dye
reduction values are presented for MAP over a large range of cell titres.
Access to this data will provide researchers with a reference which
shows quite clearly the expected growth/viability profile for MAP under
many

experimental

already

been

conditions.

adopted

by

the

The
dairy

application
industry

to

of alamarBlue
monitor

has

microbial

contamination in milk.^^’^^ As MAP may be one of the only pathogens to
survive following pasteurization, the application of an isolation method
such as IMS

supplemented by a viability assay such as alamarBlue may

be a useful tool in its detection. Moreover, most laboratories will have
access to the low cost technology and equipment required to replicate or
advance

this

study.

In

particular,

the

range

of

potential

future

applications for this study is significant. In particular, it will facilitate
comparisons between different growth parameters or between different
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strains of MAP which will be particularly useful for virulence or
physiological studies. Furthermore, the assay format can be extended to
screen for novel anti-MAP compounds, the presence of contamination in
milk following pasteurization (putatively MAP) and for determining the
antibiotic resistance profile of individual isolates. To prove this concept
the MIC value for rifampicin was determined as 1.95pg/ml (Fig. 2.7).
The cut-off point was unequivocal, reproducible and consistent with pre
established values for MAP.
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Based on the results presented, it is concluded that viability of

Mycobacterium avium subsp. paratuberculosis can be detected using
alamarBlue indicator dye. As the incubation time required for dye
reduction varied dramatically between M. smegmatis and MAP, it is
recommended that optimization of experimental conditions such as cell
numbers and incubation time is performed prior to evaluation of each
new

species.

Following

optimization,

the

use

of

alamarBlue

for

detection of viability can be readily employed. MABA demonstrates
good correlation between visual observation of the wells during the
assay

and

endpoint

%

dye

reduction

calculations,

although

more

extensive and absolute information can be obtained from the calculated
data. Optimization of this assay and interpretation of the subsequent
calculated data illustrates the influence of initial cell numbers, cellular
ineubation time and addition of dye on the viability of MAP. Finally this
report illustrates how MABA may be used for multiple applications as a
cheap (approximately 10 euro cents per sample), rapid and reproducible
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indicator

of

viability

especially

when

screening

novel

anti-MAP

compounds using a platform and technology which is widely accessible.
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CHAPTER 3

CHAPTER 3

Isolation, characterization and evaluation of
potential anti-mycobacterial peptides
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3.1
The

ABSTRACT
objective

of this

study

was

to

evaluate

the

efficacy

of

8

antimicrobial peptide producing bacteria previously untested against
mycobacteria.
Four of these isolates produced bacteriocins and four isolates
were cyclic di-peptide producers. Assessment of these bacteria and the
antimicrobials they produce revealed that there are many factors such as
media composition, acid production and physical characteristics which
may influence their inhibitory capabilities. In total, 7 isolates exhibited
potent activity against M. smegmatis. Two bacteriocins in particular,
(nisin and lacticin), displayed potent activity against M. smegmatis in a
broth-based

matrix.

This

activity,

combined

with

their

'generally

regarded as safe' status (GRAS) suggests these bacteriocins warrant
further evaluation as possible anti-mycobacterial agents.
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3.2 INTRODUCTION
Host defence antimicrobial peptides are paramount for the successful
survival

of most

organisms.

These

peptides

are

produced

by

all

organisms, including the eukaryotic cells of humans.^ Human peptides
known as defensins have previously demonstrated the capacity to inhibit
a wide range of organisms and have been put forward to clinical trials
for application as therapeutics.

The antimicrobial peptides produced by

bacteria (Bacteriocins) also represent a large and diverse group of
proteins

which

resemble

eukaryotic

defensins.^

Unlike

antibiotics,

bacteriocins are ribosomally synthesized and have a relatively narrow
killing spectrum."^

This study focuses on the screening and evaluation 8 previously
characterised antimicrobial producers which have not been tested
against mycobacteria. The bacteriocins are produced by Lactococcus
(nisin and lacticin 3147) and Staphylococcus (C55 and neuman) species.
Both nisin and lacticin are produced by ‘generally regarded as safe’
(GRAS) organisms, which facilitates their incorporation into
antibacterial therapies.Although derived from the same species,
lacticin and nisin have distinct differences, the primary distinction being
that nisin is a one component peptide and lacticin is a two component
peptide (Ltna and LtnP (formerly LtnAl and LtnA2), with the
synergistic action of both peptides required for activity.
bacteriocins are discussed in detail in chapter 4.
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These

The bacteriocins C55 and neuman are both staphyloeoeoeins. The
o

lantibiotic activity of S. aureus C55 was first identified in 1969 and
further characterised in 1998.^ S. aureus C55 demonstrates bacteriocin
activity from two distinct peptide components, termed staphyloeoeoeins
C55a, C55p.'^ Although produced from different species, both lacticin
and C55 are closely related, exhibiting 86% (Ltna and C55a) and 55%
(LtnP and C55p) identity in their component peptides.'* In fact, when
the alpha or beta peptides from lacticin were replaced with the
corresponding peptides from C55 or vice versa, the bacteriocins
remained active.

11

Staphylococcal
studied

in

recent

bacteriocins
years

are

highlighted

among
by

the

the

most

thoroughly

identification

of

S.

epidermidis products epidermin, Pep5, and epilancin.^ Recently, novel
staphyloeoeoeins such as BacRl have also been identified.
lantibiotic

from

S.

neuman

is

also

novel,

it

has

not

As the
yet

been

characterised and consequently, it is not known if it is a single or twocomponent peptide.

The other four bacteria investigated in this study {Lactobacillus

plantarum FST 1.7, Lactobacillus plantarum FST 1.9 (TMW),
Lactobacillus amylovorus (LA) and Weissella cibaria (WC) produced a
class of antimicrobials known as cyclic di-peptides.

This class of

compound has previously been shown to have antiviral, antifungal,
antibacterial and anti-tumour properties.The cyclic di-peptide
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producing Lactobacillus plantarum FST 1.7 has previously been
screened for in vitro antimicrobial activity and was shown to be active
against spoilage moulds and some bacteria. Previous isolation of
antimicrobial compounds from the cell-free supernatant of L. plantarum
FST 1.7 producing bacteria identified lactic acid, phenyllactic acid and
the two cyclic di-peptides cyclo (1-Leu-l-Pro) and cyclo (1-Phe-l-Pro) as
the major components responsible for this activity.

'

Interestingly, L.

plantarum FST 1.9 also produces these antimicrobial with the exception
of cyclic di-peptides cyclo (1-Leu-l-Pro).
The purpose of this study was therefore to investigate the antimycobacterial activity of 8 characterised organisms which have
previously demonstrated enhanced activity against a number of other
Gram-positive organisms (Table 3.1).

Antimicrobial producers*

Antimicrobial produced'’

(n=8)
Lactococcus lactis NZ9700

Bacteriocin (nisin)

Lactococcus lactis 3147

Bacteriocin (lacticin)

Staphylococcus neuman

Bacteriocin (neuman)

Staphylococcus aureus

Bacteriocin (C55)

Lactobacillus plantarum FST (1.7)

Cyclic di-peptide

Lactobacillus

Cyclic di-peptide

FST (1.9)

Lactobacillus amylovorus

Cyclic di-peptide

Wescillia cibaria

Cyclic di-peptide

Table 3.1: A summary of all bacterial isolates used in this chapter. Antimicrobial
producers (a) were previously characterised by the Department of Microbiology in
University College Cork. Bacteriocins produced by these bacteria (b), contain both
single (nisin) and two component peptides (lacticin and C55). The bacteriocin of S.
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neiunan has not yet been fully characterised. Cyclic di-peptide producing bacteria
(c), were obtained from the department of Food and Nutritional Sciences in UCC.

3.3 MATERIALS AND METHODS

3.3.1 Influence of plastic on the inhibition of M. smegmatis by cyclic
di-peptide producing bacteria

The

influence

producing
compounds

of plastic

strains
it

was

was

on the

efficacy

of the

cyclic

During

initial

testing

evaluated.

noticed

that

potency

of the

cyclic

di-peptide
of

these

di-peptides

producing strains decreased dramatically when grown in plastic culture
tubes. As a result of this, identical isolates were grown in both plastic
and glass bottles (25ml). Following overnight incubation in MRS broth,
the cultures were centrifuged in their respective tubes at 14,000r.p.m for
15 minutes. From the glass tubes, a graduated glass Pasteur pipette was
used to spot 20pl of CFS onto MB plates seeded with M. smegmatis. A
regular pipette tip was used to spot 20|al of cell free supernatant (cfs)
from the culture grown in the plastic tube. The contribution of acid to
the inhibitory effect of aliquots from both glass and plastic matrices was
also evaluated by testing both neutralized and non-neutralized samples.
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3.3.2

Culturing

conditions

and

media

for

known

antimicrobial

producing isolates obtained from University College Cork (UCC)

As part of this study, two Staphylococcal strains (S. neuman, and S.
aureus C55), two Lactococcal strains (L. lactis NZ9700 and L. lactis
3147), three Lactobacillus strains {L. plantarum FST 1.7, L. plantarum
FST 1.9 (TMW) and L. amylovorus (LA)), and one Weissella cibaria
strain (W. cibaria FST 1.3 (WC)) were screened for anti-mycobacterial
activity.

Each

antimicrobial

strain
activity,

has

been

previously

although none

have

identified
previously

as

having

been tested

against mycobacteria. Lactobacillus and Weissella isolates were grown
in MRS media overnight at 30°C. Lactococcus strains were grown in
Ml 7 media supplemented with 0.5% glucose at 30°C overnight. The
potential inhibitory effect of acid was neutralized by adding 0.2%
sodium bicarbonate in agar based matrices and broths were adjusted to
pH 7 with NaOH.

3.3.3 Influence of media composition on bacteriocins produced by
Staphylococcus species

To determine the influence of media composition on the production of
bacteriocins,

individual

colonies

of

each

bacteriocin

producing

Staphylococcus strain were isolated by streaking on 4 different types of
medium (Tryptic Soy Agar, Mueller Hinton 11 agar. Nutrient Agar and
Brain Hearth Infusion agar). Following UV irradiation to kill producing
strains, the efficacies of each antimicrobial producer on each medium
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was assessed by overlaying plates with supplemented Middlebrook (MB)
agar seeded with 10% M. smegmatis (lO^CFU/ml). Plates were then
incubated for 3 days at 37°C and were subsequently screened for antimycobacterial activity.

3.3.4

Assessment

of the

anti-mycobacterial

activity

of cell

free

supernatant (cfs) from nisin and lactiein producing strains
Bacteriocin activity was initially assessed using a number of agar based
methods. In total three assay methods were employed; a) spot assay b)
deferred antagonism assay (overlay assay) and c) well diffusion assay.
Spot assays were employed to assess the antimicrobial activity of
unpurified lantibiotic in the form of cell-free supernatant (cfs). Briefly,
50pl of cfs from overnight cultures of the lactiein 3147- or nisinproducing strains were spotted on Middlebrook 71110 agar seeded with
M. smegmatis (lO^CFU/ml).

Deferred antagonism assays (overlay assays) were performed by
isolating

individual colonies of an overnight culture of the relevant

producing strain on GM17 agar and allowing them to grow overnight
before overlaying with either Middlebrook 7H10 agar seeded with the
appropriate indicator mycobacteria. Plates were incubated 37°C for 2-3
days.
Agar well diffusion assays were carried out as follows. Molten
agar

(20ml)

was

seeded

with

the

95

target

strain

(10%).

Cell

free

supernatant (50pl) was added to wells of approximately 4.6mm in
diameter which were aseptically bored in the agar. Plates were incubated
at 37°C for 2-3 days.

3.3.5 Minimum inhibitory concentration of nisin and lacticin
against M. smegmatis

Initial assessment of the inhibitory potential of the bacteriocins nisin
and lacticin against mycobacteria was performed on fast growing M.

smegmatis.

Minimum

inhibitory

concentration

(MIC)

assays

performed on the Versa Max Microplate Reader (Bioscience)

were
with

Softmax Pro 4.8 software. Using the kinetic software, growth curves
were monitored over 85 hours at an absorbance reading of 600nm. The
MIC value is defined as the lowest concentration of an antimicrobial
which prevents visible growth of a test strain.

Briefly,

1ml of M.

smegmatis (lO^CFU/ml) was added to 9mls of Middlebrook 7H9 broth
supplemented with 10% OADC.

lOOpl of this culture were directly

added to a 96 well microtitre plate. Purified nisin or lacticin 3147
(UCC), were individually serially diluted 1:2 in Middlebrook 7H9 broth
and

lOOpl of each dilution were added to the 96 well plate. The

concentration of both bacteriocins ranged from 50pg/ml-0.097pg/ml.
Absorbance readings at 600nm were recorded every hour for 85 hours.
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3.4 RESULTS
The production and/or the activity of the antimicrobials produced by a
range of different species including Lactobacillus, (cyclic di peptides)

Weissella (cyclic di peptides), Lactococcus (bacteriocins nisin and
lacticin) and Staphlococcus (bacteriocins neuman and C55) were
influenced by various parameters such as growth media, acid production
and physical affinities to plastic matrices.

3.4.1 The influence of plastic on the potency of cyclic di-peptide
producing bacteria
While screening the antimicrobial producing bacteria from UCC, it was
also noticed that the compounds produced by Lactobacillus and

Weissella (cyclic di-peptides) had reduced efficacy following growth in
a plastic matrix. Consequently, the potential adverse effect of plastic on
the antimicrobials was investigated. To evaluate the affinity of cyclic
di-peptides for plastic, bacteria were grown in both plastic and glass
tubes. They were also spotted onto seeded M. smegmatis plates with
plastic pipette tips and glass Pasteur pipettes respectively. As can be
seen in Fig. 3.1, the cyclic di-peptides produced by bacteria grown in
plastic (top) have substantially smaller zones of inhibition than those
grown in glass tubes (below), with the exception of L. plantarum 1.9.
Therefore it is postulated that cyclic di-peptides have a strong affinity
for plastic and glass materials should be used during their preparation.
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3.4.2 The influence of acid on the potency of cyclic di-peptide
producing bacteria
It is also apparent that the acid produced plays a significant role in the
inhibition of M. smegmatis. Spots on the left hand side of all plates (Fig.
3.1) represent the cell free supernatant which has not been neutralized.
The spots on the left hand side of the plates (Fig. 3.1) are substantially
smaller and represent inhibition by the cyclic di-peptides alone, the acid
being neutralised by the addition of NaOH. From these results it is
apparent that Lactobacillus plantarum FST 1.7 demonstrates the most
activity against M. smegmatis. Both W. cibaria FST 1.31 (WC) and L.
amylovorus (LA) also demonstrated good activity against M. smegmatis
whereas L. plantarum 1.9 (TMW) had no inhibitory effect once
neutralised. The pH values of cyclic di-peptide producing bacteria
before and after neutralization are given in Table 3.2.

Cyclic di-peptides in contact with Plastic

Cyclic di-peptides in contact with Riass

B= Before Neutralization

A= After Neutralization
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Fig. 3.1: Activity of cyclic di-peptides produced by Lactobacillus and Weissella
(WC) species. Cell free supernatant (CFS) was taken from samples grown in plastic
(top) and glass (bottom). The efficacy of the CFS was also assessed before
neutralization (left of each plate) and after neutralization (right of each plate).

Bacteria

Initial pH

Adjusted pH

Weissella cibaria
(WC)
Lactobacillus amylovorus
(LA)
Lactobacillus plantanim
FST 1.9 (TMW)
Lactobacillus plantarum
1.7 (FST)

4.63

7.05

3.80

7.07

3.80

7.19

3.82

7.15

Table 3.2: pH val ues of the cell free supernatant (cfs) containing cyclic di
peptides. The pH was adjusted to ~7.0 to remove the effect caused by lactic and
phenyllactic acid.

3.4.3 Evaluation of the effect of media composition on two
bacteriocin producing (staphylocococins, neuman and C55)

Staphylococcus strains
During the screening process, it was noticed that the activity of
bacteriocin-producing Staphylococcus species ceased when growth
medium was changed from BHI to the routinely employed Mueller
Hinton medium. Consequently, the activity of both staphlococcin
producers were evaluated on four different types of media, (TSA, BHI,
MHl 1 and NA) which were chosen because they are also commonly used
for propagation of a wide variety of bacteria. Following incubation of
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overlaid M. srnegmatis for 3 days, each plate was checked and
photographed. Based on these results, it was noticed that the medium on
which the producing isolates were grown played a significant role on the
production and/or the mode of action of the antimicrobials (Fig. 3.2 and
Fig 3.3).
Based on the results seen in Fig. 3.2 and Fig. 3.3, BHI is the optimal
medium to use when screening for antimicrobial activity of these
bacteriocins. When grown on this agar, both S. neuman and S. aureus
caused significant inhibition of M. srnegmatis. Therefore, it can be said
that the composition of BFII media is optimal for the production of the
antimicrobial peptides produced by Staphylococcus species.

In contrast to this, the inhibition seen on TSA medium is
significantly lower. Additionally, the composition of the MHII and
nutrient agar completely inhibit the production and/or the mode of
action of the antimicrobial peptides. This data not only confirms BHI as
the only suitable matrix for screening antimicrobial activity for
Staphylococcus bacteria but also reiterates the potential pitfalls of using
solid based matrices for evaluation of antimicrobials, as previously
outlined in the literature.^’Furthermore, it highlights the advantage of
rapid broth based assays such as MABA for the identification of novel
antimicrobials. The activity of each staphlococcin in each medium is
summarised in Table 3.3.
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(b)

|a|

rSh
CSS

(c)

(d)

Fig. 3.2, S. aureus which produces the two component bacteriocin C55, grown on
Tryptic Soy Agar (a) Brain Heart Infusion agar (b), Muller Hilton II agar (3) and
Nutrient agar (d). AH plates were overlaid with M. smegmatis and incubated for 3
days at 3 7°C.

(a)

(b)

f.|tv

(d)

Ic)

Fig. 3.3: S. neuman grown on Tryptic Soy Agar (a) Brain Heart Infusion agar (b),
Muller Hilton II agar (3) and Nutrient agar (d). AH plates were overlaid with M.
smegmatis and incubated for 3 days at 3 7°C
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Bacteriocin producer

TSA

MHII

NA

Staphylococcus aureus (C55)

+++

+

4

444

+

4

-

44

Staphylococcus neuman (neumon}

BHI

Table 3.3 : Activity of bacteria producing anti-mycobacterial compounds in a range
of agar matrices. All isolates were overlaid with M. smegmatis (I O^CFU/ml). The
inhibition caused by each isolate was scored as follows; + + + = very good activity,
+ + == good activity + = poor activity and — = no activity. TSA = Tryptic soy agar,
MHII = Mueller Hinton agar, NA = Nutrient agar and BHI = Drain Heart Infusion
agar.

3.4.4 Activity of nisin and lacticin on M. smegmatis
The remaining two bacteriocins, (Laetocococins nisin and lacticin
3147), are produced by L. lactis. Initially, overlay assays were employed
to evaluate the inhibitory effect of both lacticin and nisin against M.

smegmatis. While the lacticin 3 1 47-producing strain failed to inhibit M.
smegmatis when agar based assays were employed (as represented in
Fig. 3.4a), nisin production by L. lactis NZ9700 successfully inhibited
the target strain (Fig. 3.4b).

As expected, large zones of clearing were

noted on areas where large concentrations of L. lactis NZ9700 were
streaked. However, when colonies were in isolation (Fig. 3.4 (circled in
red)), some did not produce nisin (left) whereas others maintained
production, but at a reduced level (right). Based on these results, our
initial

conclusion

was

that

nisin

was

capable

of

mycobacterial

inhibition, while lacticin did not inhibit mycobacteria in an agar based
matrix.
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Fig 3.4.- Lacticin producing L. lactis 3147 (a) and nisin producing L. lactis NZ9700
(b) overlaid with M. smegmatis. To avoid acidic interference, agar was neutralized
with 0.2% sodium bicarbonate.

The production of nisin and lacticin bacteriocins was confirmed by
overlaying both lactocococin producers with L. lactis cremoris H.P.
which is highly susceptible to both bacteriocins (not shown).

3.4.5 Broth-based assessment of purified nisin and lacticin against M.
Smegmatis
Prompted by previous results which highlighted the adverse effect media
may have on bacteriocin activity, it was decided to assess the activity of
purified lacticin 3147 and nisin against M. smegmatis using broth based
assays. Purified lacticin and nisin were made available by UCC. In
contrast to agar-based approaches, these assays established that lacticin
3147 also possesses potent activity against M. smegmatis (Fig. 3.5).
Both nisin and lacticin had MIC values of 25p,g/ml against M. smegmatis
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(lO^CFU/ml). Strong inhibition was also noted at a concentration of
12.5gg/ml for both bacteriocins (Fig. 3.5 and Fig. 3.6). Assays were run
as a single experiment due to a lack of purified nisin and lacticin.
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Fig. 3.5 : MIC assay of lacticin 3147 on Mycobacterium smegmatis (2x10 CFlJ/ml) at concentrations of
50fig/ml, 25fig/ml, 12.5/jg/ml, and 6.25jug/ml. The MIC value was determined as 25fig/ml. Strong
inhibition of M. smegmatis was also seen at I2.5/jg/ml. Lacticin 3147 peptides LtnAI and LtnA2 were
added at a I : I ratio.
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MIC assay of nisin on Mycobacterium smegmatis (2xJ(/’ CFU/ml) at concentrations of

50fig/ml, 25/4g/ml, I2.5fjg/ml, and 6.25/jg/ml. The MIC value was determined as 25jug/ml. Strong
inhibition of M. smegmatis was also seen at 12.5fig/ml.

3.5

DISCUSSION
With the ever emerging threat of antibiotic resistant bacteria

worldwide, the search for novel antimicrobials to supplement or even
one day replace existing antibiotics is of paramount importance.
Mycobacteria are one species which are causing growing concern,
especially since the emergence of multidrug resistant (MDR) and
extensively drug resistant (XDR) M. tuberculosis. One class of novel
antimicrobials which have attracted much attention as therapeutic agents
are the antimicrobial peptides. Peptides produced by eukaryotic cells
known as defensins have already been marketed and have demonstrated
significant potency against a wide range of pathogenic bacteria. Similar
proteins produced by bacteria (bacteriocins) have also been identified
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for potential therapeutic applications with some already marketed for
veterinary use/’ These bacteriocins are gene encoded, can be easily
modified, may have dual modes of action and are active against drug
resistant pathogens.

Previous studies have already demonstrated a diverse range of
Staphylococcus (bacteriocins produced by Staphylococcus species)
including Bac

C55^, 414,^' IYS2^^, lysostaphin^^ and the

epidermidins.^"^ Interestingly, previous studies have demonstrated that
some of these peptides inhibit the growth of numerous mycobacterial
species, most likely through cell wall lysis.

In this study 8 known antimicrobial producers were screened for
anti-mycobacterial activity. These bacteria had previously demonstrated
significant activity against other Gram-positive strains but had not been
tested against the more robust mycobacteria. Four of these bacteria
produced bacteriocins and four produced cyclic di-peptides. A total of
seven of the eight strains tested displayed significant activity against M.

smegmatis. One strain, the cyclic di-peptide producing L. plantarum
TMW, did not exhibit any activity against M. smegmatis (Fig. 3.1).
However, the other three cyclic di-peptide producing bacteria
demonstrated significant activity against M. smegmatis, even when the
acidic effect was neutralized. When the acidic effect was not
neutralised, extremely strong inhibition of M. smegmatis was seen,
presumably conferred by a combination of lactic and phenyllactic acid.
Previous studies have identified lactic acid, phenyllactic acid and the
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two cyclic di-peptides cyclo (1-Leu-l-Pro) and cyclo (l-Phe-l-Pro) as the
major components responsible for inhibition by L. plantarum FST 1.7.
18

Interestingly, L. plantarum FST 1. 7 demonstrated the most potent

activity against M. smegmatis while L. plantarum FST 1.9 demonstrates
no activity. The only difference between the antimicrobials produced by
both strains is that L. plantarum FST 1.7 also produces cyclic di-peptide
cyclo (1-Leu-l-Pro) while L. plantarum FST 1.9 does not. Therefore,
cyclo (1-Leu-l-Pro) may be the active compound conferring inhibition to
L. plantarum FST 1.7.

This bacterium has previously been shown to be inhibitory to a
wide range of organisms including moulds. The other Lactobacillus
species L. amylovorous (LA) also demonstrated significant inhibition.
Additionally, W. ciharia, also displayed strong anti-mycobacterial
properties. An adverse characteristic of these compounds was their high
affinity for plastic which reduced their concentrations significantly
during preparation. However if they are cultured in glassware and not
exposed to plastic they have been shown to maintain their potency (Fig.
3.1). This affinity for plastic may be advantageous in future
purification studies but significantly impeded its routine use.

Initial evaluation of the bacteriocins suggested that all but lacticin
3147 displayed activity in agar based assays. However, it was
established that media composition played a significant role in the
ability of the staphylocococins to be produced and/or to inhibit M.
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smegmatis. When S. neuman and S. aureus C55 were cultured in BHI
medium (Fig. 3.2 and Fig. 3.3), both demonstrated potent activity when
overlaid with h4. smegmatis. However, the inhibitory activity of both
bacteriocins decreased dramatically when cultured on Tryptic Soy Agar
and no activity was seen when grown on nutrient agar and Muller Hinton
agar. Based on these results, it is apparent that some ingredients in the
media adversely affect the production and/or the mode of action of these
staphylocococins.

The Lactocococins nisin and lacticin 3147 produced by L. lactis
NZ9700 and L. lactis 3147 respectively were also initially assessed in
agar based assays. Although nisin was active against h4 smegmatis,
lacticin 3147 demonstrated no activity. The media was not altered on
this occasion as numerous previous studies have reported potent activity
of lacticin producing L. lactis when grown on GM17 agar against a wide
range of test strains. Therefore, the lack of inhibition by lacticin against
M. smegmatis is most likely due to the cell wall of mycobacteria. To
determine if the agar also played an adverse role in physically
preventing lacticin peptides LtnAl and LtnA2 from binding at the
mycobacterial cell wall, broth based assays were also performed using
purified nisin and lacticin (UCC). In contrast to agar based assays,
these broth based assays highlight the potent activity of lacticin against
mycobacteria. MIC assays confirmed minimum inhibitory concentration
values of 25pg/ml for both lacticin and nisin (Fig. 3.5 and Fig. 3.6).
Strong inhibition of M. smegmatis was also seen at 12.5pg/ml. These
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inhibitory values are similar to inhibitory concentration of the front line
anti-mycobacterial drug isoniazid which had an MIC value of 4-16
|ig/ml against M. tuberculosis AWC.

In summary, 7 of the 8 antimicrobial producing isolates obtained
from UCC demonstrated significant activity against mycobacteria and
merit further investigation. As both lacticin and nisin demonstrated
activity in a purified form and were produced by organisms with GRAS
status, it was decided to investigate their anti-mycobacterial activity
against a cohort of pathogenic mycobacteria.
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4.1 ABSTRACT
The aim of this study was to use the micro tit re alamarBlue assay
(MABA) to investigate and compare the anti-mycobacterial efficacies
of the lantibiotics nisin and lacticin 3147 against a representative
cohort

of clinically

significant

mycobacteria,

i.e.

Mycobacterium

tuberculosis H37Ra, Mycobacterium avium paratuberculosis ATCC
19698 (MAP) and Mycobacterium kansasii ClTll/06. Triplicate assays
indicated that lacticin 3147 displayed potent activity against all strains
of mycobacteria with MIC90 values of 60mg/L and
kansasii

and

MAP,

respectively.

Lacticin

3147

15mg/L for M.
was

particularly

effective against M. tuberculosis (H37Ra) with an MIC90 value of 7.5
mg/L. Nisin, although inhibitory, was generally less potent against all
strains of mycobacteria with MIC90 values of 60 mg/L for M. kansasii,
and >60 mg/L for MAP and M. tuberculosis (H37Ra). Thus lacticin
3147 is a potent anti-mycobacterial peptide which shows superior
activity over nisin at physiological pH.
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4.2 INTRODUCTION
The extent and diversity of mycobacterial disease is a global
problem, impacting significantly on both human and animal health.
Mycobacterium tuberculosis is a Gram-positive pathogen which is the
main etiological agent of tuberculosis, and recent statistics from the
World Health Organization (WHO) estimate that there were 9.27 million
incident cases of TB in 2007.* Furthermore, with an estimated 500,000
Multi Drug Resistant Tuberculosis (MDR-TB) cases reported and at least
one case of extensively drug resistant TB (XDR-TB) reported in 55
countries and territories by the end of 2008,* the identification and
development of novel antimicrobial compounds is now more important
than ever. However, with the exception of rifabutin and rifapentine, no
novel drugs have been marketed for TB in the 40 years after the release of
rifampicin. An additional worry is the increasing number of pathogenic
mycobacteria other than tuberculosis (MOTT), which are being implicated
as causative agents of disease,

especially in AIDS patients. One such

species, Mycobacterium avium paratuberculosis (MAP), the etiological
agent of Johne's disease in animals, has caused significant controversy
with reports suggesting its association with Crohn’s disease in humans.
Another Mycobacterium, M. kansasii, is responsible for serious pulmonary
infections
arthritis.

and

some

non-life

threatening

infections

such

as

septic

n

In recent years an enhanced appreciation for the efficacy of
the antimicrobials known as lantibiotics has resulted in them being the
focus of much attention as a possible alternative to current antibiotic
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O

1 c

regimes. '

Lantibiotics are gene encoded, post-translationally modified
o

antimicrobial
lanthionine

peptides

and/or

which

are

distinguished

p-methyllanthionine

residues,

by

the

unusual

dehydrated

serines

o

and/or threonines. To date more than 50 different lantibiotics have been
identified with different structures and modes of action,

and recent

comprehensive reviews on lantibiotics have highlighted their potential
therapeutic applications.’^''^

Nisin A and lacticin 3147 are two

of the most extensively

characterized lantibiotics. Nisin is the prototypical lantibiotic and it has
been approved by the U.S Food and Drug Administration for inclusion in
food and veterinary products.Lacticin 3147 differs from nisin by
virtue of requiring two peptides for optimal activity, i.e. Ltna and Ltnp
(formerly LtnAl and LtnA2).’^ Notably, both nisin and lacticin 3147 are
active at nanomolar concentrations'^ and can inhibit antibiotic resistant
bacteria.

Moreover,

both

antimicrobials

possess

more

than

one

mechanism of action in that they inhibit peptidoglycan synthesis and
form

pores

in the

membranes

of target

cells.

Both

activities

facilitated by binding to the peptidoglycan precursor, lipid II

'

are
(Fig.

4.1), unlike some conventional anti-mycobacterials such as rifampicin,
which require transportation across the plasma membrane before they
can be effective.

22
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Fig. 4.1; Amino acid structures of nisin (a) and lactic in 3147 Ltna (b). Lacticin
3147 requires the presence of the sister, Ltn^, peptide (not shown) for activity. The
lipid II binding region of nisin, adapted from Hsu el al,^^ and the predicted binding
sites of Ltna, as predicted by Cotter et al,^'* are highlighted in grey.

It is notable that the structure of mycobacterial lipid II differs from all
other bacterial lipid II structures investigated to date. This is due to an
alternative synthesis pathway as well as modifications on both the NAcetyl

Muramic

acid

and

the

peptide

side

chain

components.

Peptidoglycan synthesis in mycobacteria is depicted in Figure 4.2. While
nisin has been found to be active against non-pathogenic Mycobacterium
smegmatis and Mycobacterium bovis strains,neither it nor lacticin
3147

have

been

comprehensively

assessed

with

respect

to

their

antimicrobial activity against clinically significant human and animal
mycobacterial pathogens. The purpose of this study therefore was to
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assess the efficacy of both bacteriocins against a representative cohort
of pathogenic mycobacterial species.

Capsule
pohsacdtandes

NAG
AA colic acid layer"
Arabmogalactan
Pepridogh can

NAM

8

Modifications
1 'H COCH-HN-aceytlior COCH tX-gh-coi:

:

^ I

i,______ i...j

Pyrophosphate

Cytoplasmic membrane
Upid n

2 = OH NH2 Of OCH3

t

3 = OH. NH2 or OCH3

4 = OH. NH2 or OCH3

Lipid I

5 = Deca hepta and octa prenyl pPosphate

Cy loplasm

/|\

(Pol-P carrier)

L‘DP-MurN'Ac-pnii:q>q:inds

O =NAM

fT] =.Alanine

O =NAG

fil = Glutamic Acid

= Pyrophosphate

ftT) = Lysine

Fig. 4.2: Schematic cross section of the mycobacterial cell envelope. The model
shows the later stages of Mycobacterium lipid II assembly (right) and the
subsequent synthesis of peptidoglycan from its precursor lipid II. Also shown (left)
are the natural modifications (1-5) observed within the mycobacterial lipid II as
outlined by Mahapatra et al.^^ Modifications are seen on the N-aceytl region
(COCH3) of NAM (I), the carboxyl group of the glutamic acid (2), lysine (3) and
the terminal alanine (4) of the pentapeptide. The lipid moiety (Pol-P) is decaprenyl
phosphate (5) which differs from the usual lipid moiety (undecaprenyl phosphate)
identified in all other bacteria investigated to date.
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4.3 MATERIALS AND METHODS

4.3.1 Mycobacterial strains and culturing conditions

Mycobacterium kansasii CITll/06 (10 days) and M. tuberculosis H37Ra
(11 days) were routinely grown at 37°C in Middlebrook 7H9GC broth
(MB) (Sigma-Aldrich, Arklow, Co. Wicklow, Ireland) supplemented
with glycerol (0.2%) and 10% oleic acid-albumin-dextrose-catalase
(OADC) (Unitech, Dublin, Ireland). MAP ATCC 19698, also grown in
MB containing OADC, was supplemented with 0.2% mycobactin J
(Synbiotics Europe, Lyon, France) and was incubated at 37°C for 8-12
weeks. All strains were stocked in 40% glycerol and stored at -80°C.

4.3.2 Purification of lacticin 3147 and nisin A

The lantibiotics were purified as described previouslyThe
producing cultures Lactococcus lactis MG 1 363pMRC01 pOM02 (lacticin
3147) and L. lactis NZ9700 (nisin) were grown overnight at 30°C in two
liters of modified tryptone yeast broth. After centrifugation at 7000
r.p.m for 15 minutes, the cell pellet was re-suspended in 300ml of 70%
isopropanol (adjusted to pH 2) without trifluoroacetic acid (TFA), in
the case of lacticin and 70% isopropanol with 0.1% TFA for nisin.
Peptides were concentrated via centrifugation and rotary evaporation of
the supernatant (adjusted to pH 4) before being applied to a lOg (60ml)
Varian C-18 Bond Elut Column (Varian, Harbor City, CA) pre
equilibrated with methanol and water. The columns were washed with
100 mis of 20% ethanol and peptides were eluted in 100 mis of 70% IPA
0.1% TFA. Aliquots (15 ml) were concentrated to 2 ml through the
118

removal of propan-2-ol by rotary evaporation. 1.5ml aliquots were
applied to a Phenomenex (Phenomenex, Cheshire, UK) C12 reverse
phase (RP)-HPLC column (Jupiter 4u proteo 90 A, 250 x IQ.O mm, 4pm)
equilibrated with 25% propan-2-ol and 0.1% trifluoroacetic acid (TFA).
The column was subsequently developed in a gradient of 30% propan-2ol containing 0.1% TFA to 60% propan-2-ol containing 0.1% TFA at a
flow rate of 1.2 ml/min. Active fractions were pooled, lyophilized and
stored at -80°C.

4.3.3 Preparation of mycobacterial cells for the MABA assay

Owing to the slow-growing nature of pathogenic mycobacteria, standard
agar and broth MIC assay methods were deemed insufficient for accurate
analysis. Thus, the reliable and established microtitre alamarBlue assay
(MABA) method of detection was employed.

'

Isolates of M. kansasii,

MAP and M. tuberculosis were grown in MB broth as described above.
At log phase, a

10 ml culture of each mycobacterial strain was

centrifuged at 15,000 rpm for 20 minutes using a bench top centrifuge.
After the removal of the supernatant, the pellet was washed in fresh MB
broth and re-suspended in 10 ml of fresh supplemented MB broth. The
turbidity was

adjusted to

match

McFarland

standard

no.l

(3x10^

CFU/ml) with MB broth. A further 1:20 dilution of the culture was then
performed in MB broth to generate a sufficient volume of culture.
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4.3.4 Determination of minimum inhibitory concentrations against
clinical isolates using the microtitre alamarBlue assay
Sterile deionised water (300|il) was added to all outer-perimeter wells of
a 96 well plate to minimize evaporation of the medium in the test wells
during incubation. In the same 96 well plate, a serial 1:2 dilution of
each lantibiotic (lacticin 3147 contained equimolar concentrations of
both Ltna and LtnP) was then performed in MB broth (lOOpl). The final
concentrations ranged from 0.11 mg/L to 60 mg/L and each dilution
series was prepared in triplicate. Positive controls were prepared by
adding lOOpl of the appropriate mycobacterial strain to lOOpl to
lantibiotic free broth. Negative controls contained no bacterial cells.
Positive and negative controls were also prepared in triplicate.
Subsequently an equal volume of the mycobacterial strain to be assessed
was transferred to each well under investigation. The plates were sealed
with parafilm and incubated at 37°C. Following incubation for 3 days, 7
days and 1 1 days for M. kansasii, M. tuberculosis and MAP,
respectively, 20pl (10% of the final volume in the well) of a fresh
alamarBlue reagent (AbD Serotec) were added to each well and the
plates were re-incubated for 24 hours after which time absorbance at 570
and 600nm was determined. Subsequent percent reduction values based
on alamarBlue conversion were determined using the appropriate
formula^' and the relative growth in each well was compared to that of
the positive control. The MIC90 was defined as the lowest concentration
of lantibiotic which prevented the growth of over 90% of the bacterial
population, relative to the positive control.
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4.4 RESULTS

4.4.1 AlamarBlue-based MIC determination
AlamarBlue is a redox indicator that yields a colorimetric change in a
response to metabolic activity.

Relative inhibition of mycobacteria by

nisin and lacticin 3147 was assessed by quantifying the absorbance
(570nm and 600nm) of all wells to facilitate the calculation of dye
reduction

values

remained

blue

(%)

(i.e.

using

low dye

the

appropriate

reduction

formula.

values)

were

o 1

Wells

indicative

that
of

inhibition of the target strain, while wells which turned pink (high dye
reduction values) were indicative of growth.

From these calculated dye reduction values, the relative growth
(%) and corresponding inhibition values were obtained, taking the value
of the positive control in each case as 100%. From these values it was
possible to determine the MIC90 value, which is defined as the lowest
concentration of lantibiotic which prevented the relative growth of more
than 90% of the target strain. Overall, the relative growth of all test
strains varied from 1.2% to 71.6% under the experimental conditions
examined. To reflect physiological pH, assays were carried out at pH 7.
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4.4.2 MIC90 values for nisin and lacticin 3147 against M. tuberculosis

M. tuberculosis H37Ra was the most sensitive strain with an MIC90
vaiue of 7.5mg/L (Fig. 4.3). At this coneentration, the relative growth of

M. tuberculosis was inhibited by 91%. Increasing the lacticin 3147
concentration further resulted in even greater inhibition and culminated
in 98.8% inhibition in the presence of 60mg/L (the highest concentration
of lacticin 3147 employed). Interestingly, lacticin 3147 also exhibited
activity at the lowest concentration employed, i.e. O.llmg/L, where over
50.3% inhibition was observed.

With respect to nisin, the highest concentration of the lantibiotic
used, i.e. 60mg/L, failed to inhibit the pathogen by 90% and thus the
MIC90 value was recorded as >60mg/L. The assays performed did permit
some insight into the sensitivity of the strain to nisin in that it was
shown that nisin inhibited 76.3% of the M.

tuberculosis culture at

60mg/L nisin. At 30mg/L nisin, 68.2% of the M. tuberculosis growth
was inhibited and subsequent dilutions of nisin established that nisin is
still active at concentrations as low as 0.11 mg/L, as demonstrated by
50.9% inhibition at this concentration (Fig. 4.3).
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Fig, 4.3: Relative growth of Mycobacterium tuberculosis H37Ra in the presence of
nisin A and lacticin 3147.

4.4.3 MIC 90 values for nisin and lacticin 3147 against M. kansasii

Of the strains tested M. kansasii CITll/06 was the least susceptible to
lacticin 3147 with an MIC90 value of 60mg/L, Relative growth inhibition
was 93% at this concentration (Fig. 4.4). Below 15mg/L, the potency of
lacticin 3147 became significantly decreased. However, even at the
lowest concentration of lacticin 3147 employed (0.1 Img/L), activity was
still apparent as represented by a 29.2% inhibition of M. kansasii (Fig.
4.4). In comparison, nisin was more active against M. kansasii CITll/06
than the other strains tested with an MIC90 value of 60mg/L. At this
concentration, 94.5% inhibition of M. kansasii growth was noted. This
dropped to 67.5 % inhibition at 30mg/L nisin and, as expected, even
further for the lower concentrations. However, even at the lowest
123

concentration of nisin tested (O.llmg/L), inhibitory activity was still
detected (30.3% inhibition) (Fig. 4.4).
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Fig, 4.4: Relative growth oj Mycobacterium kansasii ClTl 1/06 in the
presence of nisin A and lacticin 3147.

4.4.4 MIC90 values for nisin and lacticin 3147 against MAP

For lacticin 3147, the MIC90 for MAP ATCC 19698 was 15mg/L (90.6%
reduction). Furthermore, 95.2% and 94% inhibition of the MAP culture
were recorded at concentrations of 60mg/L and 30mg/L, respectively,
while strong inhibition, 86%, was also observed when 7.5 mg/L lacticin
3147 was utilized (Fig. 4.5). At the lowest concentration employed,
O.llmg/L, lacticin 3147 successfully inhibited more than 50% of the
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MAP population. Although nisin showed quite good efficacy against
MAP, 60mg/L failed to bring about 90% inhibition with inhibition
peaking at 81% (Fig. 4.5). A decrease in efficacy was seen with lower
concentrations of nisin, with moderate activity still apparent at very low
concentrations (0.46-0.11 mg/L) (Fig. 4.5).

Fig. 4.5; Relative growth of Mycobacterium avium paratuberculosis ATCC 19698 in
the presence of nisin A and lacticin 3147.

4.4.5 Comparison of the relative unti-Mycobacterium activities of
lacticin 3147 and nisin

Under these experimental conditions, lacticin 3147 consistently showed
superior activity at higher concentrations (Table 4.1). M. tuberculosis
was the most susceptible species of mycobacteria, particularly to
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lacticin which was at least 8 times more potent than nisin (Fig. 4.3).
Lacticin 3147 brought about as much as 38% greater inhibition at
equivalent concentrations compared to

nisin

(7.5mg/L).

While this

difference in relative growth remained relatively constant between the
concentrations of 15mg/L-7.5mg/L, below 0.93mg/L both nisin and
lacticin 3147 had an equivalent inhibitory effect against M. tuberculosis.

Lacticin 3147 also exhibited superior potency against M. kansasii
(Fig. 4.4), with 3 1 % less relative growth in the presence of lacticin 3147
when compared with nisin (15mg/L).

Although the MIC90 values for

both lantibiotics were the same, the general trend of inhibition indicated
that lacticin 3147 was more potent. However, at concentrations lower
than 1.8mg/L, the activity of both lantibiotics was comparable.

Lacticin 3147 also displayed strong inhibitory activity against
MAP with an MIC90 value at least 4-fold lower than that of nisin
(15mg/L and <60mg/L respectively) (Fig. 4.5). As with the other two
strains,

both

lantibiotics

had

similar

inhibitory

capacity

at

lower

concentrations (e.g. O.llmg/L). The difference in % relative growth
between

both

lantibiotics,

(23.6-24.6%

relative

growth),

almost constant over concentrations of 1 5mg/L-3.75mg/L
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remained

MICgo (mg/L)

Lantibiotic
M. tuberculosis
H37Ra

M. kansasii
CITll/06

MAP
ATCC19698

Lacticin 3147

7.5

(+/- 0.36)

60

(+/- 0.75)

15

(+/- 0.30)

Nisin

>60

(+/-0.18)

60

(+/-0.13)

>60

(+/- 2.02)

Table 4.1; MlCyo values of lacticin 3147 and nisin against pathogenic
mycobacteria. MIC^o, lowest concentration of lantibiotic that prevented
growth of >90% of the bacterial population relative to the positive
control; MAP, Mycobacterium avium subsp. paratuberculosis

4.5

DISCUSSION

Antimicrobial

peptides

therapy

many

with

are rapidly

peptides

becoming a realistic

demonstrating

potent

alternative

activity

against

pathogens in clinical trials. "" Although bacteriocins are traditionally
associated with food applications,

it is evident from the literature that

they possess notable levels of activity against clinical pathogens.'
This study is important in that it is the first occasion upon which the
efficaey of lacticin 3147 against a Mycobacterium sp. has been tested
and compared with the aetivity of nisin. It is also significant that the
mycobacteria chosen for this study (which are implieated in both human
and animal disease) showed considerable susceptibility to both agents.
This study also establishes lipid II as a promising anti-mycobacterial
target

and

confirms

that

the

binding

of the

bacteriocins

to

the

mycobacterial lipid II is not compromised by the extensively modified
lipid II strueture in myeobacteria.
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The microtiter alamarBlue assay (MABA), previously used to
detect

the

viability

of

MAP

(chapter

2),

facilitated

the

rapid,

inexpensive and accurate evaluation of the anti-mycobacterial activities
of both nisin

and

lacticin.

Of the two

lantibiotics,

lacticin

3147

demonstrated greater potential as a therapeutic agent. This can be
attributed to its activity at physiological pH 7, which contrasts with that
of nisin which is poorly soluble, and thus less active, at this pH.

’

The

lower activity of nisin at physiological pH has reportedly also been an
issue with

respect to

pathogens.

its use

in the treatment of mastitis-causing

From the data presented here it is apparent that lacticin

3147 inhibits mycobacteria at concentrations which are comparable to
those of antibiotics currently employed against these pathogens.
These values are in some cases superior to those of the first line antimycobacterial drug isonazid which had MIC values of 4-16mg/L against
M. tuberculosis, as determined by Wanger et al

39

Whilst the in vitro efficacy of lacticin 3147 against mycobacteria
is encouraging, stability, delivery and in vivo efficacy studies will all
need to proceed before the true potential of the lantibiotic as a clinical
anti-mycobacterial
mycobacteria

to

can
reside

be
in

assessed.
the

The

unique

phagosomal

site

ability
within

of

some

pulmonary

macrophages makes their eradication extremely difficult. Moreover, the
delivery

of

anti mycobacterial

agents

which

traverse

the

plasma

membrane and maintain stability and activity is rare. However, recent
studies have demonstrated that administration of bacteriocins as a
128

complex with liposomes provides a successful mechanism of delivery
and inhibition, thus prolonging survival time of mice in an acute
tuberculosis model/’ In this context, lantibiotics undoubtedly possess
sufficient potential to merit further investigation.
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CHAPTER 5

CHAPTER 5

The bioengineered lantibiotics, nisin S, T and V,
display enhanced potency against clinically signiflcant
mycobacteria

Published in Bioengineered Bugs 2010; 1(6): 1-5
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5.1 ABSTRACT

Nisin A is the most widely characterized lantibiotic investigated
to date and has been the focus of much interest as a potential therapeutic
agent.

Consequently,

this

has

resulted

in

the

search

for

novel

lantibiotics and more commonly, the engineering of novel variants from
existing peptides with a view to increasing their activity, stability and
solubility.
The objective of this study was to evaluate the activity of 4 novel
nisin variants which have previously demonstrated activity against other
Gram-positive species. Three variants, Nisin S (K22S), Nisin T (K22T)
and Nisin V (M21V) displayed enhanced anti-mycobacterial activity
when compared to the native nisin A peptide. The fourth, (Nisin P)
exhibited only equivalent activity to nisin A and as a consequence was
excluded from subsequent testing. All variants have previously been
identified as having a single mutation on the hinge region of the nisin
(e.g. K22S had a lysine (K) substituted with a serine (S) at position 22
of the peptide).
The

microtitre alamarBlue

assay

(MABA)

was

employed

to

identify the enhanced activity of these novel variants against M.
tuberculosis

(H37Ra),

M.

kansasii

(CITl 1/06),

M.

avium

subsp.

hominissuis (C1T05/03) and M. avium subsp. paratuberculosis (MAP)
(ATCC 19698) while M. smegmatis was used for screening the nisin
clone library, primarily because of its fast growing properties. Nisin S
was the most potent variant against M. tuberculosis, M. kansasii and M.
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avium subsp. hominissuis, retarding growth by a maximum of 29%
compared to Nisin A. Variations within sub-species were also observed.
For example, nisin S reduced growth of Mycobacterium avium subsp.
hominissuis by 28% and Mycobacterium avium subsp. paratuberculosis
(MAP) by 19%. In contrast, nisin T reduced growth of MAP by 27% and
M. avium hominissuis by 16%. Nisin S, Nisin T, and Nisin V are potent
novel anti-mycobacterial compounds, which have the capacity to be
further

modified,

potentially

generating

compounds

with

other

beneficial characteristics. This is the first report to demonstrate an
enhancement of efficacy by any bioengineered bacteriocin against
mycobacteria.
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5.2

INTRODUCTION
Mycobacterium tuberculosis, the etiological agent of tuberculosis

(TB), is responsible for approximately 9.27 million incident cases of TB
annually, resulting in approximately 2 million deaths.' The recent
emergence of drug resistant mycobacteria, particularly XDR-TB, has
prompted the World Health Organisation (WHO) to set clear objectives
to control this threat.' The rising incidence of human and animal
infection by non- tuberculosis mycobacteria (NTM) has also become a
serious public-health concern.

NTM can cause a broad spectrum of

diseases including pulmonary infections resembling tuberculosis^ and
extra pulmonary infections affecting lymph nodes, skin and soft tissue.
Among NTM, Mycobacterium avium subsp. paratuberculosis (MAP), the
causative agent of Johne's disease in ruminants, has been the focus of
much attention in recent years, partly as a consequence of its association
with Crohn's disease in humans.

Bacteriocins have been suggested as a possible alternative to
antibiotics for many drug resistant infections. '

This is due to their

multiple mechanisms of action, broad spectrum activity against a wide
variety of Gram-positive targets, gene encoded nature (making them
excellent templates for bioengineering) and their ability to be delivered
to the site of infection.However, although lantibiotics have been
extensively researched, little work has been done to investigate their
potential in treating mycobacterial diseases.'^
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Nisin
ineorporated

A

is

the

prototype

lantibiotic

and

has

been

safely

into a wide range of commercial products since its

acceptance by the Food and Drug Administration (FDA) as a food
additive in 1988.’^ As with all lantibiotics, synthesis of the mature nisin
peptide involves extensive post-translational modification resulting in
the

formation

of

methyllanthionine,

the
as

unusual
well

as

amino

acids

dehydrated

lanthionine

amino

acids.

Q

and

p-

Nisin

is

produced by Lactococcus lactis which is generally regarded as safe
(GRAS) for food applications. Furthermore, it is generally used as a
food preservative, although it has recently been applied therapeutically
in the form of an anti-mastitis product called ‘Wipe-out’ (ImmuCell
Corporation, 56 Evergreen Drive, Portland, ME04103).^

The bio-engineering of lantibiotics has been particularly useful
with respect to elucidating the importance of specific residues and
domains within the peptides.

In particular, the N-terminal region

responsible for binding lipid II in the cell wall of target cells was
elucidated, as was the C-terminal region which inserts into the cell
membrane to cause pore formation.

Most noteworthy is the work

focusing on the central hinge region which allows the aforementioned
domains to move relative to one another.'In contrast however, the
generation of lantibiotics with enhanced features has been infrequently
reported. There has however been some success, such as the generation
of nisin variants with enhanced solubility at neutral pH
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or increased

antimicrobial activity against non-pathogenic strains.

Interestingly it

has been established that modification of the hinge region in nisin Z (a
natural variant of nisin A which differs by only one amino aeid) led to
the identification of variants (N20K, and M21K) with increased efficacy
against

Gram-negative

Salmonella.

; o

Perhaps

species,
more

i.e.

Shigella,

significantly,

Pseudomonas

variants

with

and

enhanced

activity against specific Gram-positive pathogens, such as S. aureus, S.
agalactiae, and L. monocytogenes, have also been generated.'^ The
enhanced activity of three peptides, i.e. nisinK22T, N20P and M21V
(hereafter nisin T, P and V respectively), (Fig. 5.1) has been confirmed
against non-mycobacterial targets in studies with purified peptides.
However, nisinK22S (hereafter nisin S) has not been evaluated in
purified form to date.
Here we carry out an investigation to determine if any of
these four nisin variants display enhanced antimicrobial activity against
the unique cell wall of four representative species of pathogenic
mycobacteria.

Fig. 5.1: Amino acid structure of nisin A. Dark circles at the hinge region indicate
amino acid differences between nisin A and its derivatives nisin P, nisin V, nisin S
and nisin T.
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5.3 MATERIALS AND METHODS:
5.3.1 Bacterial strains and culturing conditions.
Four common infectious species of mycobacteria were chosen as targets
for antimicrobial activity studies. These were (period of growth in
brackets) Mycobacterium tuberculosis H37Ra (11 days), Mycobacterium
kansasii CITll/06 (10 days), Mycobacterium avium subsp. hominissuis
(CIT05/03) (10 days) and Mycobacterium avium subsp. paratuberculosis
(MAP) (ATCC

19698) (6-8 weeks). Each was routinely grown in

Middlebrook 7H9 broth (MB broth) (Sigma Aldrich), supplemented with
10% oleic acid-albumin-dextrose-catalase (OADC; Unitech), at 37°C.
Culturing

of

Mycobacterium

avium

subsp.

paratuberculosis

also

required the addition of 0.2% Mycobactin J (Synbiotics). The rapid
growing

Mycobacterium

smegmatis

MC2155,

also

grown

in

supplemented MB broth, was used as a mycobacterial indicator strain for
initial agar based assays.
L. lactis NZ9800 harbouring plasmid-associated nisin A and nisin
variants'^ were grown in M17 broth (10ml) (Oxoid) supplemented with
0.5% glucose (GM17), Chloramphenicol (lOpg/ml) and X-gal (5-bromo4-chloro-3-indolyl-p-D-galactopyranoside) (1 3pg/ml).

5.3.2 Nisin /i/Vigg variants provided by UCC
In a study by colleagues in UCC, saturation mutagenesis of the nisin
hinge region (N20, M21, and K22) (Fig. 5.1) revealed novel peptide
variants which demonstrated enhanced activity against several Gram139

positive species.’^ Saturation mutagenesis is an in vitro mutagenesis
strategy within a narrow region of a gene (in the case, the region
encoding the hinge region of the nisin peptide). It was employed to
generate all possible nisin hinge peptide variants. These variants were
subsequently screened for enhanced anti-mycobacterial activity. These
hinge mutants were generated using a high copy plasmid (pCI372nisA).
The corresponding wildtype control L. lactis NZ9800 pCI372nisA also
contained this plasmid to ensure comparable evaluation of inhibitory
activities.
To initially determine if clones demonstrated enhanced activity
over the wildtype nisin A producing strain, deferred antagonism assays
were performed by spotting lOpI of the nisin A producing strain L.
lactis NZ9800 pCI372-nisA and the relevant variant producers L. lactis
NZ9800 pCI372nisA-K22S,

L.

lactis NZ9800 pCI372nisA-K22T,

L.

lactis

NZ9800 pCI372nisA-M21V and L. lactis NZ98()0 pCI372nisA-N20P on GM17
agar plates and allowing them to grow overnight. Each spot was then
irradiated under ultra violet light for 10 minutes to kill the nisin
producing

L.

lactis

strains

and

subsequently

over-laid

with

supplemented MB agar (0.75% W/V agar) seeded with the fast growing
indicator strain M. smegmatis MC 155.

5.3.3 Purification of wildtype nisin A and hinge variants.

To determine if an enhancement of activity was a result of increased
production or increased potency, each variant was evaluated in purified
140

form. The unmodified nisin A peptide and the 3 nisin variants (nisin V,
nisin S and nisin T) were purified using the protocol described in
chapter 4.*^ Briefly, overnight cultures of L. lactis NZ9800pCI372
producing either nisin A or each of the nisin variants, were inoculated
into IL modified TY broth (1% inoculum) and incubated overnight at
30°C. Cells were harvested by centrifugation at 7000 r.p.m for 15
minutes. The cell pellet was re-suspended in 300 ml of 70% isopropanol
and

0.1%

trifluoroacetic

acid

(TFA)

(pH

2.0).

Peptides

were

concentrated using centrifugation and rotary evaporation. Following
HPl.C analysis, active fractions were eluted, lyophilized and stored at 80°C.'‘’

5.3.4 Analysis of the relative activities of enhanced nisin hinge
variants against a pathogenic cohort of pathogenic mycobacteria

The previously employed microtitre alamarBlue assay (MABA)

was

employed to detect viability of target mycobacterial cells in the
presence of each nisin variant.
The mycobacterial strains were grown to late log phase and a
10ml culture of each target strain was centrifuged at 15,000 RPM for 20
minutes using a bench top centrifuge (Model CR 4-12 Jouan Inc, U.K).
The supernatant was removed and the pellet was washed in fresh
Middlebrook 7H9GC broth. The pellet was then re-suspended in 10ml of
fresh supplemented MB broth (containing 0.2% mycobactin J in the case
of MAP) and adjusted to match McFarland standard no. 1 (3 x 10
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o

CFU/ml). A further 1:20 dilution of the culture was then performed in
MB broth.
The MABA was performed in triplicate in a sterile 96 well
microtitre plate. All outer perimeter wells were filled with sterile water
(300pl) to prevent evaporation of test wells. Positive controls (no nisin)
and negative controls (no mycobacterial cells) were included for each
test strain. Sub-lethal concentrations of wild-type nisin A or a variant
peptide were added to each well (containing lOOpl of the target strain)
at a final concentration of lOpg/ml (20pg/ml for MAP).

Following 24

hours incubation, 20pl of alamarBlue (AbD Serotech) (10% final volume
of the well) were added to each well. Subsequent readings were taken at
570 and 600nm over a 6-day period. Plates were covered and re-sealed
with parafilm and incubated at 37°C following each reading. The time
taken for a visual colour change in all wells varied from four days (M.
avium hominissuis) to thirteen days (MAP), with M. kansasii and M.
tuberculosis requiring four and six days incubation respectively.

The

activity of each nisin variant, relative to the wild-type nisin A, was
initially observed visually. Once the positive control produced a strong
colour change indicating cell viability, quantitative measurements of all
wells for each mycobacterial strain (in the presence of wildtype nisin A
and variants) were taken and calculated using the appropriate formula.
Background values from the negative controls were subtracted from each
test well.
In the case of each individual species of mycobacteria, the wildtype nisin dye reduction value was taken as 100% and the relative anti142

mycobacterial activity of each nisin variant was directly compared to
that. This was carried out separately for each individual test species due
to their differing growth rates.

5.4 RESULTS

5.4.1 Anti-mycobacteria activity of nisin hinge variants, nisin P,
nisin V, nisin S and nisin T which were identified in UCC

Four variants, (N20P (nisin P), M21V (nisin V), K22S (nisin S) and
K22T (nisin T) were selected for initial agar-based studies to assess the
anti-mycobacteria activity of the peptides compared to that of native
nisin A. Mycobacterium smegmatis was chosen as a target strain due to
its fast growing properties. This study indicated that nisin S, T and V all
possess greater anti-mycobacterial activity (as evident from zones of
inhibition; i.e. diameter of the colony - diameter of the total zone of
clearing) which were 2.2mm (nisin V), 2.7mm (nisin T) and 4mm (nisin
S), than their nisin A counterpart (the producer of which failed to
generate a measurable zone of clearing) (Fig. 5.2).

As nisin P did not exhibit enhanced activity it was excluded from
subsequent investigations. To more accurately assess the activity of
nisin S, T and V, these peptides were purified and equimolar (sublethal) concentrations were used to determine their activity against each
of the

four

species

of mycobacteria
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(Mycobacterium

tuberculosis

H37Ra, Mycobacterium kansasii, Mycobacterium avium hominissuis and
Mycobacterium avium paratuberculosis) using the MABA.

K

OT

WT

N20P

M21V

K22T

K22S

Fig. 5.2: Agar diffusion assay of nisin A and its derivatives Nisin P, Nisin V, Nisin
T and Nisin S, overlaid with M. smegmatis.

5.4.2 Efficacy of nisin S against four pathogenic mycobacteria

Variant nisin S exhibited the greatest activity against Mycobacterium
tuberculosis H3 7Ra, Mycobacterium kansasii, and Mycobacterium avium
hominissuis. This bioengineered variant more effectively inhibited all

four species than wild-type nisin A. M. kansasii was particularly
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susceptible as growth was reduced by 29% relative to that which
occurred in the presence of nisin A (Fig. 5.3). The sensitivity of M
hominissuis and

M.

tuberculosis was

comparable,

(28% and 26%

reductions in growth respectively), relative to that brought about by
nisin A (Fig. 5.3). MAP was the least susceptible in that there was only
a 19% increase in activity. Thus, a substitution of a lysine with a serine
at residue 22 (K22S), increased the efficacy of nisin A against a range
of mycobacteria by an average of 26%.

Nisin A

■ Nisin S

100 ji:
o

80 60 -

(U

o
X)

40 -

(L>

20 (U

Cd,

0 -

M. tuberculosis

M. avium subsp.
hominissuis

M. avium subsp.
paratubercuiosis

M. kansasii

Mycobacterium species

Fig. 5.3: Activity of nisin S (K22S) and wild-type nisin A against a cohort of
pathogenic mycobacteria. Efficacy was evaluated using alamarBlue colorimetric
indicator dye. Although inhibition by nisin A was apparent, the corresponding dye
reduction value was taken as 100% relative growth, facilitating direct comparison
of nisin A to the activity of nisin S.
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5.4.3 Efficacy of nisin T against four pathogenic mycobacteria

Nisin T also demonstrated enhaneed activity, relative to wild-type nisin
A, against the four targets. MAP was the most susceptible species in that
nisin T brought about a 27% decrease in growth relative to nisin A,
thereby establishing it to be the most potent anti-MAP variant. K22T
decreased the relative growth of h4. kansasii and M. tuberculosis by 24%
more than nisin A. K22T also caused 16% more inhibition than nisin A
against M. hominissuis (Fig. 5.4). It is noteworthy that while the
activities of nisin T and nisin S against M. tuberculosis and M. kansasii
were very similar, their relative activities against MAP and M avium
hominissuis, both subspecies of M. avium, varied. Overall, relative
mycobacterial growth was decreased by 23% when nisin T rather than
nisin A was employed.
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NisinA ■NisinT

M. tuberculosis

M. avium subsp.
hominissuis

M. avium subsp. M. kansasii
paratuberculosis

Mycobacterium species
Fig. 5.4; Activity of nisin T (K22T) and wild-type nisin A against a cohort of
pathogenic mycobacteria. Efficacy was evaluated using alamarBlue colorimetric
indicator dye. Although inhibition by nisin A was apparent, the corresponding dye
reduction value was taken as 100% relative growth, facilitating direct comparison
of nisin A to the activity of nisin T.

5.4.4 Efficacy of nisin V against four pathogenic mycobacteria

Variant nisin V also displayed potent activity against each species of
mycobacteria. This potency was enhanced relative to nisin A but was
reduced relative to that of nisin S and T. MAP was the most susceptible
species with a 23% decrease in relative growth, while potency was least
enhanced against M. tuberculosis (10% decrease in relative growth). The
growth of M. kansasii and M. avium hominissuis was reduced by 20%
and 16%, respectively, relative to that which occurred in the presence of
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nisin A (Fig. 5.5). Nisin V brought about an average 17% increase
inhibition relative to nisin A.

Nisin A ■ M21V variant

M. tuberculosis

M. avium subsp.
hominissuis

M. avium subsp.
paratuberculosis

M. kansasii

Mycobacterium species
Fig. 5.5: Activity of nisin V (M2 IV) and wild-type nisin A against a cohort of
pathogenic mycobacteria. Efficacy was evaluated using alamarBlue colorimetric
indicator dye. Although inhibition by nisin A was apparent, the corresponding dye
reduction value was taken as 100% relative growth, facilitating direct comparison
of nisin A to the activity of nisin T.

5.5 Discussion

Lantibiotics are well established anti-microbial agents with many
attractive

attributes.

They are

gene encoded,

active

against drug

resistant bacteria at low concentrations*^ and do not require access into
the mycobacterial cell to exert their effect, unlike conventional antimycobacterial drugs like rifampicin.

While the identification of nisin

derivatives with enhanced activity is itself a rare event, this is the first
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report to demonstrate the increased efficacy of any bioengineered
bacteriocins

against

mycobacteria.

Moreover,

this

reiterates

the

usefulness of MABA and its application as a viability indicator when
screening banks of bioengineered peptides. This may facilitate the rapid
identification of anti-mycobacteria compounds with enhanced activity,
stability, solubility and/or pH range.
Considering that the intentional mutagenesis of lantibiotics was
initiated in the early 1990s, ‘
enhanced

lantibiotic

it is somewhat surprising that such few

variants have been identified.

Recent work’^

employed saturation and site directed approaches in which enhanced
variants were identified, producing the first such peptides to display
enhanced activity against Gram-positive pathogens.
In relation to this work, the main objective was to evaluate the
efficacy of four nisin variants (nisin P, nisin S, nisin T and nisin V),
previously identified as having enhanced activity against other Gram
positive species.
Following initial screening assays using M smegmatis, it was
apparent that 3 (nisin V, nisin S, nisin T) of the 4 mutants also
displayed enhanced activity over the wildtype (nisin A) against M.
smegmatis (Fig. 5.2). The other variant (nisin P) had less or only equal
activity to the wildtype and therefore was not purified. Each enhanced
variant was subsequently purified and demonstrated significant activity
retarding 29% more growth than nisin A. The increased efficacy of nisin
S and nisin T is of particular interest in that both variants contain a new

149

incorporated hydroxy-amino acid at the same position but each has
differing activities. Interestingly each newly introduced residue, i.e.
valine, serine and threonine (in nisin V, S and T, respectively), were
much smaller than the residues initially present i.e. methionine (M) and
lysine (K). The corollary also seems to be true as the introduction of
larger residues such as arginine have previously been found to have a
negative impact against other targets.*^
Previous observations suggest that the enhanced activities of the
nisin variants are strain-and species-specific.'^ Sub-species fluctuations
are also apparent in this study i.e. variant nisin S reduced the growth of
M. avium hominissuis by 28% and MAP by 19% whereas nisin T
contrastingly reduced MAP growth by 27% and M. avium hominissuis
growth by 16%. It may be that a detailed understanding of the basis for
the enhanced activity of these peptides coupled with the creation of new
generations of bioengineered lantibiotics could yield new 1 anti biotic
variants with particular potency against species and sub-species of
pathogenic mycobacteria
The generation of species-specific lantibiotics with dual modes of
action would be an exciting step forward in the development of novel
anti-mycobacterial drugs. Moreover, as these variants are the result of
just a single nucleotide mutation on the nisin structural gene, it could
mean their acceptance may be more readily and rapidly facilitated by
food and clinical regulators.'^ In conclusion, the creation, identification
and evaluation of enhanced variants nisin T, nisin S and nisin V may
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represent the first step in producing species or even sub-species specific
bio-engineered anti-mycobacterial peptides.
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CHAPTER 6

CHAPTER 6

Evaluation of chemically engineered quinoline
derivatives as potential novel anti-mycobacterial drugs

Two manuscripts from this chapter have been published in
the journal Molecules:

1. Investigating the activity spectrum for ring-substituted 8hydroxyquinolines. Molecules. 2010 Jan 12; 15(1):288304.

2. Investigating biological activity spectrum for novel
styrylquinazoline analogues. Molecules. 2009 Oct
23;14(10):4246-65.

154

6.1 ABSTRACT
Quinolines have shown great potential in treating many fungal, and
bacterial infections, including many pathogenic mycobacterial infections
associated with AIDS. The widely known anti-mycobacterial drugs
quinolones are direct derivatives of quinolines, differing in structure by
the presence of a carbonyl group on carbon number 4 of the quinolone
moiety. In this study, the Microtitre alamarBlue Assay (MABA) was
employed to screen a total of 39 novel compounds, derived from two
classes

of quinolines

[(styrylquinazolines

(16

compounds)

and

8-

hydroxyquinolines (23 compounds)], for anti-mycobacterial activity.
These compounds were synthesised by colleagues in Zentiva (Czech
Republic) and were separated into series 1-5 based on their chemical
structure.

Series

1

styrylquinazolines

and
while

2

are

all

series

derived

3-5

are

from

the

derived

class
from

of
8-

hydroxyqui no lines.
In vitro anti-mycobacterial screening of the compounds was
performed against four species of mycobacteria (A/, smegmatis, M.
avium hominissuis, M. abscessus and M. kansasii) using the MABA.
Although most styrylquinazoline compounds (series 1

and 2) were

inactive, 3 compounds (5, 13 and 14) exhibited significant biological
activity,

in some cases outperforming the anti-mycobacterial drug

pyrazinamide.

With

the

exception

of M.

smegmatis,

compound

5

displayed potent activity against all test strains with MIC90 values as
low as 20pg/ml recorded against M. kansasii.
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The 8-hydroxyquinolines compounds (series 3-5) also exhibited
significant activity against some or all of the mycobacteria tested. Six
compounds (30, 32, 35, 36, 37 and 38) demonstrated biological activity
which was comparable to or higher than at least one of the antimycobacterial drugs isoniazid and pyrazinamide. With the exception of
compound 30, all 8-hydroxyquinoline compounds possessed either a
carboxyl group and/or a methoxy functional group which are responsible
for this potent activity. In particular, compound 32 inhibited all species
of mycobacteria tested while compound 38 was particularly potent
against M. smegmatis (MIC90 = <6pg/ml) and M. kansasii (26pg/ml).
Based

on

these

results,

one

styrylquinazolinone

(compound

5)

containing the functional group 2,4 OCH3, and two styrylquinazoline
compounds (compounds

13 and 14) containing respective functional

groups 2-OCH3 and 3-OCH3 displayed anti-mycobacterial activity. Of
the 8-hydroxyquinolone compounds, 6 displayed significant activity
against a wide range of anti-mycobacterial

species.

In particular,

compounds 32, 35, 36, 37 and 3 8 from series 5 all merit further
investigation as potential anti-mycobacterial drugs. All compounds
contained

either

a

carboxyl

and/or

a

methoxy

functional

group.

Compound 30 from series 4 also displayed activity against a number of
mycobacteria. Interestingly, this compound possessed an inverted copy
of the natural quinoline moiety linked by an aryl nucleus. Based on the
number of active quinoline compounds identified, the strategy of
generating chemical variants of current anti-mycobacterial compounds
should increase the pipeline of novel drugs.
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Although all anti-mycobacterial studies were performed in CIT, work
performed in the Check Republic is included to put the study into
context.

A

full

description

of quinoline

synthesis

is

provided

in

known

as

appendix 1 and 2.

6.2 INTRODUCTION
The

anti-mycobacterial

fluoroquinolones,

are

a

drugs
family

quinolones,
of broad

also

spectrum

synthetic

drugs

commonly used to treat bacterial, fungal and mycobacterial disease'"*^
including many pathogenic mycobacterial infections associated with
AIDS.*'^ Th eses drugs are direct derivatives of quinolines, differing in
structure by the presence of a earbonyl group on carbon number 4 of the
quinolone moiety (Fig 6.1).

Quinoline

Quinolone

Fig 6.1: Chemical structure of quinoline and quinolone molecules. The quinolone
molecule contains an additional carbonyl (C = 0) at carbon number 4.

The

most

active

representatives

of this

class

of compounds

are

designated fluoroquinolones, acquiring their name from the presence of
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a fluorine atom on the number 6 or number 7 carbon on the quinoline
moiety.
Fluoroquinolones are active against Mycobacterium tuberculosis
and are the first new anti-mycobacterial drugs to be available since the
discovery of rifampin.^ Fluoroquinolones include norfloxacin, ofloxacin,
pefloxacin, enoxacin, and ciprofloxacin

o

and are now part of the drug

regimens recommended for treating rifampin-resistant tuberculosis.^
Moreover, several new fluoroquinolones, such as sparfloxacin and
moxifloxacin demonstrate greater in vivo bactericidal activity against M.
tuberculosis than some anti-tuberculosis drugs.The mechanism of
action of the quinolone anti-bacterial agents is believed to result from
the combination of their abilities to penetrate into bacterial cells and to
inhibit

DNA gyrase, an essential bacterial enzyme that maintains

superhelical twists in DNA. 11-12
Since the description of the first quinolone
quinolone

analogs

have

been

synthesized.'"^

more than 10,000

This

had

led to

the

identification of many novel anti-mycobacterial drugs,including the
Di aryl quinolines,^ one of which (TMC207) has shown more potent
activity than current first line anti-mycobacterial drugs, thus leading to
clinical

trials.'^

TMC207

inhibits

a

novel

target,

namely

the

mycobacterial ATP synthase enzyme.^ Therefore, no cross resistance
with available drugs is expected since the target of the diarylquinolines
differs from that of the currently available anti-TB drugs.
Recently, a series of compounds derived from 8-hydroxyquinoline
and styrylquinazoline derivatives were synthesized by collaborators as
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The general structures of 8-hydroxyquinoIines and styrylquinazolines
are shown in Fig.6.2.

8-hvdroxvquinolines

Styrylguinoline

Styriyquinazolines

yX.

^

N'

OH :■

Hydroxyl group

Fig. 6.2. Structure of quinoline derivatives. The presence of a hydroxyl (OH)
functional group on the number 8 carbon characterises the 8-hydroxyquinolines
(left). The styrylquinolines are characterised by the presence of a styryl moiety
(highlighted in red) connected to the quinoline moiety by an ethendiyl spacer
(center). The aryl nucleus of the styryl moiety may contain substitution patterns of
functional groups in place of the R-group, thus generating distinct molecules with
varying structures and activities I'he styrylquinazolines differ from styrylquinolines
by the presence of a nitrogen (N) group (circled in green) at position number 3 of
the quinoline moiety (right). Additionally, styrylquinazolinones possess a carbonyl
group on the fourth carbon.

Both styrylquinazolinones (compounds

styrylquina. lines (compounds 12-16) were evaluated in this study.
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l-ll)

and

6.3 MATERIALS AND METHODS
6.3.1 Quinolines screened in this study

A total of 39 compounds, 16 styrylquinazolines (11 styrylquinazolinones
and 5 styrylquinazolines) and 23 8-hydroxyquinolines were screened for
anti-mycobacterial activity. A complete list of compounds is seen in
Table 6.1.

Name of compound

Class of compound

Substituted functional group

1

St>T>iquinazolinone

H

2

St>T>'lquinazolinone

2-OCH3

3

St>T>1qumazolinone

3-OCH3

4

St>T>^qumazoHnone

4-OCH3

5

St>T>'lquinazolinone

2.4-OCH3

6

St>Tvlqumazolinone

3-CL

7

St>T>'Iquinzizolinone

2-BR

8

St>T>'lqirinazolmone

3-BR

9

Styr>'lquinazolinone

4-BR

10

St>T>dquinazolmone

4-CHO

11

St>T>1quinazolinone

2.3.4-OH

12

St>T>'lquinazoIine

H

13

St>Tylquina2oline

2-OCH3

14

St>T>'lquinazoltne

3-OCH3

15

St>T>'lquinazoHne

4-OCH3

16

St>TylqumazoHne

2,4-OCH3

17
18
19

20
21
22
23
24

Hydroxyquinolines
Hydroxyquinolines
Hydroxyqumolines
Hydroxyquinolines
Hydroxyquinolines
Hydroxyquinolines
Hydroxyquinolines
Hydroxyquinolines

Position of substitution (R)

Series

5-N02
5-S03H-7-N02
.vS03H-7-Br
5-S02NHCH(CH3)2
.vS02NHC2H4Ph

OH

5-S02NHC4H8^

'r

Continued on page 161
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30

Hydroxyquinolines
Hydroxy quinoline s
Hydroxyquinolines
Hy dr oxy quinoHne s
Hydroxyquinoline s
Hydroxyquinoline s

31

Hydroxyquinoline s

25
26
27
28
29

2-OH
4-OH
2,4-OH
3,5-OH
2-OH-5-OAC

”rx
32

Hydroxyquinolines

33

Hydroxyquinolines

34

Hydroxyquinolines

5

35

Hydroxyquinolines

5

36

Hydroxyquinolines

5

37

Hydroxyquinolines

5

38

Hydroxyquinolines

..r

5
OM.

Hydroxyquinolines

39

o

Table

6.1:

A

OM

list of quinoline derivatives

5

^

evaluated

for anti-mycobacterial

activity. Compounds 1-16 are derived from styrylquinazolines while compounds 17-

39 are 8-hydroxyquinolines. The structures of the replacement functional groups are
seen in column 3.
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6.3.2 General procedures for synthesis of styrylquinazoline
derivatives (compounds 1-16)

All styrylquinazoline derivatives were prepared according to scheme
6.1. Compounds 1-11 (series 1) were synthesised as follows. A mixture
of compound 1 (scheme 1) (0.01 mol) and the appropriate aldehyde (0.02
mol) was mixed thoroughly and irradiated in monomode cavity of
microwave reactor using pulse sequence (3x5 minutes with 30 sec.
intervals) at 250 W. During irradiation, the temperature was controlled
between the range 150-180°C. After the reaction, the mixture was cooled
and washed with boiling ether. The product was crystallized from acetic
acid.

Compounds 12-16 (series 2) were synthesised using a mixture of
styrylquinazolinone derivatives

1-11

(scheme

1)

(0.01

mol), N,N-

dimethylaniline (0.02 mol) and phosphorus oxychloride (0.015 mol) in
dry benzene (50 mL). These were stirred and heated under reflux for 3 h.
The reaction mixture was then cooled and filtered. The filtrate was
diluted with benzene (30 mL) and the solution washed with water (50
mL), twice with 20 % aqueous NaOH (50 mL) and finally twice with
water. After drying with MgS04, the organic solvent was evaporated
and the product obtained was crystallized from heptane.
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o

o

0

d

4

0
,OH

Ci
N Compounds 12-16

ami Coadthom: a) Ac;0. MW; b) XH.;aq. MW: c) XH^CiHjOH. MW: d) alckhyde. MW:
e) POCIj.

Scheme 1. Synthetic pathway and general formula of prepared styrylquinazoline

derivatives.

6.3.3 Chemical structure of styrylquinazoline compounds
Sixteen

styrylquinazoline

derivatives

series

1

and

series

2

were

synthesised for in vitro evaluation against four mycobacterial strains. As
compounds 1-11 (series 1) possess a carbonyl group (=0) on the number
4 carbon these compounds are termed styrylquinazolinones (Fig. 6.2).
The R-group, attached to the quinoline moiety by an ethendiyl spacer,
contains various substitution patterns generating a series of distinct
compounds

with

differing

activities.

Compounds

12-16

(series

2)

contain the same general structure. However, the carbonyl group on the
carbon number 4 of the quinoline moiety is replaced by a Cl group.
Replacement of the functional groups on the number 4 carbon (circled in
red) is highlighted in figure 6.3.
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i

: 0‘:
r

ii
■n

r

.

.

I

^

-

-

^

■

Series 2

Series 1

Fig. 6.3: Chemical structure of series I and series 2 of the styrylquinazolinone and
styrylquinazoline compounds evaluated.

The introduction of the carbonyl group

(left) and the chlorine group (right) on the carbon number 4 of the quinoline moiety
are highlighted in red. The functional groups which replace the R~group on the
styryl moiety are listed in Table 6.1.

6.3.4 General procedures for synthesis of 8-hydroxyquinoiine
compounds 17-39 (series 3, series 4 and series 5)
All 8-hydroxyquinoline derivatives were prepared according to scheme 2
and scheme 3. Compounds 17-23 were obtained from 8hydroxyquinoline through chlorosulfonation and amination. Compound
24 was obtained from commercially available 8-hydroxy-2aminoquinoline by acylation in acetic anhydride. Styryquinolines 25-30
were obtained from 5,7-dichloro-8-hydroxyquinaldine and the
appropriate aldehyde in a two-step reaction in acetic anhydride followed
by pyridine/water. Compounds 31-39 were synthesised as previously
described.
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SO:;rCI

17-19, 24

Reagenii oTui condihonz a) HjSO+HNOi, Br:, Ac:0, b) ClSOvH, 0 *C, c) MeOH, amrae;

d) a)d«hydc. AcjO, P>'H:0.

Scheme 2. Synthetic pathway and general formula of prepared 8hydroxyquinoline derivatives 17-30.

Reagents and conditions, a) aldehyde, acetanhydride, pvTidine H^O; b) aniline, benzene,

reflux; c) HNO3/H2SO4. 0 °C.

Scheme 3. Synthetic pathway and general formula of prepared 8hydroxyquinoline derivatives 31-39.
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6.3.5 Chemical structure of 8-hydroxyquinolines
A total of 23, 8-hydroxyquinolines compounds (17-39) from series 3-5
were evaluated for their in vitro anti-mycobacterial activity against four
mycobacterial strains. The 8-hydroxyquinolines compounds from series
3 (17-24) are native quinoline moieties with functional groups replacing
the R-group on the benzene ring (Fig, 6.4). The hydroxyl group (OH),
providing the 8-hydroxyquinolines with their nomenclature, is seen at
carbon number 8.

Series 4 (compounds 25-30) have significantly larger and more
complex structures than Series 3.

The active quinoline moiety of this

series contains two chlorine (Cl) groups on carbon number 5 and carbon
number 7. Similar to the styrylquinazoline, this moiety is connected to
the substitutable R-groups by means of an ethendiyl spacer, possessing
various combinations of functional groups (Fig. 6.4). Although these
compounds contain this styryl moiety, they are still classed as 8hydroxyquinolines due to the presences of the hydroxyl group on the
quinoline moiety. The general chemical structure of compounds from
series 3 and series 4 are illustrated in Fig. 6.4.
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Series 3

Series 4

Fig. 6.4 .* Chemical structure of series 3 (left) and series 4 (right) of the 8hydroxyquinolines. Series 3 contain modification of the R-group directly on the
quinoline moiety. Series 4 possess an additional aryl nucleus connected by an
ethendiyl spacer. The quinoline moiety of series 4 contains two chlorine groups and
the aryl nucleus contains a pattern of substitution functional groups (9-14) in place
of the R-group.

Series 5 (8-hydroxyquinolines compounds 31-39) compounds were
categorised by the presence of methoxy (OMe) groups on the benzene
ring attached to the quinolone moiety and/or the presence of carboxyl
groups on the number 6 and 7 carbons (Table 6.1).

6.3.6 Mycobacterial strains and culture conditions
Clinical isolates of Mycobacterium avium complex (CIT19/06) (10 days
growth),

Mycobacterium

Mycobacterium

kansasii

abscessus

(CIT 11 /06)

(CIT21/06)

(5

(10
days

days

growth),

growth)

and

Mycobacterium smegmatis (mc(2) 155) (3 days growth) were grown from
stocks

(-80°C)

(10%

inoculum)

in

Middlebrook

broth

(MB),

supplemented with 10% OADC supplement (Becton Dickinson U.K.) and
0.2% glycerol.
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6.3.7 Evaluation of the anti-mycobacterial activities of quinoline
derivatives using MABA

At log phase growth, a 10ml culture of each species was centrifuged at
15,000 RPM for 20 minutes using a bench top centrifuge (Model CR 412 Jouan Inc U.K). Following the removal of the supernatant, the pellet
was washed in fresh Middlebrook 7H9GC broth and re-suspended in
10ml of fresh supplemented MB broth. The turbidity was adjusted to
match McFarland standard no. 1 (3 x 10^ CFU/ml) with MB broth. A
further 1:20 dilution of the culture was then performed in MB broth to
generate a sufficient volume of cells for the assay.

The antimicrobial susceptibility spectrum of each Mycobacterium
species was investigated against all 39 compounds using MABA. Sterile
deionised water (300|al) was added to all outer-perimeter wells of the
plates to minimize evaporation of the medium in the test wells during
incubation. Each species of mycobacteria (lOOpl) was then added to
wells

containing

dilutions

of each

compound.

Dilutions

of each

compound (lOOpl) were prepared in duplicate. For all synthesized
compounds, final concentrations ranged from 100 pg/ml to lOpg/ml. All
compounds were prepared in dimethy-sulfoxide (DMSO) and subsequent
dilutions were made in supplemented MB broth. The microtitre plates
were sealed with parafilm and were incubated overnight at 37°C in the
case of M. smegmatis and M. abscessus and for 5 days in the case of M.
kansasii and M. avium complex. Following incubation, 20pl (10%) of
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alamarBlue (AbD Serotec) were mixed into each well and readings were
taken at 570nm and 600 nm, initially as a background subtraction and
subsequently after 24 hours re-incubation. Background subtraction is
necessary for some compounds as their colour may interfere with
interpretation of any visual colour change. The MIC was defined as the
lowest concentration of drug which prevented the growth of 90% of the
mycobacterial

population relative to the

positive

control.

Percent

reduction values of the dye were calculated using the appropriate
formula. 21

6.3.8 In vitro anti-fungal susceptibility testing

The broth microdilution test was used for the assessment of in vitro
antifungal activity of the synthesized compounds against Candida
albicans ATCC 44859 (CA), Candida tropicalis 156(CT), Candida
krusei ATCC 6258 (CK), Candida glahrata 20/1 (CG), Trichosporon
asahii 1188 (TA), Aspergillus fumigatus 231 (AF), Absidia corymbifera
272 (AC), and Trichophyton mentagrophytes 445 (TM). Fluconazole
(FLU) was used as the standard of a clinically used anti-mycotic drug.
The procedure was performed with twofold dilution of the compounds in
RPMI 1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH
7.0 with 0.165 mol of 3-morpholinopropane-1-sulfonic acid (MOPS,
Sigma, Germany). The final concentrations of the compounds ranged
from 500 to 0.975 pmol/L. Drug-free controls were included. The MIC
was defined as an 80% or greater (IC80) reduction of growth in
comparison with the control. The values of MICs were determined after
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24 and 48 h of static incubation at 35 °C. For T. mentagrophytes, the
final MICs were determined after 72 and 120 h of incubation.

6.4

RESULTS:

6.4.1 In vitro anti-mycobacterial evaluation of styrylquinazoline
derivatives

Of the

16

styrylquinazoline

(compounds 5

an d

13)

derivatives

d emonstrated

tested,

two

in

particular

significant inhibitory activity,

principally against M. kansasii, M. avium complex and M. ahscessus
(Table 6.2).
Compound 5 had an MIC90 value of 80pg/ml for both M. avium

complex and M. ahscessus. It was far more potent against M. kansasii
with an MIC90 value of 20pg/ml (Table 6.1). Compound 13 had an MIC90
value of 80pg/ml and 60pg/ml against M.

avium complex, and M.

kansasii respectively (Table 6.2). Compound 14 also had an MIC value
of 60pg/ml against M. kansasii despite the fact it was inactive against
all other test strains. This suggests these three compounds act better
against M. kansasii. Compound 5 was more active than the first line
anti-tuberculosis drug isoniazid (INH) in the case of M. ahscessus.
Interestingly all compounds were inactive against M. smegmatis (Table
6.2).
With the available data it is difficult to attempt to determine any
structure-activity

relationships.

However,

it

is

noticeable

that

compounds from series 2, eontaining the chlorine group (Cl) on carbon
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4, seem to demonstrate higher anti-mycobacterial activity than the series
1 compounds containing the carbonyl group; i.e. 2 of the 5 compounds
of series 2 demonstrated activity whereas only 1 of the 11 series 1
compound had notable activity (Table 6.2).

M. smegmatis

MIC90
M. abscessus M. kansasii

M. avium complex

Series 1
1
2
3
4
5
6
7
8
9
10
11

>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
80
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
20
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
80
>100
>100
>100
>100
>100
>100

Series 2
12
13
14
15
16
INH
PZA

>100
>100
>100
>100
>100
39
>100

>100
>100
>100
>100
>100
>100
>100

>100
60
60
>100
>100
<10
>100

>100
80
>100
>100
>100
<10
>100

Table 6.2: MIC90 values of styrylquinazoline compounds I-l I (series I)
(styrylquinolinones) and 12-16 (series 2) against four mycobacterial species.
Compounds which exhibited MICgo values of interest are highlighted in red. These
values were compared to the controls isoniazid (INH) and pyrazinamide (PZA).
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6.4.2 In vitro anti-fungal susceptibility testing of styrylquinazoline
derivatives
All quinazoline derivatives 1-16 were tested for their in vitro antifungal
activity against eight fungal strains. The antifungal activity of all the
compounds were in the range from >125 to >500 pmol/L and therefore
as compounds have poor efficacies, their activities are not presented in
detail. The substitution of benzylidene part of the molecule by 3-OCH3
(3, 14) or 2,3,4-OH (11) seems to contribute to antifungal activity
within both series of compounds.

6.4.3 In vitro anti-mycobacterial evaluation of 8-hydroxyquinolines
Of the 23 8-hydroxyquinoline compounds tested, 6 demonstrated
significant efficacies against each of the four mycobacterial species
tested. No compounds from scries 3 (compounds 17-24) demonstrated
anti-mycobacterial activity. These compounds were smaller than the
larger compounds from series 4 (compounds 25-30) and series 5
compounds (31-39). Only one compound (compound 30) from series 4
demonstrated efficacy while 5 compounds (compounds 32, 35, 36, 37
and 38) were active in series 5.

Compound 30 demonstrated significant potency against M.
smegmatis (MIC90 = 40pg/ml) and M. kansasii (MIC90 = 40pg/ml) and
was more active than the anti-mycobacterial drug pyrazinamide (PZA).
Compound 30 also had comparable activity with isoniazid (INH) in the
case of M. smegmatis (Table 6.3). In a concurrent study, compound 30
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also demonstrated significant activity as an anti-fungal agent against

Candida albicans ATCC 44859 (CA), Candida tropicalis 156, (CT),
Candida krusei ATCC 6258 (CK), Candida glahrata 20/T (CG),
Trichosporon beigelii 1188, (TB), Aspergillus fumigatus 231 (AF),
Absidia corymbifera 272 (AC), and Trichophyton mentagrophytes 445
(TM). Fluconazole (FLU) was used as the standard of a clinically used
antimycotic drug.

Evaluation of the 8-hydroxyquinolines from series 5 revealed
substantial activity by five of the nine compounds tested, namely
compounds 32, 35, 36, 37 and 38 (Table 6.3). Compound 32
demonstrated the broadest spectrum of activity, inhibiting all species of
mycobacteria. This compound also exhibited significant activity with
MIC90 values of 26pg/ml against M. smegmatis and M. abscessus and
52pg/ml against M. kansasii and MAC (Table 6.3). In contrast,
compound 35 was active only against M. abscessus. Compound 36
displayed activity against all strains but M. smegmatis. Compound 37
demonstrated activity against M. kansasii and MAC with MIC90 values
of 26pg/ml while compound 38 was by far the most potent compound
with MIC90 values of <6pg/ml and 26pg/ml against M. smegmatis and M.

kansasii respectively (Table 6.3).
All other compounds were inactive against mycobacteria. All
active compounds were more potent than the anti-mycobacterial drug
pyrazinamide which had MIC90 values of greater than lOOpg/ml (Table
6.3). The other control compound isoniazid (INH) was also inactive
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against M. abscessus but demonstrated potent activity against all other
strains with MIC90 values of 39 gg/ml against M. smegmatis and <10
pg/ml against M. kansasii and M. avium complex (Table 6.3).
Nevertheless, with the exception of compounds 37 and 38, all active 8hydroxyquinolines from series 5 were more active against M. abscessus
than isoniazid, a first line anti-mycobacteria drug. Compound 32 was
also more active than isoniazid when tested against M. smegmatis.
Although isoniazid was more potent than all series 5 compounds against
M. kansasii and M. avium complex, the novel compounds still
demonstrated significant activity (Table 6.3).

M. smegmatis

MIC90 pg/ml
M. abscessus M, kansasii

M. avium complex

Series 3
17
18
19
20
21
22
23
24

>100
>100
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
>100
>100
>100
>100

Series 4
25
26
27
28
29
30

100
>100
100
>100
100
40

>100
>100
>100
>100
>100
>100

>100
>100
>100
>100
>100
40

>100
>100
>100
>100
>100
>100

Series 5
31
32
33
34

>100
26
>100
>100

>100
26
>100
>100

>100
52
>100
>100

>100
52
>100
>100
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35
36
37
38
39
PZA
INH

>100
>100
>100
<6
>100
>100
39

39
26
>100
>100
>100
>100
>100

>100
39
26
26
>100
>100
<10

>100
52
26
>100
>100
>100
<10

Table 6.3: MICgo [fjg/mlj of compounds 9-14 (series 2) of the 8-hydroxyquinolines
against four mycobacterial species. Also seen are the MICgo values of antimycobacterial drugs pyrazinamide (PZA) and isoniazid (INH) against each strain.

Based on the chemical structures of these compounds (Table 6.1),
it is difficult to attempt to determine any structure-activity
relationships, although some observations can be made. Compounds 32
and 38 were the two most potent compounds against the cohort of
bacteria tested (Table 6.3). It is interesting that the structure of both
compounds is extremely similar with the only difference being the
absence of a methoxy (OMe) group on carbon number two of the fused
benzene ring (Table 6.1). This suggests that removal of this methoxy
group at the number two carbon position enhances the activity of the
quinolone derivative and causes the compound to have a broader
spectrum of activity. In contrast however, compound 38 with both
methoxy groups is more potent against M. smegmatis and M. kansasii
(Table 6.3). However, the addition of the extra methoxy group causes
the compound (38) to become inactive against both M. abscessus and
MAC. Interestingly, both potent molecules had a nitro (NO2) group on
both the number 5 and number 7 carbon, presumably essential for this
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activity (Table 6.1). This can be dedueed as compound 31 (inactive
against all strains) had an identical structure to compound 38, with the
exception of the replacement of the NO2 group with a carboxyl group.
Therefore the presence of NO2 at carbon number 7 may be essential for
activity (Table 6.1).
The other active compounds 36 and 35 also provide information
about the importance of these groups. Compound 36 is identical in
structure to the inactive 31, with the exception of the absence of the
NO2 group on the number 5 carbon (Table 6.1). Therefore the presence
of two NO2 groups (compound 32) on the carbon number 5 and number 7
confers activity whereas the presence of the NO2 group on the carbon
number 5 and a carboxyl group on carbon number 7 does not (31) (Table
6.3). However, if a carboxyl group is on the carbon number 7, in the
absence of the NO2 group on carbon 5, then activity is restored
(compound 36) (Table 6.1). It would appear that this is only the case if
two methoxy groups are present on the fused benzene ring (compound
36) as the absence of a methoxy group on carbon 4 causes inactivity of
the compound (compound 39) (Table 6.1). Compound 35 was also active
against some species of mycobacteria (Table 6.3). This compound also
contained a carboxyl group on carbon 7 of the quinolone moiety as well
as a chlorine group (Cl) on the number 3 carbon of the fused benzene
(compound 35) (Table 6.1). The compound became inactive when the
hydroxyl group and carboxyl group, located at respective carbons 8 and
7 on the quinoline moiety, were moved to carbons 5 and 6 respectively
(compound 37) (Table 6.1).
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6.4.4 In vitro anti-fungal susceptibility testing of 8-hydroxyquinoline
derivatives

Quinoline derivatives 17-26, 28 and 30 were tested for their in vitro
anti-fungal activity. The results are shown in Table 6.4. Two compounds
19 and 30 showed very high anti-fungal activity, comparable or higher
than the standard fluconazole. Compounds 17, 18 and 20-23 did not
show any antifungal activity. Compound 24 showed only moderate
activity especially against Candida albicans ATCC 44859. According to
the results presented in Table 6.4, it can be concluded that bulky
substituents and low lipophilicity decreased antifungal activity. A
bromo moiety (compound 19) seems to be very important for high
antifungal effect. Compounds with a nitro moiety (/.e., 17, 18) did not
show any activity. Compound 30 showed the highest anti-fungal activity
within series 4. The compounds 25-28 showed only a moderate activity
especially against Ahsidia corymhifera and Trichophyton
mentagrophytes. Compound 25 (2-OH substitution) possessed less
activity than 27 and 28 (4-OH or 3,5-OH respectively).
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Compound no,

17
18
19
20
21
22
23
24
25

26
28
30
FLU

a

CA
24h
48h

24h
48h

CK
24h
48h

>500
>500
250
250
0.77
1.95
125
500
125
250
125
125
>125
>125
15.6
62.5
>125
>125
125
>125
>125
>125
0.98
3.9
0.06
0.12

>500
>500
250
250
1.95
3.9
500
500
250
250
125
125
>125
>125
31.25
31.25
>125
>125
125
>125
>125
>125
1.95
7.81
0.12
>125

>500
>500
250
250
3.9
3.9
250
500
250
250
125
125
>125
>125
62.5
62.5
>125
>125
125
>125
>125
>125
0.98
1.95
3.91
15,62

MIC (mrwI/L)
CG
TB
24h
24h
48h
48h
>500
>500
250
250
1.95
3.9
500
500
125
250
125
125
>125
>125
31.25
62.5
>125
>125
125
>125
>125
>125
0.49
1.95
0.98
3.91

>500
>500
250
250
3.9
3.9
500
500
250
500
125
125
>125
>125
62.5
125
>125
>125
125
>125
>125
>125
3.9
15.62
0.24
0.48

AF
24h
48h

AC
24h
48h

TM
24h
48h

>500
>500
250
250
0.77
1.95
500
500
250
250
125
125
>125
>125
62.5
62.5
>125
>125
125
125
125
125
3.9
15.62
>125
>125

>500
>500
250
250
7.8
7.8
125
250
125
125
125
125
>125
>125
62.5
62.5
>125
>125
31.25
62.5
62.5
62.5
15.62
31.25
>125
>125

>500
>500
250
250
1.95
1.95
250
250
62.5
125
125
125
>125
>125
62.5
62.5
>125
>125
15.62
62.5
15.62
15.62
3.9
7,81
1.95
3.91

le 6.4: In vitro antifungal activity (1C80) of compounds 17-26, 28 and 30
compared with fluconazole (FLU) standard. The MIC determination
was 1)erformed accordin g to the CLSI reference protoco 1.

6.5

DISCUSSION

Among the new anti-TB drugs, the quinoline class of compounds
has shown promising activity against many mycobacterial species
including drug resistant tuberculosis. Quinolines have previously been
shown to have great potential as effective, easily accessible antimycobacterial agents, which can help to shorten the duration of anti-TB
therapy.

This is of paramount importance as no single agent exists
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which is effective in the clinical treatment of tuberculosis, nor is there
any combination of agents that offers the possibility of therapy of less
than six months duration.
The development of novel drugs through the chemical
modification of pre-existing drugs not only provides a rich bounty of
derivative compounds which may be modified to an almost infinite scale
but also compounds which may have different modes of action to the
drug from which their structure was derived.
One successful compound identified using such a strategy is the
diarylquinoline based molecule (R207910 or TMC207) whieh inhibits
TB with very high potency (().()6pg/ml).^'^ Subsequent to its
identification, numerous studies have demonstrated TMC207 as a potent
antimycobacterial drug.

‘

Substitution of drugs included in the World

Health Organization's first-line tubereulosis treatment regimen
(rifampin, isoniazid, and pyrazinamide) with TMC207 accelerated
bactericidal activity, leading to complete culture conversion after 2
months of treatment in some combinations.^"^ Indeed, a single dose of
TMC207 inhibited mycobacterial growth for 1 week.^"^ Mutants selected
in vitro suggest that TMC207 affects the proton pump for ATP synthase
unlike eonventional quinolones which target DNA gyrase.^"^ Inhibition of
this proton pump impedes the conversion of ADP+P to ATP, required for
cellular energy. Other targets of bacterial energy metabolism have also
become the focus of promising new research.
Similar studies which have reeently evaluated other quinoline
molecules with azole side chains have led to the identification of two

179

compounds with sub micromolar activity against the nonreplicating
persistent bacteria (NRP-TB) resistant to rifampin, isoniazid, and
streptomycin. The results suggest that quinoline-isoxazole-based antiTB compounds are promising leads for new TB drug development. 3 0
This particular study evaluated the efficaey of two classes of
quinoline derivatives, namely styrylquinazoline and 8hydroxyquinolines. The styrylquinazoline compounds were divided into
two series based on the addition of an oxygen (series 1) or chlorine
group (series 2) on the carbon number 5. Three strains (compounds 5, 13
and 14) demonstrated potent activity against numerous species of
mycobacteria. Compound 5 was extremely active against all species with
the exception of M smegmatis which showed resistance to all
styrylquinazoline tested. Compound 5 exhibited potent activity against
M. avium complex, M. ahscessus and M. kansasii with MICgo values of
80pg/ml, 80}ig/ml and 20pg/ml respeetively. (Table 6.1). Compound 13
also demonstrated significant activity against most species of
mycobacteria. In the case of M. abscessus, both 5 and 13 were more
active than isoniazid, a first line anti-tuberculosis drug (INH).

The seeond elass of anti-mycobacterial compounds tested were the
8-hydroxyquinolines. The molecules were classified on the basis of a
hydroxyl functional group on the number 8 earbon and were divided into
three series (series 3-5) based on the type of functional group they
possessed. A total of six 8-hydroxyquinolines (Compounds 30, 32, 35,
36, 37 and 38) exhibited activity against the mycobacterial species
tested. Interestingly, five of the six active 8-hydroxyquinolines
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compounds belong to series 5 which contain various methoxy
substitution patterns on the attaching aryl nucleus. The remaining
compound was from series 4 and did not have any methoxy functional
groups. However this compound (30) demonstrated good antimycobacterial and anti-fungal activity. Previous studies have also
demonstrated 92-100% growth inhibition in the presence of quinolines
containing methoxy substitutions.

Based on the results obtained in this

study, it was evident that two compounds in particular (32 and 38),
merit further investigation. Both compounds were identical in structure
with the exception of the methoxy group on carbon number two of the
aryl nucleus which is absent in compound 32. As a result, this compound
displayed a broader spectrum of activity, inhibiting all strains of
mycobacteria.

The structure/activity interaction of these compounds provided an
insight into the chemical changes which may be tolerated within each
molecule. Analogous to the systematic modification of gene encoded
bacteriocins using bioengineering approaches, these molecules may be
systematically modified and subsequently assessed for an enhanced
activity. This approach of using existing molecules as templates for the
generation of future molecules seems to be a more beneficial method,
rather than the screening of novel molecules. One recent successful
example of this approach is the identification of the previously
mentioned diarylquinolines.

181

The continuous search for novel anti-mycobacterial drugs through
the modification of existing templates has provided numerous clinically
approved drugs and certainly merits continuing consideration in this
regard. Indeed the success of this approach is highlighted by a recent
application (1st July 2010), which looks to patent the use of substituted
quinoline derivatives for the treatment of drug resistant mycobacterial
disease.

Moreover, with the development of novel rapid viability

assays for slow growing bacteria, such as MABA,

these compounds

may now be directly evaluated against pathogenic strains of
significance, rather than fast growing evolutionarily distinct relatives or
‘model’ strains, such as M. smegrnatis which may have significantly
different sensitivity ranges compared with other mycobacterial species.

182

6.6

REFERENCES

1

Jampilek, J. et al Quinaldine derivatives: preparation and biological activity.
MedChem. 1,591-599 (2005).
Musiol, R. et al. Antifungal properties of new scries of quinoline derivatives.
Bioorg Med Chem. 14, 3592-3598 (2006).
Harris, C. R. & Thorarensen, A. Advances in the discovery of novel
antibacterial agents during the year. Curr Med Chem. 11, 2213-2243 (2004).
Sissi, C. & Palumbo, M. The quinolone family: from antibacterial to anticancer
agents. Curr Med Chem Anticancer Agents. 3, 439-450 (2003).
Andries, K. et al. A diarylquinoline drug active on the ATP synthase of
Mycobacterium tuberculosis. Science. 307, 223-227 (2005).
Carta, A. et al. Anti-mycobacterial activityof quinolones. Triazoloquinolones a
new class of potent anti-mycobacterial agents. Anti-Infective Agents Med.
Chem. 7, 134-147 (2008).
Aubry, A., Pan, X. S. et al. Mycobacterium tuberculosis DNA gyrase:
interaction with quinolones and correlation with antimycobacterial drug
activity. Antimicrob Agents Chemother. 48, 1281-1288 (2004).
Zweerink, M. M. & Edison, A. Inhibition of Micrococcus luteus DNA gyrase
by norfloxacin and 10 other quinolonecarboxylic acids. Antimicrob. Agents
Chemother. 29, 598-601 (1986).
Blumberg, H. M. et al. American Thoracic Society/Centers for Disease Control
and Prevention/Infectious Diseases Society of America: treatment of
tuberculosis. Am J Respir Crit Care Med. 167, 603-662 (2003).
Ji, B. et al. In vitro and in vivo activities of moxifloxacin and clinafloxacin
against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 42, 20662069 (1998).
Domagala, J. M. et al. New structure-activity relationships of the quinolone
antibacterials using the target enzyme. The development and application of a
DNA gyrase assay. J Med Chem. 29, 394-404 (1986).
Morita, J., Watabe, K. et al. Mechanism of action of new synthetic nalidixic
acid-related antibiotics: inhibition of DNA gyrase supercoiling catalyzed by
DNA gyrase. Agric. Biol. Chem. 38, 663-668 (1984).
Lesher, G. Y., Froelich, E. J. et al. 1,8-Naphthyridine Derivatives. A New Class
of Chemotherapeutic Agents. J Med Pharm Chem. 91, 1063-1065 (1962).
Zhanel, G. X., Walkty, A. et al. The new fluoroquinolones: a critical review.
Can J Infect Dis. 10,207-238 (1999).
Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant
tuberculosis. N Engl J Med. 360, 2397-2405 (2009).
Polanski, J. et al. Analogues of the styrylquinoline and styrylquinazoline HIV-1
integrase inhibitors: design and synthetic problems. Acta Pol Pharm. 61, 3-4
(2004).
Podeszwa, B. et al. Investigating the antiproliferative activity of quinoline-5,8dione analogues on tumour cell WnQsBioorg. Med. Chem. Lett. 17, 6138-6141
(2007).
Musiol, R. et al. Investigating biological activity spectrum for novel quinoline
analogues. Bioorg Med Chem. 15, 1280-1288 (2007).
Polanski, J., Niedbala, H et al. Fragment Based Approach for the
Investigation of HIV-1 Integrase Inhibition. 7, 99-105 (2007).

2
3
4
5
6

7

8

9

10

11

12

13
14
15
16

17

18
19

183

20

21
22

Behforouz M, Cai W et al. Synthesis and evaluation of antitumor activity of
novel N-acyllavendamycin analogues and quinoline-5,8-diones. Bioorg Med
Chem. 1,495-510 (2007).
ww^w.abdserotec.com/uploads/BUFO 12-technical-datasheet-2008.
Upadhayaya, R. S. et al. Conformationally-constrained indeno[2,l-c]quinolines-a new class of anti-mycobacterial agents. Org Biomol Chem. 8, 2180-2197
(2010).

23
24
26

27
28

29

30
31

32

33
34

Kotz, J. Targeting Tuberculosis. Nature Chemical Biology. (2005).
Andries, K. et al. A diarylquinoline drug active on the ATP synthase of
Mycobacterium tuberculosis. Science. 307, 223-227 (2005).
Dhillon, J., Andries, K. et al. Bactericidal activity of the diarylquinoline
TMC207 against Mycobacterium tuberculosis outside and within cells.
Tuberculosis (Edinb), (2010).
Diacon, A. H. et al. The diarylquinoline TMC207 for multidrug-resistant
tuberculosis. N Engl J Med. 360, 2397-2405 (2009).
Franzblau, S. A potentially new treatment for tuberculosis; will a
diarylquinoline work for leprosy? Int JLepr Other Mycobact Dis. 73, 32
(2005).
Huitric, E., Verhasselt, P. et al. In vitro antimycobacterial spectrum of a
diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 51,
4202-4204 (2007).
Bald, D. & Koul, A. Respiratory ATP synthesis: the new generation of
mycobacterial drug targets? FEMS Microbiol Lett. 308, 1-7 (2010).
Lilienkampf, A. et al. Structure-activity relationships for a series of quinolinebased compounds active against replicating and nonreplicating Mycobacterium
tuberculosis. J Med Chem. 52, 2109-2118 (2009).
Yi, W. et al. Design, synthesis and biological evaluation of hydroxy- or
methoxy-substituted phenylmethylenethiosemicarbazones as tyrosinase
inhibitors. Chem Pharm Bull. 57, 1273-1277 (2009).
(http://www.faqs.org/patents/app/20100168133).
Carroll, J. et al. Optimization of a rapid viability assay for Mycobacterium
avium subsp. paratuberculosis by using alamarBlue. Appl Environ Microbiol.
75, 7870-7872 (2009).

184

CHAPTER 7

CHAPTER 7

In silica identification of ATP-binding cassette
(ABC) and Major Facilitator Superfamily (MFS)
drug transporters in the Mycobacterium avium
subsp. paratuberculosis genome
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7.1 ABSTRACT
The sequenced genome of Mycobacterium avium subsp. paratuberculosis
K-10 (MAP) was mined using in silico analysis for the purpose of
identifying transporters from the two main superfamilies, namely the
ATP binding cassette superfamily (ABC) and the Major Facilitator
Superfamily (MFS). A total of 67 ABC transporters (39% of all
transporters in MAP) and 33 Major Facilitator Superfamily transporters
(19%) were identified. Cumulatively, these transporters represent 58%
of all transporters of the MAP genome and 4% of the total protein
coding genes on the genome. A more detailed analysis of the genes
specifically responsible for drug efflux focused on 15 ABC transporters
and 16 MFS transporters, all putatively responsible for the transport of a
wide

variety

macrolides,

of

anti-bacterial

flouorquinolones,

substrates
glycosides,

including
cyclic

tetracycline,

di-peptides

and

antimicrobial peptides. One transporter identified as a multidrug MFS
efflux system (MAP2516) was used to test the accuracy of this in silico
analysis.

Subsequent

minimum

inhibitory

concentration

assays

demonstrated this efflux system conferred antibiotic resistance to the
host E. coli cells harbouring the plasmid associated MAP2516 gene.

186

7.2 INTRODUCTION
Mycobacterium avium subsp. paratuberculosis is the causative agent of
Johne’s disease,'"^ a chronic granulomatous enteritis of ruminants
responsible for significant annual economic losses for the agricultural
sector worldwide.Shedding of MAP from contaminated teats is the
primary transfer route to offspring and commercial milk. Worryingly,
several reports have identified the ability of MAP to survive subsequent
milk pasteurization processes.

Furthermore, MAP has been associated

with many cases of human Crohn’s disease, implicating it as a possible
causative agent of this disease. '
refute this evidence

However, there are also reports to

10-11

The robust nature of mycobacteria is partly due to their thick,
lipid rich cell

wall.

abundance

data

of

However, the genomic
highlighting

the

role

era has provided an
of

efflux

pumps

in

mycobacterial survival, with cumulative research studies implicating
efflux pumps as a major underlying factor in intrinsic resistance. 1 2
Efflux pumps responsible for drug resistance are of particular interest
due to the recent emergence of Multi Drug Resistance (MDR-TB) and
Extremely Drug Resistant Tuberculosis (XDR-TB).Recent evidence
suggests that the multidrug resistance of tuberculosis is associated with
constitutive or inducible expression of these efflux systems.*^ Although
it is known that efflux pumps contribute to the intrinsic resistance of
mycobacteria to drugs,the overall significanee of efflux pumps in
intrinsic resistance is not yet fully understood.
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Two of the largest and most diverse superfamilies of efflux pumps
are the

ABC

superfamiliy and the

Major Facilitator

Superfamily

(MFS). 17-18
The ABC transport systems are defined by the presence of ATPhydrolyzing proteins (also known as ATPases or nucleotide-binding
domains (NBD)) which all share a common evolutionary origin.*^ ABC
transport proteins generally exist as dimers, in total consisting of four
domains, two nucleotide-binding domains (NBD) (ATP-ases) and two
transmembrane domains (TMD).'^ Directionality of the translocation
process can be deduced from the presence or absence of a fifth
component; the extracytoplasmic substrate binding lipoprotein (SE3P)
(also termed receptor).

ABC efflux systems lack this constituent,

whereas in bacterial ABC importers the SBP is essential for function.

n

The domains of the ABC transporters may be encoded on a single gene
or along an operon consisting of multiple genes. For example many ABC
transporters are encoded on two genes each encoding a transmembrane
and ATP binding (ATPase) region.

The

MFS

represents

the

largest

group

of secondary

active

membrane transporters, and its members transport a diverse range of
substrates. MFS transporters use proton motive force to drive the
transport of substrates.
conferring

resistance

These
to

a

efflux
large
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systems
number

are
of

responsible
drugs

for

including

fluoroquinolones

21-23

Generally MFS efflux systems are encoded on a

single gene and possess a simpler structure. 24

Fig. 7.1: The ATP dependent ABC superfamily (right) and the proton-motive-force
dependent transporter of the MFS (left)^^

Worryingly, the horizontal transfer of genes responsible for these
efflux pumps is a regular occurrence and a single pump may confer
resistance to a wide array of chemically and structurally diverse
compounds. Consequently, this has led to the development of new and
more effective drugs, which may be soon supplemented with efflux
pumps inhibitors, preventing the extrusion of these drugs.

This study

set out to identify the major drug transporters in MAP and identify the
189

putative substrates which they transport. This approach may facilitate
drug regimes to be put in place which will not be impacted upon by
active intrinsic efflux of the drugs which are chosen. Moreover, it may
facilitate the identification of novel efflux inhibitors which may be
beneficial in clinical practice.

7.3 MATERIALS AND METHODS:

7.3.1 Computational analysis

This analysis integrated four different software tools to identify the
main

features

sequence

of drug

motifs,

transporters;

classification

sequence

of protein

similarity,

domain

specific

structures

and

structural similarity (transmembrane segments). The complete genome
of MAP K-10 was retrieved from the National Centre for Biotechnology
(Accession No. NC_002944).^^ Searches of MAP genes and sequence
similarity between potential drug transporters and proteins characterized
in other organisms were carried out using Specific Iterated BLAST (PSI
BLAST) analysis (Expect Threshold = 0.001, Matrix = PAM70 Gap cost
=

6:2

with

a

low

complexity

(http://blast.ncbi.nlm.nih.gov/Blast.cgi).

Specific

region

filter)

sequences

of

previously characterised drug transporters were identified and accessed
on the Transport Classification Database (www.tcdb.org).

97

Following

the identification of putative drug transport genes on the MAP K-10
genome,

genes

directly

upstream

characterized using PSI-BLAST. 26
190

and

downstream

were

also

Searches for specific motifs conserved to members of the ABC
and MFS transporters respectively were identified using Motif Genome
(www.motif.genome.jp/).' The presence of transmembrane segments
(TMS) was confirmed using the TMHMM 2.0^^ and Sosui^^ server tools.
Classification of protein domain structures was performed using protein
structure classification database CATH (http://www.cathdb.info/). 3 1

7.3.2 Bacterial strains and culture conditions
MAP 19698 was routinely grown at 37°C in Middlebrook 7H9GC broth
(MB) (Sigma Aldrich), supplemented with glycerol (0.2%), 10% oleic
acid-albumin-dextrose-catalase

(OADC;

Unitech) and

Mycobactin J

(0.2%) Synbiotics Europe) and incubated at 37°C for 8-12 weeks.
ElectroMAX™ DH5a-E™ competent E. coli cells, used as the cloning
host, were purchased from Invitrogen (Bio Sciences Ltd., Crofton Road, Dun
Laoghaire) and subsequently cultured on LB media containing kanamycin
(50pg/ml) at 37°C.

7.3.3 Cloning procedures
As a proof of concept for the in silico analysis, a gene predicted to
encode a putative MFS efflux pump (MAP2516) was amplified by
polymerase chain reaction (PCR) from MAP 19698 chromosomal DNA
using

specific

primers

PMV2516F

and

PMV2516R containing the

restriction enzyme sites for BAMHI (5’) and Hpal (3’) (Table 7.1).
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MAP2516 was ligated with the Mycobacterium-E coli shuttle vector
PMV261.^^ Plasmid DNA was isolated using the High Pure Plasmid
Isolation Kit (Roche) prior to transformation of ElectroMAX™ DH5aETM by electroporation. The presence of the insert (MAP2516) was
confirmed using primers PMV2516F and PMV2516R and subsequent
sequence analysis by MWG.

Primer Name
"MAP2516F
‘’MAP2516R
‘^PMV2516F
‘^PMV2516R

Sequence
5’- CATGGATCCATGCCTGACACG-3'
5' - CATGTTAACTCACGGACCCGG - 3'
5' - AAATCTAGAGGTGACCACAACGACGCGC - 3'
5' - CCGCGGCCATGATGGCCGG - 3'

Table 7.1. Primers used for cloning of MAP2516 into the PMV26I vector^’^ and for
subsequent confirmation that ligation was successful f

Restriction sites used for

subsequent cloning are highlighted in red.

7.3.4 Drug Susceptibility Test
Minimal inhibitory concentrations (MIC) of drugs were determined in
LB broth. Drug susceptibility tests were performed at concentrations
ranging from 500mg/L-0.24mg/L for chloramphenicol, rifampicin,
isoniazid, tetracycline, erythromycin, penicillin, and ampicillin in
triplicate. Plates were incubated at 37°C overnight and OD600 readings
were taken following 24h incubation. Positive controls were E. coli
DH5a cells harbouring the PMV261 vector, absent of the MAP2516
insert.
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7.4

RESULTS:

7.4.1 Identification of ABC and MFS transport systems on the MAP
K-10 genome

To identify members of the MFS and ABC families in the MAP K10 genome, homology searches using PSI-BLAST were performed on
each gene. Genes confirmed as being members of the MFS or ABC
families were more closely scrutinized on the basis of family signature
motifs and the presence of transmembrane segments. This facilitated the
identification

of

genes

and

subsequent

protein

subunits

which

contributed to the final structure of the transporter. Using M. avium
complex as a model, PSI-BLAST analysis of each putative transporter
gene was compared with those of the MAP genome. This approach
identified a total of 100 transporters belonging to the MFS and ABC
families (67 ABC transporters and 33 from the MFS transporters).

The number of ABC transporters and MFS transporters identified
in this study were compared with the number of MFS and ABC
transporters present on the genomes of M.

bovis,

M.

leprae,

M.

smegmatis, M. tuberculosis, as identified by the Membrane Transport
database (www.membranetransport.org).
Table 7.2.
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These results are tabulated in

MAP
K-10

M. bovis
BCG

M. leprae
TN

M. smegmatis
MC2155

M.tuberculosis
H37RV

The ATP-binding Cassette
(ABC) Superfamily

67 (39%)

47 (29%)

25 (59%)

109 (26%)

44 (30%)

The Major Facilitator
Superfamily (MFS)

33 (19%)

32 (20%)

0 (0%)

112(29%)

28(19%)

Table 7.2: Number of ATP dependant ABC transporters and MFS transporters in

MAP K-10 and other mycobacterial pathogens. The number of transporters in each
family is also represented as a percentage of the total number of transporters on the
genome.

These results were cross referenced with the new Transporter
Protein Analysis Database (www.membranetransport.org),

which just

recently included MAP K-10. This database confirmed our findings,
identifying all transporters identified by this study. However, our
analysis

also

identified

3

additional

drug

transporters,

1

MFS

transporter and 2 ABC transporters, not listed as drug transporters on
the Membrane Transport Database. These putative transporters are
MAP_1331c

of

the

MFS

superfamily

and

MAP_3465/MAP_3466 of the ABC superfamily.

MAP_1457

and

This database also

provided information on the total number of transporters in the MAP K10 genome (170 transporters). However, taking into consideration the 3
transporters which were identified in this study, not included by the
transport

classification

database,

the

total

number

transporters in the MAP genome may be 173 (Fig. 7.2).
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of

putative

67

73

The ATP-binding cossctlc
(ABC) Stipcrfomilv of MAP
K-10

x

The Major Facillilolor
Supcrfamily (MFS) of
MAP K-10
I Cumulative other
transporters of MAP K-10

11= 1

Fig. 7.2: Transporters of the MAP genome.

The ABC (67 transporters) and MFS

(33 transporters) superfamilies represent 58% of the total transporters on the
genome. The remaining 42%) (73 transporters) is a cumulative total of all other
transporters on the genome.

7.4.2 Comparison of the total number of all transport proteins with
other mycobacterial species
Table 7.3 demonstrates the number of transporters MAP K-10 possesses
in comparison to other mycobacterial species. This data is based on data
from the transport classification database supplemented by data on MAP
identified in this study. Based on these results, it is clear that MAP K10 possesses a large amount of transport proteins (173 transporters)
when compared to all other mycobacterial species, namely on the
genomes of M. bovis, M. leprae and M. tuberculosis. For example, M.
leprae contains only 56 transport proteins, interestingly possessing no
195

MFS

transporters.

In

M.

contrast,

smegmatis

contains

a

disproportionately large amount of transporters, 423 in total (Table 7.3).
This is approximately 2.5 times more than MAP K-10 and 7.5 times
more than M. leprae. However this may be explained in part by the
equally disproportionate large genome of M. smegmatis (7Mb), when
compared with each other species of mycobacteria analysed.

Genome Size (Mb)
Total Transporter
proteins

MAP

M. bovis

M. leprae

M. smegmatis

M. tuberculosis

K-10

BCG

TN

MC2155

H37RV

4.83

4.0

3.26

7

4.4

173

164

56

423

148

Table 7.3: Total number of transporters in MAP K-10, M. bovis BCG 11 7 3 P2, M.
leprae TN, M. smegmatis MC2155 and M. tuberculosis H37Rv (below). The
respective genome sizes are also listed (above).

7.4.3 Identification of specific motifs of the MFS transporters on the
MAP genome

In addition to BLAST analysis, transmembrane structure and motif
folding were also analysed. These results also confirmed all genes as
being members of the MFS or ABC transporters. Members of the MFS
have previously been identified as possessing specific motif sequences.
These motifs are identified as Motif A and Motif B which are conserved
throughout the MFS, and Motif C, only identified in 12 and 14-TMS
family members.

However, alignment of members with 12-TMS with
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members with 14-MFS indicated that motifs A and B were specific only
to 14-TMS members. Motif C was also specific to 14-TMS members,
although this motif was more conserved between 12-TMS and 14-TMS
members than motifs A and B. Alignment of 5 MFS genes which contain
14 transmembrane regions (MAP0618, MAPI 137, MAP1596, MAP2534
and MAP 3739) is seen in Fig. 7.3. Motifs A, B and C are similar to
those of M. tuberculosis

although some variation is noted.

Based on these results, specific motifs A, B and C of 14-TMS
members

of

MAP

may

be

postulated

as

follows;

Motif

A

(GxxxD[R]xGx[K]xxxx), Motif B (L[I]xxRxxQGx[G]xx), and Motif C
(xxxxGP[LJxG) where x represents any residue, and residues in brackets
indicate those most frequently observed in a single position in more than
75% of aligned transport proteins (Fig. 7.3). All other residues are
conserved among all five 14-TMS MFS transporters. MFS transport
proteins which did not have 14 transmembrane segments did not appear
to have these motifs.

197

AAVLLLX|3RLGDRFGRKRLF LXGXAVFTVXSVLCALA-

400.

110

ATVI PI TGWAADRFGTKRLF
1 AAMPLLGRASDRFGRKLVL
Tl VTALVGKLGDLYGRKRVF
AALLLSAGRLGDRI GARRCY
AVVLLVAGRLGDRFGTKNLY
A A L L L T VG^V S DR L GR K F^L F

T

---------------------------------

-GSXAXLI AARXXQGVGGGVLXP

______ 12Q___________ m____________I 140

m6sVLI

FTLGSLLCAVA------PNI LLl.
Q'5'SL AL FMVGSVVT AL AGH\AGDFHL 1.
qAaVLFFVAGSVLCGL A------QSMAMl.
LliGLAVFSI ASVLCALA- - - ASSAE^
L|l GL AVFTVASVV\CGL A------ GSAAMJ.
LtGVAVFTVASALCVAS------RTESPl.

Motif A

150

i LFRVVQGVGGGftILLP
I GGRTI QGVASGjLLP
VGARALQGI GGG^I TV
I AARTI QGVGAAyLl P
I AARVVQGVGAGyLTP
LAARAJLQGJ. GG^^ VFG

Motif B

A
AVGVVV3AAGG>^GSVLGPLXGGXL VDXXG- V\RW FXI NVPXGVI
180
190
200
210
LMAVGGI PI LLGPI GGPI L GGVNL I GAYG- WKW FLi NLPI GLT
VLGGI GAAQEL,GSVLGPLYG FI VF L F HDV\RY VF W NVPLTLI
YOGI LGAVFGVJTTVI GPL L GGY FT DY L S- V\RWAF VWN VP VSVI
AVAVVWTI GGMGFAAGPLI GpL L VST F G- \ARSI FLI Nl PAAAI
AVSV\AGATAGAASL VGPL AGi^VL VDGLG- WGW FFVNVPI GVL
AVGL AMAAGA.^AAT_LGPL1 GGGL VEI GT- WGVM FAI NVPVGVA
Motif C

Fig, 7.3: Identification of specific motifs A, B, and C of the I4- TMS MFS

transporters in MAP K-10 genome.

7.4.4 Identification of MFS systems involved in the transport of
antibacterial substrates
Particular attention was paid to the MFS transporters specifically
involved in putative drug transport. A total of 16 MFS transporters
(Table 7.4) were identified based on sequence similarity to existing drug
and multidrug transport proteins (www.tcdb.com). PSI-BLAST analysis
was used to compare these previously characterised transport systems to
all genes on the MAP K-10 genome. As MFS pumps are encoded on a
198

single gene, a total of 16 genes were identified as being responsible for
the 16 transport systems. As can be seen in Table 7.4, the efflux pumps
members of the MFS superfamily are responsible for the transport of a
vast array of antibacterial substrates.

Based on the results seen in Table 7.4, the major facilitator
superfamily proteins are encoded by a single gene. The permease
regions of the MFS transporters generally contained 14 TMS, from
which specific motifs A, B and C were identified (Fig. 7.3), but
permeases containing 6, 10, 11, 12, and 13 transmembrane segments
were also identified.

199

(3
■(3

3

(3

3
k.
•3

C3

a

•5—>

"a

JS

a
■C)

o

<u
.£

X)
u.

<U
c

73

3
3

o

TD

(3"
"O

c

3
<U
O
>.
C

73

‘c

o
3

JH

>

3

(50
.£

(50

eo

(50

3

C

C

■O
3

T3
3

T3
_3

"O

.3

o

o
_c

c
om

3

(50
3

Q

S-i

-o

(U

!o
3
x>
o
Sm
0^

t/i
(50

c/5
(50

3
U.

3
kn

3

T3
CL .2
o .23

(U

3
^

-a

a.

S)

~a

c

3
CO
(U
3
"c«
O

o
3

.S
-S

.3

O

-3
3

O.

O
3
3

^

o

"53

-H.
3

CL .>

(50
3
T3
_3

.9’■*->

3
S

3
S

•3
S

o

s>

3

■!=?
CL

3

3
T3

73

M £

£

O

3
3

3
3

t:
3

O
3
3 .3
C
-!-•

(50
3

CO

3
3
u,
*->

(50
3

(50
3

£
(50
3

”3
_3

T3

3
3
.3

3
3
.3

3
3
.3

CO

CO

CO

(50
3

00 (50
3 3
3
S-.
"3 "3

T3

*-1
3
t:
o
CL

^
35
3

"3
3

3

3

CO

Cj

---------

cr CL
(50
3

3

3

o

-a

(50 00 o
.£ .£ ^
‘•3 ’-S £

•3
_3
3
3
.3

3

■as
cu

-a

CO

CO

CO

(50
3
k.
"3

(50
3
Uh
"3

(50
3
k*3

(50 "3
3 C
k- 3
T3 -

3

3

3

3 •—

3

3

3

S

S

S

-a
(50

3
CO

Q- CL

(50
a

^ -2

.£•
.&■
.9" .9.9'
‘■4->
‘-t-l ’•4->
'■*->
S

(>5
3

(50

•n
<N
£L

s ^

(50
<55

L,

a
-a
(3
a
■3

s
B

a.

0£|
a>

3

c/5

o
CL
»5

a

(3

O

O

■3'

m

<N

"rf

'o

7-

■3-

•3'

r<5

3-

fN

B

<u
E
V3

8

O
CL

3
b.
H

(50
u
'3‘
'3‘
O

o
CL.

<
S

o
rs|
3"

I

cu
<

2

OO

On

VO

VO

O

O

CL

CL

< <

3
105
r3

3
m

m

VO
m
m

VO
ON
•05

m
^1
1
1 cl' CL CL CL
CL
< < < <

ac

3
(N
m
VO

O

CL
<

u

VO

(50
O
(N

-3•3‘
(N

105
(N

CL

CL

CL

<

< <

I

m
105
(N

CL
<

a

105
3(o
k.

I CL
<

o
o
OJ

3

-a

V
8
3
L.
.8

-a
50
(3

3 C
5-* .3

3

3

(50

CO

3

§

8
3
(50
(50
3
"3

-3

a

.£

73

bO
3
't3

(50
3

"

3
•S

3

3

3

£

.£

-3
3
3

50
o
c

o

3

>55

o

3
U
"3
o,

a

3

E

3

Cj
a

C

3

o

c
'5

a
_o

3
r-'
"

-Q

7.4.4 Identification of ABC transport systems involved in the
transport of antibacterial substrates

The ABC transporters were identified using the same approach which
identified the MFS transporters. A total of 15 ABC drug transporters
were identified which have the putative ability of transporting multiple
drugs.

Additionally,

ABC

systems

may

also

transport

peptide

transporters, potentially capable of antimicrobial peptide efflux.In
contrast to the MFS transporters, a total of 37 genes were responsible
for the 15 ABC transport systems, composed of multiple subunits.

Based on the results seen in Table 7.5, ABC transporters are
encoded by

1, 2, 3, 4 or 5 separate genes (Table 7.5). Several

permutations may exists which encode the multi-subunit MAP ABC
transporter. For example, a single gene may encode for a permease while
another gene encodes for an ATP binding protein (2 separate genes)
(MAP 1 1 84-MAP 1 1 85). One ATP binding protein may sometimes provide
energy for two permeases (3 genes) (MAP 1236c-MAP 1238c) or even 3
permeases (Map 1086-1090) (4 genes). In some cases, a single gene may
translate into a fused permease and ATP binding protein (1 gene) (MAP
1531). Finally, directionality of the translocation process (influx or
efflux) can be deduced from the presence or absence of a fifth
component, the extracytoplasmic substrate binding domain. ABC efflux
systems lack this constituent, whereas in bacterial ABC importers the
201

substrate binding protein is essential for function. Based on the presence
on this extracellular binding protein, 3 of the 15 ABC transporters
(MAP 1 086-MAP 1 090,

MAP0409-MAP0412

and

MAP2488-MAP2491)

were identified as importers rather than exporters. Interestingly, all
importers were putative oligopeptide transporters, involved in the influx
of peptides. These are highlighted in bold in Table 7.5.

Therefore, ABC transporters are composed of multiple subunits
which may exist in random combinations. Based on this study, a single
permease of the ABC transporters contains 6 transmembrane segments.
However, duplication of these permeases generally results in ABC
transporters containing 12 transmembrane segments (Table 7.5).

It is noteworthy that a number of ATPases were also identified
which lacked the required permease proteins upstream and downstream
on the MAP genome. However, it is unknown if these genes (Map_2533,
Map_3295, Map_4119) are actively expressed.
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7.4.5 Minimum Inhibitory Concentrations of E. coli DH5a:PMV261
and DH5a-PMV261:MAP2516
To determine if the putative MFS efflux pump MAP2516 confers
resistance to MAP, minimum inhibitory concentration (MIC) assays
were performed on both the E. coli DH5-a cells harbouring the
Mycobacterium-E. coli expression vector PMV261 containing the MAP
MFS efflux pump MAP2516 (DH5a-PMV261 :MAP25 16) and E. coli
DH5-a cells harbouring PMV261, absent of the MAP2516 insert. From
the results in Figure 7.4 and Figure 7.5 it is clear that MAP2516 is
responsible for the efflux of chloramphenicol and tetracycline
respectively.

•f. coli DH5a:PMV261:MAP2516

T. coli DH5a:PMV261

500

250

125

62.5

31.25 15.62

7.81

3.9

1.95

0.97

0.48

Concentration of chloramphenicol (pg/ml)
Fig. 7.4: Chloramphenicol resistance of E. coli DH5a cells harbouring plasmid
PMV261 with (red) and without (blue) the MAP2516 insert. The absorbance
readings at 600nm were taken following 24 hours incubation.
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■E. coli DH5a:PMV261:MAP2516
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Figure 7.5: Tetracycline resistance of E. coli DH5a cells harbouring plasmid
PMV261 with (red) and without (blue) the MAP25I6 insert. The absorbance
readings at 60()nm were taken following 24 hours incubation.

From the results in figures 7,4 and 7.5, it appears that MAP2516 confers
strong resistance to both chloramphenicol (Fig. 7.4) and tetracycline
(Fig. 7.5), resulting in a two fold increase in resistance to both. A
number of other antibiotics, namely rifampicin, isonazid and penicillin
were also employed to check for potential resistance to these drugs.
However, the growth of the wild-type DH5a-PMV261 strain was
comparable or greater than that of the DH5a-PMV261 :MAP25 16 strain
(data not shown). Based on these results, it is apparent that single efflux
pumps such as MAP2516 have the ability to confer significant resistance
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to multiple classes of antibiotics. Given that a total of 31 drug
transporters (16 MFS and 15 ABC transporters) were identified in this
study, the overall contribution of drug resistance by drug transporters
may be hugely significant during the survival and resistance of MAP in
a clinical setting.

7.5 DISCUSSION
Drug-resistant microorganisms are a major worldwide health issue as a
number of important human pathogens have now acquired mechanisms
that make them largely resistant to all currently available treatment
regimens.

Efflux of antibiotics has been identified as a relevant

contributor to this bacterial resistance in clinical practice and is now
recognised as an important cause of intrinsic antibiotic resistance in
mycobacteria.

Of the 5 superfamilies of transporters which exist,

in

(the

particular,

ABC

transporters

and

the

MFS

two

transporters)

cumulatively represent the largest number of transporters, more than
58% of all MAP transporters. In this study, in silico analysis was used
to identify 67 members of the ABC transporters and 33 members of the
MFS transporters.
Transport systems responsible for drug transport as well as their
putative substrates were identified by means of sequence similarity
searches

with

proteins

antibacterial compounds.

previously

identified

as

transporters

of

Previous studies on mycobacterial efflux

pumps have identified many MFS and ABC transporters responsible for
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efflux

of

drugs

fluoroquinolones,
tetracyclines.

from

the

cell,

chloramphenicol,

including
isonaizid,

aminoglycosides,
rifampin

and

One recent study identified a novel MFS multidrug

efflux (Rv0194) pump in the genome of M. tuberculosis. Interestingly
BLAST analysis of this gene identified 32% and 37% homology with
MAP2499 and MAP2500 respectively. These genes have been identified
in this study as transmembrane ATP binding proteins which transports
many

classes

of antimicrobials

including

tetracycline,

penicillin,

oxacillin, cyclic peptides and antimicrobial peptides such as nisin
(Table 7.5).
In mycobacteria, two MFS efflux pumps have previously been
associated with fluoroquinolone transport, the Rvl634 efflux pump of
M. tuberculosis and the LfrA efflux pump of Mycobacterium smegmatis.
The mycobacterial efflux pump identified in M. tuberculosis (Rvl634)
conferred resistance to various fluoroquinolones as well as norfloxacin
and ciprofloxacin.

Interestingly, when cloned into M. smegmatis host,

Rvl634 increased the MIC of M. smegmatis to ciprofloxacin by a factor
of two and by a factor of 8 against M. bovis. In the MAP genome,
multiple homologues of this gene (Rvl634) were identified as drug
transporters. In fact 50% of the MFS transporters identified as drug
transporters (Fig. 7.4) had 25% or greater homology with this gene
suggesting their role in ciprofloxacin resistance. These genes were (%
Identity in brackets) MAP1336 (68%), MAP1596 (27%), MAP2534
(31%),

MAP3739C

(32%),

MAP1632c

(41%),

MAP0618

MAP0619 (26%), MAPI 137 (26%) and MAP2441c (30%).
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(25%),

The second MFS transport protein LfrA was identified as a
fluoroquinolone transporter in M. smegmatis. This protein sequence of
LfrA also showed homology with those identified in Table 7.5. These
genes were (% Identity in brackets) MAPI596 (27%), MAP2534 (28%),
MAP3739C

(30%),

MAP1632c

(31%),

MAP0618

(24%),

MAP0619

(23%), MAPI 137 (26%), MAP2441c (29%) and MAP2516 (27%). LfrA
has been shown to confer low-level resistance to fluoroquinolones,
ciprofloxacin, acridine and some quaternary ammonium compounds in
M.

smegmatis^^ when over-expressed. Disruption of the IfrA gene

decreased the MIC of ethidium bromide and acriflavine by a factor of
eight and increased ethidium bromide accumulation. Also, it produced a
twofold

decrease

rhodamine.

in

the

MlCs

of ciprofloxacin,

doxorubicin

and

T7

Tetracycline resistance as a result of efflux pumps has been
described in many bacterial species.
pumps

have

previously

been

The 'Tet(V)' and Tap' efflux

identified

in

multiple

species

of

mycobacteria.^^ Homology studies of protein sequences with the MAP
genome demonstrate significant homology with certain genes.

For

example the Tet(V) protein of M. smegmatis demonstrated 25% identity
with MAP2516 while the TAP protein of M. fortuitum demonstrated 71%
identity with MAP2516.

Therefore,

based on in silico analysis,

MAP2516 was identified as a probable multidrug resistance protein
responsible for the efflux of tetracycline (Fig. 7.4). This was confirmed
following

cloning

of

the

MAP2516

gene

into

E.

consequently conferred a two fold increase in resistance.
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coli,

which

It has also been shown that the expression of the Rvl258c gene in
M. tuberculosis increases upon induction by rifabutin and ofloxacin,
isonaizid treatment and thiolactomycin treatment, suggesting that efflux
pumps

contribute

to

multi-drug

resistance

in

tuberculosis. 3 8

M.

However, MAP2516 did not confer resistance to isonazid or rifampicin
in this study (data not shown).

MAP1 868c (EfpA_l) and MAP2915c (EfpA_2) are also both
putative MFS

efflux

pumps located

on the

MAP

genome.

These

transporters have significant homology with their EfpA homologue in M.
smegmatis and M. tuberculosis, (68% and 88% identity respectively).
Sequence similarity with known transporters suggests that these MFS
transporters are multidrug transporters with substrates that include
tetracenomycin, gentamycin, paromycin, cephamycin and actinorhodin.
Previous studies have demonstrated that deletion of the efpA homologue
in M.

smegmatis resulted in a twofold increased susceptibility to

ethidium bromide, gentamicin INH, erythromycin and FQs, and an
eightfold increased susceptibility to acriflavine. A fourfold decrease in
susceptibility to rifamycins and chloramphenicol was also noted.

The putative ABC transporter encoded by genes DrrA, DrrB and
DrrC of MAP (Table 7.5) is also a probable multiple drug efflux
transporter which is a probable transporter of daunorubicin. The M.
tuberculosis

homologues

drrABC

encodes
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a

putative

doxorubicin-

resistance transporter

1 Q

and the DrrAB genes expressed in M. smegmatis

confer resistance to a broad range of clinically relevant antibiotics,
including
streptomycin

tetracycline,
and

erythromycin,

chloramphenicol.

The

ethambutol,
DrrABC

norfloxacin,

proteins

of

M.

tuberculosis demonstrates similarities with the MAP DrrABC proteins;
DrrA (54%), DrrB (30%) and DrrC (33%). Interestingly, this transporter
also demonstrates similarity with the MAP3533/MAP3532 transporter
which only contains two proteins. Protein DrrA is homologous to
MAP3532 (42%) while DrrB and DrrC are less similar to MAP3532c,
(28% and 24% identity respectively). MAP3532c and MAP3533c were
both identified in this study as being putative drug transporters while
these proteins are not listed on the membrane transport database
(www.membranetransport.org)

33

A recent study also identified the Rv2686c-2687c-2688c operon
as a multidrug ABC transport system."^® The permeases Rv2686c and
Rv2687c are not homologous to any genes of the MAP genome.
However, the Rv2688c protein, an ATP binding protein, is homologous
to MAPI 184 (34%), DrrA (33%), MAP3533 (40%), MAP2413 (29%) and
MAP1331C (31%). Nevertheless, ATP binding proteins are relatively
conserved by nature and cannot be used to identify the substrates which
are transported. This does however, strongly suggest that MAP1331c
acts as a transport system despite its omission from the membrane
transport database.
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The existence of antibiotic efflux pumps and their impact in a
clinical setting must now be fully acknowledged prior to the selection of
novel antimicrobials. Recent clinical studies have focused on treating
Crohn’s patients with antimycobacterial drugs. One study in particular
has stimulated significant debate on the role MAP plays in Crohn’s
disease.

This study concluded that following a parallel, placebo-

controlled, double-blind, randomized trial of 2 years, on Crohn’s
patients,

with

anti-mycobacterial

drugs,

Mycobacterium

avium

subspecies paratuberculosis does not play a significant role in the
pathogenesis of Crohn’s disease in the majority of patients.'^' However
the role of efflux systems and their ability to dilute the intracellular
concentrations

of these

drugs was not acknowledged.

This

study

suggests the MAP genome possess efflux systems with the capabilities
of removing at least two of the three drugs used in this study, rifabutin
(a derivative of rifamycin) and clarithomycin. Therefore we suggest that
a systematic review of the antibiotic profile of MAP should be re
evaluated prior to a similar study being performed in the future.

A method of combating such efflux and ultimately drug resistant
bacteria, includes design of specific, potent efflux inhibitors which may
improve control of infectious diseases in the near future. It has been
shown that reserpine, a plant alkaloid can inhibit multiple bacterial
efflux systems'^^ including those in M. tuberculosis, thereby rendering it
more susceptible to isoniazid. MAC strains have also been shown to be
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inhibited by the efflux pump inhibitors phenothiazines, thioridazine and
chlorpromazine as well as by verapamil. 16

This study has highlighted the role mycobacterial efflux pumps
may play in drug resistance and the importance of understanding the
substrates they carry. Ultimately, the existence of antibiotic efflux
pumps and their impact upon therapy must now be taken fully into
account for the selection of novel antimicrobials which may eventually
be supplemented by efflux pump inhibitors.
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CONCLUSIONS

8.0 CONCLUSIONS

Due to their existing broad spectrum activity against a wide range of
targets, dual modes of action and gene-encoded nature, bacteriocins
are excellent anti-mycobacteria drugs. Based on the results of this
study,

nisin

and

particularly

lacticin

3147

exhibit

potent

anti-

mycobacterial effects against all test strains. Moreover, they make an
ideal target for bioengineering-based development to generate more
potent antimicrobial drugs. Previous studies have identified nisin V
(M21V) as being active against all drug resistant pathogens tested
which validates bioengineering strategies for peptide improvement and
design as well as serving to highlight the potential of bioengineered
lantibiotics (namely nisin V, nisin S and nisin T) as antimicrobials for
clinical use. This study has also validated this approach demonstrating
the enhanced activity of each variant against mycobacterial species.
The

potency

of

nisin

V

particularly

against

mastitis

causing

bacteria has merited calls for its application as a novel anti-mastitis
agent.

In

an

analogues manner, future

investigations

may identify

bioengineered lantibiotics with specific activities targeting the unique
cell wall of mycobacteria. However, the mechanisms responsible for the
enhanced activity of nisin V, nisin S and nisin T are as of yet unknown
and will need to be elucidated to gain an overall understanding of their
structure-activity relationship.
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Given the high numbers of deaths caused by tuberculosis each
year, the WHO have made clear the

necessity for new drugs and

technologies and a means of controlling M. tuberculosis is desirable.
Additionally, M. avium subsp. paratubercuiosis is of particular concern
given its impact on agricultural losses worldwide and its possible link to
Crohn's disease. However the role of the host immune system may be a
critical factor in

defining any

regimes to treat

MAP

infection,

as

emerging genetic data on Crohn's disease point to a defect in innate
immunity

to

specifically

intracellular
detailing

pathogens

MAP

has

like

MAP.

suggested

Recent

successful

literature

therapeutic

strategies may require combinations of drugs capable of killing or
inhibiting MAP in concert with drugs to control the host inflammatory
response directed against the infection. As antimicrobial peptides such
as defensins and bacteriocins have previously demonstrated inhibition
of MAP

and

alleviation

inflammation,

of host

bioengineered

immune

response

bacteriocins

and

with

consequent

both

these

characteristics may provide an alternative to a drug cocktail approach.
Another

advantage

particularly

nisin,

to
is

the
that

application
modern

of

large

bacteriocin
scale

derivatives,

fermentation

and

purification procedures are already in place providing a foundation for
large scale production of nisin-like compounds. The results of this study
highlight

the

importance

of

using

pre-existing

agents, both chemical (Quinolines) and

biological

blueprints for the rational design of novel drugs.
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anti-mycobacterial
(Bacteriocins), as

However, as a consequence of pathogenic mycobacteria having a slow
growth

rate, the

identification of bioengineered

anti-mycobacterial

drugs requires a rapid and inexpensive technology. This study has
illustrated the advantages of MABA and the potential role it may play in
the identification of novel anti-mycobacterial agents. MABA is not only
rapid and simple to use but it is relatively inexpensive when compared
to standard susceptibility assays such as the BACTEC MG IT 960. In
concert with existing technologies such as Immunomagnetic separation
(IMS)

which

efficiently

isolate

specific

cells

from

clinical

or

environmental samples, MABA may also be used for the rapid detection
of viable

mycobacteria

from

both

food

and

clinical

sources.

This

approach in concert with in silico analysis of cell surface antigens
specific to each mycobacterial species may facilitate rapid isolation and
viability testing of pathogenic species. This IMS-MABA assay may have
many future applications such as the accurate detection of viable MAP
cells following pasteurization, a method not currently in existence.

Although there is a paucity of literature on anti-mycobacterial
bacteriocins, this study provides a solid foundation from which the
design of future bioengineered anti-mycobacterial bacteriocins may be
achieved.

Given

the

potent

nature

demonstrated

by

bacteriocins

lacticin 3147 and nisin A as well as the bioengineered nisin variants
nisin V, nisin T and nisin S bacteriocins certainly merit consideration for
future in vivo studies.
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Abstract: In this study, series of ring-substituted 2-styrylquinazolin-4(3//)-one and
4-chloro-2-styrylquinazoline derivatives were prepared. The syntheses of the discussed
compounds are presented. The compounds were analyzed by RP-HPLC to determine
lipophilicity. They were tested for their inhibitory activity on photosynthetic electron
transport (PET) in spinach {Spinacia oleracea L.) chloroplasts. Primary in vitro screening
of the synthesized compounds was also performed against four mycobacterial strains and
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against eight fungal strains. Several compounds showed biological activity comparable
with or higher than that of the standard isoniazid. It was found that the electronic
properties of the R substituent, and not the total lipophilicity of the compound, were
decisive for the photosynthesis-inhibiting activity of tested compounds.
Keywords: styrylquinazolinone and styrylquinazoline derivatives; lipophilicity; PET
inhibition; spinach chloroplasts; in vitro antimycobacterial activity; in vitro antifungal
activity; structure-activity relationships

1. Introduction
A quinoline moiety is present in many classes of biologically-active compounds. A number of them
have been clinically used as antifungal, antibacterial and antiprotozoic drugs [1,2], as well as
antituberculotic agents [3-5]. Some quinoline-based compounds have also shown antineoplastic,
antiasthmatic and antiplatelet activity [6-11]. A series of compounds derived from 8-hydroxyquinoline
and styrylquinoline derivatives were recently synthesized as potential HIV-1 integrase inhibitors
[12-15]. Our previous study dealing with 8-hydroxyquinoline and styrylquinoline derivatives showed
that they could also possess strong antifungal activity [16,17]. According to recently reported results,
some new hydroxyquinoline derivatives also possess interesting herbicidal activities
[16,18-20]. In addition, some of the investigated quinoline derivatives also showed antineoplastic
activity [18,21].
Over 50% of commercially available herbicides act by reversibly binding to photosystem II (PS II),
a membrane-protein complex in the thylakoid membranes which catalyses the oxidation of water and
the reduction of plastoquinone [22] and thereby inhibit photosynthesis [23-25]. Some organic
compounds, e.g. substituted benzanilides [26] or substituted anilides of 2,6-disubstituted
pyridine-4-thiocarboxamides [27] or pyrazine-2-carboxylic acids [28,29] were found to interact with
tyrosine radicals TyrZ and TyrD which are situated in D1 and D2 proteins on the donor side of PS II.
Due to this interaction interruption of the photosynthetic electron transport occurred.
Tuberculosis (TB) is a worldwide pandemic. About 1/3 of the world's population is infected with
Mycobacterium tuberculosis, and almost two million people die every year as a result. A large number
of infected people are carriers of the latent form, which creates a potentially dangerous future source
of the illness. The HIV pandemic has also led to the rapid growth of the TB epidemic, and increased
the likelihood of people dying of TB. Another factor contributing to the rise in TB infections, and
consequently to the increased number of deaths, is the appearance of multiple drug-resistanee (MDR),
i.e., rise of multidrug-resistant TB (MDR-TB) [30,31].
The Mycobacterium genus is composed of the M. tuberculosis complex and other species known as
nontuberculous mycobacteria (NTM, or MOTT - mycobacteria other than tuberculosis). In recent
decades, the decrease in the prevalence of tuberculosis in developed countries has resulted in an
increase in the proportion of diseases caused by NTM [32]. Among these species, the M. avium
complex (MAC) has emerged as a major human pathogen, being a common cause of disseminated
disease and death in patients with HIV/AIDS [33].
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Chronic pulmonary disease is the most common clinical manifestation among the diseases caused
by NTM, and the most common pathogens are the species belonging to the MAC, followed by
M. kansasii. The clinical characteristics of NTM-related pulmonary disease are, in many cases,
extremely similar to those of tuberculosis. Other clinical manifestations are caused principally by
M. fortuitum, M. smegmatis and M. abscessus due to peritoneal infection as a result of catheterization
or postsurgical infections [34]. The above mentioned non-tuberculous strains are sometimes resistant
to commonly used drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) and other
antituberculous drugs [30]. Therefore, systematic development of new effective compounds is
necessary. Similarly, there is also an urgent need for discovery of new drugs with novel modes of
action for the treatment of systemic mycoses. This is due to the rapid growth of the
immunocompromised patient population and development of resistance to current azole therapies, and
the high toxicity of polyenes [35]. It should be stressed that hydroxyquinolines and their derivatives
were introduced as antifungal or antimycobacterial agents in clinical practice and novel compounds of
this type are still being investigated [3-5,36,37].
This is a follow-up paper to our previous articles [12-21] dealing with synthesis and biological
activities of ring-substituted quinazolinone derivatives. In the context of our previously-described
azanaphtalenes, new modifieations of quinoline moiety that can trigger interesting biological activity
were investigated.
Primary in vitro screening of the synthesized compounds was performed against four mycobacterial
strains and against eight fungal strains. The compounds were also tested for their photosynthesisinhibiting activity (the inhibition of photosynthetic electron transport) in spinach chloroplasts
{Spinacia oleracea L.). Lipophilicity (log k) of the compounds was determined using RP-HPLC.
Relationships among the structure and in vitro antimicrobial activities or/and inhibitory activity
related to inhibition of photosynthetic electron transport (PET) in spinach chloroplasts of the new
compounds are discussed.
2. Results and Discussion
2.1. Chemistry
All the studied compounds were prepared according to Scheme 1. Microwave-assisted synthesis
facilitated the preparation of quinazoline-related structures. 2-Methyl-4//-benzo[(i][l,3]oxazin-4-one
was synthesized from anthranilic acid and acetic anhydride. A further reaction with ammonia or
hydroxylamine afforded 2-methylquinazolin-4(3//)-one (1) or 3-(2-hydroxyethyl)-2-methylquinazolin4(3//)-one (2). 2-Styrylquinazolin-4(3//)-ones 3a-k were obtained from appropriate aldehydes using
neat microwave-assisted synthesis [38]. Further chlorination/dehydratation with POCI3 yielded
4-chloro-2-styrylquinazoline derivatives 4a-e. Styrylquinazolines can exist as E- or Z-isomers
according to the orientation of the ethylene linker. This can greatly affect their biological activity
i.e., behaviour at the site of action and complexation mechanism(s). Thus we have studied the
isomerism of all the obtained compounds with NMR techniques and crystallography, as formerly
described for similar structures [39,40]. Fortunately this feature can be easily determined by
examination of the coupling constants of both vinyl protons in the spectra. These are much higher in
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the case of £-isomers (J> 16 Hz) compared to Z-isomers (J< 12 Hz) [39]. All styrylquinazolines were
found to be pure £’-isomers, which is in good agreement with previous results [13,17,18,39,40].
Scheme 1. Synthetic pathway and general formula of prepared quinazolinone derivatives:
O

0

O
OH

O

NH

NH2

-Hr

O

N

2

4a-e

R

Reagents and Conditions', a) AC2O, MW; b) NH^aq, MW; c) NH2C2H4OH, MW; d) aldehyde, MW;
e) POCI3.

2.2. Lipophilicity
Many low molecular weight drugs cross biological membranes through passive transport, which
strongly depends on their lipophilicity. Lipophilicity is a property that has a major effect on
absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) properties, as well as
pharmacological activity. Lipophilicity has been studied and applied as an important drug property for
decades [41].
This thermodynamic parameter describes the partitioning of a compound between aqueous and
organic phases and is characterized by the partition (log P) coefficient [42,43]. With new
computerized methods of log P calculation, the possibility of predicting hydrophobicity in large
libraries of compounds came into being. Lipophilicity computing software can usually calculate log P
and Clog P. The software calculates log P values as lipophilicity contributions/increments of
individual atoms, fragments and the pairs of interacting fragments in the chemical structure, i.e.,
increments of carbon and hetero atoms, aromatic systems and functional groups. The software
calculates lipophilicity contributions according to different internal databases/libraries, so the
calculated lipophilicity values are dependent on the software used, and the values for individual
compounds may be different. This fact, as well as various ionic/zwitterionic forms and intramolecular
interactions, may cause differences between calculated and experimentally determined lipophilicities.
Classical methods for determination of these partition constants are time consuming and not always
adequately reliable. It was recognised some time ago that the retention of a compound in reversedphase liquid chromatography is governed by its lipophilicity, and thus shows correlation with the
octanol-water partition coefficient [44]. Reversed phase high performance liquid chromatography
(RP-HPLC) provides an excellent platform for computer controlled automated measurements with
computerised data acquisition for a large number of investigated compounds. Other advantages in the
use of HPLC retention data for lipophilicity determination are the absence of need for concentration
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determination and method validation, simultaneous separation of small impurities from the main
component, sufficiency of small amounts of material for measurements and possibility of their full
automation. Therefore the investigation of the true potential of this method is of great importance [45].
The effect of stationary and mobile phase selection has been published by van der Waterbeemd et
al. [43] and more recently by Claessens et al. [46]. RP-HPLC methods have become popular and
widely used for lipophilicity measurement [47]. A general procedure is the measurement of the
directly accessible retention time under isocratic conditions with varying amounts of methanol as an
organic modifier in the mobile phase using end-capped non-polar Cis stationary RP columns and
calculating the logarithm of capacity factors (log k). Log k is the logarithm of capacity factors in
chromatographic approaches, which is related to the partitioning of a compound between a mobile and
a (pseudo-)stationary phase. Log k is used as the lipophilicity index converted to log P scale [43,45-49].
Some groups have used a Ci8 chromatographic column with methanol-water mobile phases to
obtain log ky^, i.e., the retention factor extrapolated to 0% organic modifier, as an alternative to log P
[50]. The log kyj is obtained by performing several measurements with various ratios of water/organic
solvent. Nevertheless determination of log kyj has some disadvantages in that it is time consuming due
to the various measurements that need to be undertaken before calculation of log ky, [44]. The main
reason for the measurement is that it is more convenient to perform a systematic study of log k of
various heteroaromatic compounds using mobile phases containing around 50% methanol due to
various intramolecular interactions between heteroatoms and substituents [51-53]. Therefore this study
was performed using methanol/water (55:45) as the mobile phase. The conditions (non-buflered
mobile phase) were chosen with respect to conditions of biological evaluations, which are performed
mostly under neutral conditions (pH ~ 7). The lipophilicity data can be strongly influenced by
intramolecular interactions under the applied chromatographic conditions which were investigated in
the paper [54,55].
Lipophilicities (log P/Clog P) of all eighteen compounds l-4e were calculated using two
commercially available programs (ChemDraw Ultra and ACD/LogP) and also measured by means of
the RP-HPLC determination of capacity factors k with subsequent calculation of log k. The procedure
was performed under isocratic conditions. Neither programme succeeded in resolving the differing
lipophilicity values of individual positional isomers inasmuch as the same log P/Clog P values were
calculated for 3b-d, 3g-i and 4b-d. The results are shown in Table 1 and illustrated in Figure 1.
The results obtained with respect to all compounds show that the experimentally-determined
lipophilicities (log k values) of all compounds are lower than those indicated by the calculated
log P/Clog P, as shown in Figure 1, indicating that experimentally-determined \ogk values correlate
relatively poorly with the calculated log P/Clog P. These facts are caused by both the above
mentioned limitation of the software programmes used and also possibly to intramolecular interactions
between heterocyclic nitrogens and substituents [19,54-59]. As expected, compound 3i showed the
highest lipophilicity, while compound 1 exhibited the lowest. Series 4a-e showed lower lipophilicity
(log k) than series 3a-e, contrary to all calculated log P/Clog P data. The higher lipophilicity of 3a-e
compared with 4a-e is caused by intramolecular interactions between N(3) and carbonyl oxygen in the
position 4. Similar interactions were described recently [19,55-59]. This hypothesis can be supported
by the fact that log A: of 1 was lower than 2, although this is contrary to calculated log P/Clog P. When
the lipophilicity of both compounds was calculated with intramolecular interactions between
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N(3)-H --0=0(4), the lipophilicity increased (Clog/* (1): 1.343 and Clog P (2): 2.2306). Similar facts
may be observed at 3a-e and 4a-e, therefore the experimental log k data of 4a-e were slightly lower
than those log k of 3a-e.
Table 1. Comparison of the calculated lipophilicities (log P/Clog P) with the determined
log k values, electronic Hammett's parameters (o) and bulk parameters MR (volume of
substituents) [60].
log A

log P/Clog P
ChemOffice

logP
ACD/LogP

0.1170

0.98/0.804

-0.36 ±0.59

0.7047

0.69/0.6149

-1.23 ±0.69

3j
3k

H
2-OCH3
3-OCH3
4-OCH3
2,4-0CH3
3-Cl
2-Br
3-Br
4-Br
4-CHO
2,3,4-OH

1.1148
1.1509
1.1837
1.1351
1.1982
1.5059
1.4830
1.5904
1.5927
0.8005
0.5510

3.21 / 2.997
3.09/2.916
3.09/2.916
3.09/2.916
2.96/3.005
3.77/3.710
4.04/3.860
4.04/3.860
4.04/3.860
2.96/2.350
2.05 / 1.066
Cl

4a
4b
4c
4d
4e

H
2-OCH3
3-OCH3
4-OCH3
2,4-0CH3

1.1088
1.1497
1.1827
1.1337
1.1953

5.50/4.51522
5.38 /4.43422
5.38 /4.43422
5.38 /4.43422
5.25 /4.52322

Comp.

3a
3b
3c
3d
3e
3f
3g
3h
3i

R

a [60]

MR [60]

2.37 ±0.61
2.35 ±0.62
2.35 ±0.62
2.32 ±0.62
2.20 ±0.62
2.96 ±0.61
3.14±0.64
3.14 ±0.64
3.14 ±0.64
1.79 ±0.63
1.84 ±0.63

0.0
-0.390 [61]
0.115
-0.268
-0.658
0.373

0.0
6.5
6.5
6.5
13.0
4.8
7.6
7.6
7.6
5.3
4.5

4.47 ±0.56
4.47 ±0.57
4.44 ±0.57
4.41 ±0.57
4.30 ±0.57

0.0
-0.390 [61]
0.115
-0.268
-0.658

-

0.391
0.232
1.030
—

0.0
6.5
6.5
6.5
13.0

The presence of phenolic and carbonyl moieties decreased the lipophilicity. Nevertheless, the
observation that the lipophilicity of compounds 3k and 3j was close to the lipophilicity of compound 2
was unexpected. Compound 3f showed less lipophilicity compared with 3h. On the basis of
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comparison of the lipophilicity data log k of both Br-substituted isomers 3g-3i, it can be stated that
4-bromo derivative 3i possessed higher lipophilicity than the 3-bromo isomer 3h and the 2-bromo
isomer 3g- A diverse trend can be observed at methoxy moiety substituted compounds 3b-e and 4b-e.
Compounds 3e and 4e showed the highest lipophilicity, while compounds 3a and 4a possessed the
lowest lipophilicity within individual series of methoxy moiety substituted compounds, according to
log k data. Compounds 3a and 4a showed lower lipophilicity in comparison with the results calculated
by the software. If the lipophilicity data log k of three position isomers 3b-d, 4b-d are compared, it
can be stated that 3-methoxy derivative 3c/4c possessed higher lipophilicity than 2-methoxy derivative
3b/4b and 4-methoxy derivative 3d/4d showed the lowest lipophilicity.
Figure 1. Comparison of the log P/Clog P values computed using the two programs with
the calculated log k values. The discussed compounds l-4e are ordered according to the
increase in log k values.
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Generally, based on the facts discussed above, it can be stated that intramolecular interactions,
especially within styrylquinazolinone derivatives, play a significant role in the lipophilicity of the
discussed compounds. It can be assumed that the determined log k data specify lipophilicity within the
individual series of compounds. Lipophilicity increased in the following order; 2,3,4-OH < 4-CHO <
H < 4-OCH3 < 2-OCH3 < 3-OCH3 < 2,4-0CH3 < 2-Br < 3-Cl < 3-Br < 4-Br.
2.3. Inhibition ofphotosynthetic electron transport (PET) in spinach chloroplasts
The evaluated quinazoline derivatives showed relatively low activity related to inhibition of
photosynthetic electron transport (PET) in spinach chloroplasts (Table 2). Compounds 4a and 4c
expressed the highest PET-inhibiting activity (IC50: 285 and 303 pmol/L, respectively). PET inhibition
by several compounds (1, 3a-c, 3g, 3j and 4b) could not be determined due to precipitation of the
compounds during the experiment and compound 3k interacted with the artificial electron acceptor
DCPIP (change of the colour). The PET-inhibiting activity was expressed by negative logarithm of
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value (compound concentration in mol/L causing 50% inhibition of PET). Despite the relatively
low inhibitory activity of the studied compounds as well as the relative scarcity of compounds for
which PET-inhibiting activity could be determined, the correlations between log (I/IC50) and log k or
Hammett's paraineters (o) of the R substituent for both tested groups (3d-i, as well as 4a-d) were
performed. The a values [60,61] mentioned in Table 1 were used for calculations; the a value for
R: 2,4-0CH3 was calculated from the sum of corresponding o values for R: 2-OCH3 and R: 4-OCH3.
IC50

Table 2. IC50 values related to PET inhibition in spinach chloroplasts in comparison with
3-(3,4-dichlorophenyl)-l,l-dimethylurea (DCMU) standard and in vitro antimycobacterial
activity MIC/IC90 of compounds l-3i, 4a-4e in comparison with the standard, isoniazid
(INH).
Comp.
1
2
3a
3b
3c
3d
3c
3f

PET inhibition
IC50 [pmol/L]
a

362
a
a
a

693
391
1034

H

a

3h
3i
4a
4b
4c
4d
4e
DCMU
INH

561
665
285
a

303
390
508
1.9
-

MIC/IC90 [pg/mL]
M. smegmatis
>300
>300
>300
>100
>100
>100
>100
>300
>100
>100
>100
>100
>100
>100
>100
>100

M. absessus
>300
>300
>300
>100
>100
>100
80
>300
>100
>100
>100
>100
80
>100
>100
>100

M. kansasii
>300
>300
>300
>100
>100
>100
20
>300
>100
>100
>100
>100
60
60
>100
>100

M. avium complex
>300
>300
>300
>100
>100
>100
80
>300
>100
>100
>100
>100
80
>100
>100
>100

-

-

-

-

39

>100

<10

<10

"precipitation during the experiment or interaction with DCPIP.

The importance of electronic properties of the R substituent was for the inhibitory activity (IC50 in
mol/L) of compounds 3a-i unambiguously much more significant than the compound lipophilicity
(log k):
log (I/IC50) = 3.216 (± 0.048) - 0.218 (± 0.095) a
r = 0.798, s = 0.106, F = 5.26, n = 5

(1)

log (I/IC50) = 3.545 (± 0.530) - 0.248 (± 0.374) log k
r = 0.358, s = 0.160, F = 0.44, n = 5

(2)
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Similarly, the inhibitory activity (IC50 in mol/L) of compounds 4a-e depended predominantly on
the Hammett's constants (a) of R substituents:
log (I/IC50) = 3.507 (± 0.020) + 0.324 (± 0.056) a
r = 0.971, s = 0.033, F - 33.24, n = 4

(3)

log (I/IC50) = 5.272 (± 1.900) - 1.584 (± 1.644) log k
r = 0.563, s = 0.116, F = 0.93, n = 4

(4)

From Equations 1-4 it is evident that in both studied groups of compounds (3d-i and 4a-d) the
electronic properties of the R substituent were decisive for photosynthesis-inhibiting activity. For
estimation of the potential contribution of the compound lipophilicity to its biological activity, a larger
data set for both groups of compounds tested would be necessary.
2.4. In vitro antimycobacterial evaluation
Sixteen compounds l-3i, 4a-4e were evaluated for their in vitro antimycobacterial activity against
four mycobacterial strains and the results are shown in Table 2. According to the results, it is evident
that the tested compounds were poorly soluble in the testing medium and therefore concentrations of
the compounds in the medium were not sufficient for determination of real antimycobacterial activity.
Due to this fact, it can be concluded that the majority of compounds evaluated did not show any
significant antimycobacterial activity. Only 2-[(£)-2-(2,4-dimethoxyphenyl)vinyl]quinazolin-4(3//)one (3e) and 4-chloro-2-[(E)-2-(2-methoxyphenyl)vinyl]quinazoline (4b) expressed an interesting
MIC especially against M. kansasii, M. avium complex and M. absessus. Both compounds were more
active than INH in case of M. absessus.
With the available data it is difficult to attempt to determine any structure-activity relationships,
although some observations can be made. The 4-chloroquinazoline nucleus (series 4) seems to be
more advantageous for higher antimycobacterial activity than the quinazolin-4(3//)-one scaffold
(series 3); e.g., unsubstituted 3a showed lower activity than 4a.
The benzylidene part of the molecule is also important for antimycobacterial activity. Bulk
parameters (the volume of substituents) MR [60] are also very important for activity. According to
Tables 1 and 2 it can be assumed that compounds with bulky substituents showed higher
antimycobacterial activity. Unsubstituted compounds 3a and chloro substituted 3f possessed less
activity than methoxy or bromo substituted compounds. The highest effect was shown by disubstituted
2,4-methoxy derivative 3e. The position of substituents on the benzylidene part of the molecule is
important especially for compounds within series 4; compare the activity of compounds 4b > 4c > 4d
> 4e.
2.5. In vitro antifungal susceptibility testing
All quinazoline derivatives l-4e were tested for their in vitro antifungal activity against eight fungal
strains. The antifungal activity of all the compounds were in the range from >125 to >500 pmol/L and
therefore the activities are not presented in detail. According to these results, it can be concluded that
all the compounds are almost completely insoluble in aqueous solvents as they precipitated from the
testing medium. Generally, compounds 1 and 2 showed lower activity than most compounds 3 and 4.
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The substitution of benzylidene part of the molecule by 3-OCH3 (3c, 4c) or 2,3,4-OH (3k) seems to
contribute to antifungal activity within both series of compounds.
3. Conclusions
Series of ring-substituted 2-styrylquinazolin-4(3//)-one and 4-chloro-2-styrylquinazoline
derivatives were prepared and characterized. All eighteen prepared quinazoline derivatives were
analyzed using a RP-HPLC method for lipophilicity measurement and their lipophilicity was
determined. The prepared compounds were tested for their antifungal and antimycobacterial activity
and for their activity related to the inhibition of photosynthetic electron transport (PET) in spinach
chloroplasts {Spinacia oleracea L.). 2-[(£)-2-(2,4-Dimethoxyphenyl)vinyl]quinazolin-4(3//)-one (3e)
and 4-chloro-2-[(£)-2-(2-methoxyphenyl)vinyl]quinazoline (4b) exhibited the highest in vitro
antimycobacterial activity. 4-Chloro-2-[(£)-2-(3-methoxyphenyl)vinyl]quinazoline (4c) showed the
highest PET-inhibiting activity.
4. Experimental
4.1. General
All reagents were purchased from Aldrich. Kieselgel 60, 0.040-0.063 mm (Merck, Darmstadt,
Germany) was used for column chromatography. TEC experiments were performed on aluminabacked silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV
(254 nm) and evaluated in iodine vapour. The melting points were determined on Boetius PHMK 05
(VEB Kombinat Nagema, Radebeul, Germany) and are uncorrected. The purity of the final
compounds was checked by the HPLC separation module Waters Alliance 2695 XE (Waters Corp.,
Milford, MA, U.S.A.). The detection wavelength 210 nm was chosen. The peaks in the chromatogram
of the solvent (blank) were deducted from the peaks in the chromatogram of the sample solution. The
purity of individual compounds was determined from the area peaks in the chromatogram of the
sample solution. UV spectra (k, nm) were determined on a Waters Photodiode Array Detector 2996
(Waters Corp., Milford, MA, U.S.A.) in ca 6x10"^ mol methanolic solution and log e (the logarithm of
molar absorption coefficient 8) was calculated for the absolute maximum
of individual target
compounds. Infrared spectra were recorded using KBr pellets on the FT-IR spectrometer Nicolet 6700
(Nicolet - Thermo Scientific, U.S.A.). All 'H-NMR spectra were recorded on a Bruker AM-500
(499.95 MHz for IH) instrument (Bruker BioSpin Corp., Germany). Chemicals shifts are reported in
ppm (6) to internal Si(CH3)4, when diffused easily exchangeable signals are omitted.
4.2. Synthesis
2-Methylquinazolin-4(3H)-one (1): Yield 77% of a white crystalline compound; mp 245-247 °C (lit.
mp 242-244 °C [62]); HPLC purity: 98.64%; UV (nm), Wlog e: 305.1/3.53; 'H-NMR [(CD3)2C0]
6: 2.45 (s, 3H, CHj), 7.44 (t, IH, Ar-H), 7.59 (d, J= 8.15 Hz, IH, Ar-H), 7.76 (t, IH, Ar-H), 8.13 (d,
J= 7.94 Hz, IH, Ar-H), 11.00 (s, IH, NH),
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3-(2-Hydroxyethyl)-2-methylquinazolin-4(3H)-one (2). Yield 52% of a white crystalline compound;
mp 154-156 °C; HPLC purity: 99.67%; UV (nm), Wlog e: 305.8/3.58; 'H-NMR (DMSO-^/6) S: 2.65
(s, 3H, CHs), 3.66 (q, 2H, CH2), 4.12 (t, 2H, CH2), 5.00 (t, IH, OH), 7.46 (t, IH, Ar-H), 7.57
(d, J= 8.14 Hz, IH, Ar-H), 7.77 (t, IH, Ar-H), 8.08 (d,
8.00 Hz, IH, Ar-H).
4.2.1. General procedures of synthesis of Compounds 3a-k
A mixture of compound 1 (0.01 mol) and the appropriate aldehyde (0.02 mol) was mixed
thoroughly and irradiated in monomode cavity of microwave reactor using pulse sequence
(3x5 minutes with 30 sec. intervals) at 250 W. During irradiation, the temperature was controlled
between the range 150-180 °C. After the reaction, the mixture was cooled and washed with boiling
ether. The product was crystallized from acetic acid.
2-(E)-Styrylquinazolin-4(3H)-one (3a). [63] Yield 50% of a white crystalline compound;
mp 253-255 °C (lit. mp 252 °C [64]); HPLC purity: 97.95%; UV (nm), Wlog s: 321.3/3.53;
'H-NMR (DMSO-Je) 5: 7.00 (d, J= 16.23 Hz, IH, C=C-H), 7.41 (t, HI, Ar-H), 7.42-7.49 (m, 3H,
Ar-H), 7.65-7.68 (m, 3H, Ar-H), 7.80 (t, IH, Ar-H), 7.95 (d, J= 16.16 Hz, IH, C=C-H), 8.10 (d, IH,
Ar-H), 12.35 (s, IH, N-H).
2-[(E)-2-(2-Methoxyphenyl)vmyl]quinazolin-4(3H)-one (3b). [63] Yield 76% of a white crystalline
compound; mp 234-236 °C (lit. mp 234-236 °C [64]); HPLC purity: 94.04%; UV (nm), 7.„iax/log a:
343.4/3.62; 'H-NMR (DMSC)-£/6) 5: 3.90 (s, 3H, OCH3), 7.02 (t, IH, Ar-H), 7.07 (d,y= 16.24 Hz, IH,
C=C-H), 7.11 (d, IH, Ar-H), 7.39 (t, IH, Ar-H), 7.45 (t, IH, Ar-H), 7.60 (d, IH,
Ar-H), 7.67 (d, IH, Ar-H), 7.79 (t, IH, Ar-H), 8.09 (d, IH, Ar-H), 8.15 (d,J= 16.12 Hz, IH, C=C-H),
12.36 (s, IH, N-H).
2-[(E)-2-(3-Methoxyphenyl)vmyl]quinazolm-4(3H)-one (3c). [63] Yield 68% of a white crystalline
compound; mp 239-241 °C; HPLC purity: 96.82%; UV (nm), X-max/log s: 326.4/3.58; 'H-NMR
(DMSO-t/6) 5: 3.81 (s, 3H, OCH3), 6.98 (d, IH, Ar-H), 7.01 (d,
16.81 Hz, IH, C=C-H), 7.22 (s,
IH, Ar-H), 7.23 (d, IH, Ar-H), 7.37 (t, IH, Ar-H), 7.47 (t, IH, Ar-H), 7.66 (d, IH, Ar-H), 7.80 (t, IH,
Ar-H), 7.91 (d,
16.14 Hz, IH, C=C-H), 8.10 (d, IH, Ar-H), 12.31 (s, HI, NH).
2-[(E)-2-(4-Methoxyphenyl)vinyl]quinazolin-4(3H)-one (3d). [63] Yield 33% of a
compound; mp 280-281 °C (lit. mp 284-285 °C [64]); HPLC purity: 94.36%; UV
322.7/3.59; 'H-NMR (DMSO-n^6) 5: 3.80 (s, 3H, OCH3), 6.84 (d,
16.23 Hz, IH,
2H, Ar-H), 7.45 (t, IH, Ar-H), 7.60 (d, 2H, Ar-H), 7.64 (d, IH, Ar-H), 7.78 (t,
(d, J= 16.08 Hz, IH, C=C-H), 8.08 (d, IH, Ar-H), 12.25 (s, IH, N-H).

white crystalline
(nm), A.max/log a:
C=C-H), 7.01 (d,
IH, Ar-H), 7.90

2-[(E)-2-(2,4-Dimethoxyphenyl)vmyl]quinazolm-4(3H)-one (3e). [63] Yield 57% of a white
crystalline compound; mp 228-230 °C (lit. mp 228-230 °C [64]); HPLC purity: 96.27%; UV (nm),
Wlog e: 350.1/3.67; ‘H-NMR (DMSO-r/6) 6: 3.82 (s, 3H, OCH,), 3.90 (s, 3H, OCH3), 6.63 (d, IH,
Ar-H), 6.64 (s, IH, Ar-H), 6.94 (d,
16.15 Hz, IH, C=C-H), 7.43 (t, IH, Ar-H), 7.53 (d, IH, Ar-H),
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7.64 (d, IH, Ar-H), 7.77 (t, IH, Ar-H), 8.07 (d,

15.21 Hz, IH, C=C-H), 8.08 (d, IH, Ar-H), 12.26

(s, IH, N-H).
2-[(E)-2-(3-Chlorophenyl)vinyl]quinazolin-4(3H)-one (3f). [63] Yield 93% of a white erystalline
eompound; mp 289 °C; HPLC purity: 96.51%; UV (nm), >^max/log a: 326.4/3.59; 'H-NMR (CDCI3) 5:
6.93 (d,

16.41 Hz, IH, C=C-H), 7.39 (d, 2H, Ar-H), 7.46-7.53 (m, 2H, Ar-H), 7.64 (s, IH, Ar-H),

7.79 (d,

16 Hz, IH, C=C-H), 7.77-7.83 (m, 2H, Ar-H), 8.33 (d, IH, Ar-H), 10.64 (s, IH, NH).

2-[(E)-2-(2-Bromophenyl)vinyl]qumazolin-4(3H)-one (3g). [63] Yield 71% of a white erystalline
eompound; mp 279 °C; HPLC purity: 98.84%; UV (nm), Wlog e: 326.9/3.59; ‘H-NMR (CDCI3) 5:
6.93 (d, J = 16.47 Hz,

IH, C=C-H), 7.40 (t, IH, Ar-H), 7.50 (t, IH, Ar-H), 7.67 (d,

J = 7.90 Hz, IH, Ar-H), 7.74-7.82 (m, 4H, Ar-H), 8.12 (d, J - 16.45 Hz, IH, C=C-H), 8.36 (d,
J= 7.88 Hz, IH, Ar-H), 10.96 (s, IH, NH).
2-[(E)-2-(3-Bromophenyl)vinylJquinazolin-4(3H)-one (3h). [63] Yield 43% of a white erystalline
eompound; mp 277-279 °C; HPLC purity: 97.34%; UV (nm), KJ^og c: 326.4/3.58; 'H-NMR
(CDCI3) 8: 6.91 (d,

16.33 Hz, IH, C=C-H), 7.33 (t, IH, Ar-H), 7.50-7.56 (m, 2H, Ar-H), 7.55 (s,

IH, Ar-H), 7.73 (d, ./= 16.49 Hz, IH, C=C-H), 7.76-7.82 (m, 3H, Ar-H), 8.33 (d, IH, Ar-H), 10.31 (s,
IH, NH).
2-[(E)-2-(4-Bromophenyl)vinyl]qumazolin-4(3H)-one (3i). [63] Yield 66% of a white er}'Stalline
eompound; mp 332 °C; HPLC purity: 97.64%; UV (nm), A,max/log e: 326.7/3.58; *H-NMR (DMSO-r/e)
5: 7.03 (d, IH, C=C-H), 7.49 (t, IH, Ar-H), 7.61 (d, IH, Ar-H), 7.64 (d, 2H, Ar-H), 7.66 (d, IH,
Ar-H), 7.68 (d, IH, Ar-H), 7.81 (t, IH, Ar-H), 7.91 (d, IH, C=C-H), 8.11 (d, IH, Ar-H), 12.36 (s, IH,
N-H).
2-[(E)-2-(4-Carbaldehydephenyl)vinyl]quinazolin-4(3H)-one (3j). [63] Yield 35% of a white
erystalline eompound; mp 218 °C; HPLC purity: 96.93%;. UV (nm), ^^max/log a: 337.9/3.69; 'H-NMR
(CDCI3) 5: 7.16 (d,

16.13 Hz, IH, C=C-H), 7.50 (t, IH, Ar-H), 7.69 (d, 2H, Ar-H), 7.82 (t, IH,

Ar-H), 7.87 (d, IH, Ar-H), 7.97 (d, IH, Ar-H), 8.00 (d, J= 16.21 Hz, IH, C=C-H), 8.11 (d, 2H, Ar-H),
9.95 (s, IH, CHO), 10.02 (s, IH, N-H).
2-[(E)-2-(2,3,4-Trihydroxyphenyl)vinyl]quinazolin-4(3H)-one (3k). [63] Yield 60% of a brown
erystalline eompound; mp 300 °C (deeomp.); HPLC purity: 97.67%; UV (nm), X,max/log s: 365.0/3.65;
'H-NMR (DMSO-de), 5: 6.39 (d, IH, Ar-H), 6.83 (d,
15.98 Hz, IH, C=C-H), 6.88 (d, IH, Ar-H),
7.40 (t, IH, Ar-H), 7.63 (d, IH, Ar-H), 7.75 (t, IH, Ar-H), 8.05 (d, IH, Ar-H), 8.10 (d,

16.05 Hz,

IH, C=C-H), 8.57 (s, IH, OH), 9.07 (s, IH, OH), 9.68 (s, IH, OH), 12.19 (s, IH, NH).
4.2.2. General proeedures of synthesis of Compounds 4a-e
A mixture of styrylquinazolinone derivatives 3 (0.01 mol), V,V-dimethylaniline (0.02 mol) and
phosphorus oxychloride (0.015 mol) in dry benzene (50 mL) was stirred and heated under reflux for
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3 h. The reaction mixture was then cooled and filtered. The filtrate was diluted with benzene (30 mL)
and the solution washed with water (50 mL), twice with 20 % aqueous NaOH (50 mL) and finally
twice with water. After drying with MgS04, the organic solvent was evaporated and the product
obtained was crystallized from heptane.
4-Chloro-2-(E)-styrylquinazoline (4a). [63] Yield 81% of an orange crystalline compound; mp
104 “C, (lit. mp 100-101 °C [65]); HPLC purity: 99.34%; UV (nm), Wlog s: 314.9/3.67; 'H-NMR
(DMS0-(/6) 5: 7.34 (d, J = 15.91 Hz, IH, C=C-H), 7.41 (t, IH, Ar-H), 7.47 (t, 2H, Ar-H), 7.77-7.80
(m, 3H, Ar-H), 8.02 (d, IH, Ar-H), 8.06 (t, IH, Ar-H), 8.12 (d,
16.01 Hz, IH, C=C-H), 8.26 (d,
lH,Ar-H).
4-Chloro-2-[(E)-2-(2-methoxyphenyl)vinyl]quinazolim (4b). [63] Yield 86% of a light yellow
crystalline compound; mp 153 °C; HPLC purity: 99.95%; UV (nm), Vnax/log e: 345.1/3.67; 'H-NMR
(DMSO-J6) 6: 3.98 (s, 3H, OCH3), 7.04 (t, IH, Ar-H), 7.12 (d, IH, Ar-H), 7.37 (d, J= 16.15 Hz, IH,
C-C-H), 7.40 (t, IH, Ar-H), 7.78 (t, IH, Ar-H), 7.82 (d, HI, Ar-H), 8.01 (d, IH, Ar-H), 8.06 (t, IH,
Ar-H), 8.27 (d, IH, Ar-H), 8.47 (d,
16.15 Hz, IH, C=C-H).
4-Chloro-2-[(E)-2-(3-methoxyphenyl)vinyl]qumazoline (4c). [63] Yield 81% of a light yellow
crystalline compound; mp 137 °C; HPLC purity: 98.62%; UV (nm), ?^max/log 8: 342.9/3.64; 'H-NMR
(DMSO-de) 5: 3.90 (s, 3H, OCH3), 6.98 (d, IH, Ar-H), 7.35 (d,
15.75 Hz, IH, C=C-H), 7.35-7.39
(m, 2H, Ar-H), 7.36 (s, HI, Ar-H), 7.80 (t, IH, Ar-H), 8.02 (d, HI, Ar-H), 8.06 (d, HI, Ar-H), 8.10 (d,
J= 15.82 Hz, IH, C=C-H), 8.28 (d, HI, Ar-H).
4-Chloro-2-[(E)-2-(4-methoxyphenyl)vinyl]qumazolme (4d). [63] Yield 51% of a yellow crystalline
compound; mp 130-131 °C, (lit. mp 130-131 °C [65]); HPLC purity: 97.43%; UV (nm), %iax/log e:
339.9/3.64; 'H-NMR (DMSO-r/s) 5: 3.87 (s, 3H, OCH3), 7.03 (d, 2H, Ar-H), 7.20 {d, J = 15.87 Hz,
IH, C=C-H), 7.75 (d, 2H, Ar-H), 7.76 (t, IH, Ar-H), 7.99 (d, IH, Ar-H), 8.04 (t, IH, Ar-H), 8.08
(d, ,7=15.89 Hz, IH, C=C-H), 8.25 (d, lH,Ar-H).
4-Chloro-2-[(E)-2-(2,4-dimethoxyphenyl)vinyl]quinazoline (4e). [63] Yield 48% of a yellow
crystalline compound; mp 172 °C; HPLC purity: 98.57%; UV (nm), A.max/log 8: 355.0/3.67;
IR (KBr, cm''): 2980, 2938, 1607, 1556, 1504, 1477, 1450, 1384, 1329, 959, 768, 756; 'H-NMR
[(CD3)2C0] 5: 3.88 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 6.64 (d, IH, Ar-H), 6.66 (s, IH, Ar-H), 7.27
(d, J=16.13 Hz, IH, C=C-H), 7.75 (d, IH, Ar-H), 7.60 (t, IH, Ar-H), 7.98 (d, IH, Ar-H), 8.02 (t, IH,
Ar-H), 8.25 (d, lH,Ar-H), 8.40 (d, 7=16.13 Hz, IH, C=C-H).
4.3. Lipophilicity HPLC determination (capacity factor k / calculated log k)
The HPLC separation module Waters Alliance 2695 XE and Waters Photodiode Array Detector
2996 (Waters Corp., Milford, MA, U.S.A.) were used. The chromatographic column Symmetry® Cig
5 pm, 4.6 X 250 mm. Part No. WAT054275, (Waters Corp., Milford, MA, U.S.A.) was used. The
HPLC separation process was monitored by Millennium32® Chromatography Manager Software,
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Waters 2004 (Waters Corp.). The mixture of MeOH p.a. (55.0%) and H2O-HPLC - Mili-Q Grade
(45.0%) was used as a mobile phase. The total flow of the column was 0.9 mL/min, injection 30 pL,
column temperature 30 °C and sample temperature 10 °C. The detection wavelength 210 nm was
chosen. The KI methanolic solution was used for the dead time (to) determination. Retention times (ta)
were measured in minutes. The capacity factors k were calculated using the Millennium32®
Chromatography Manager Software according to formula = (tR - tD)/tD, where Ir is the retention time
of the solute, whereas to denotes the dead time obtained via an unretained analyte. The log k values,
calculated from the capacity factor k of the individual compounds, are shown in Table 1.
4.4. Lipophilicity calculations
Log P, i.e., the logarithm of the partition coefficient for «-octanol/water, was calculated using the
programs CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, U.S.A.) and ACD/LogP
ver. 1.0 (Advanced Chemistry Development Inc., Toronto, Canada). Clog P values (the logarithm of
/7-octanol/water partition coefficient based on established chemical interactions) were generated by
means of the CS ChemOffice Ultra ver. 10.0 software. The results are shown in Table 1.
4.5. Study of inhibition photosynthetic electron transport (PET) in spinach chloroplasts
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and
Kralova [66]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was
determined spectrophotometrically (Genesys 6, fhermo Scientific, U.S.A.) using an artificial electron
acceptor 2,6-dichlorophenol-indophenol (DCIPP) according to Kralova et al. [67] and the rate of
photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements
were carried out in phosphate buffer (0.02 mol/L, pH 7.2) containing sucrose (0.4 mol/L), MgCf
(0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these experiments
and the samples were irradiated (~100 W/m^) from 10 cm distance with a halogen lamp (250 W) using
a 4 cm water filter to prevent warming of the samples (suspension temperature 22 °C). The studied
compounds were dissolved in DMSO due to their limited water solubility. The applied DMSO
concentration (up to 4%) did not affect the photochemical activity in spinach chloroplasts. The
inhibitory efficiency of the studied compounds was expressed by IC50 values, i.e. by molar
concentration of the compounds causing 50% decrease in the oxygen evolution rate relative to the
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-l,ldimethylurea, DCMU (Diuron®) was about 1.9 pmol/L [68]. The results are summarized in Table 2.
4.6. In vitro antimycobacterial evaluation
Clinical isolates of Mycobacterium avium complex CIT19/06, M. kansasii CITll/06, M. absessus
CIT21/06 and strain M. smegmatis MC2155 were grown in Middlebrook broth (MB), supplemented
with OADC supplement (Oleic, Albumin, Dextrose, Catalase, Becton Dickinson, U.K.). Identification
of these isolates was performed using biochemical and molecular protocols. At log phase growth, the
10 mL culture was centrifuged at 15,000 RPM for 20 minutes using a bench top centrifuge (Model CR
4-12 Jouan Inc. U.K). Following the removal of the supernatant, the pellet was washed in fresh
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Middlebrook 7H9GC broth and re-suspended in 10 mL of fresh supplemented MB. The turbidity was
adjusted to match McFarland standard No. 1 (3 x 10* CFU) with MB broth. A further 1:20 dilution of
the culture was then performed in MB broth.
The antimicrobial susceptibility of all four mycobacteria was investigated in 96 well plate format.
Here, sterile deionised water (150 pL) was added to all outer-perimeter wells of the plates to minimize
evaporation of the medium in the test wells during incubation. Each dilution (150 pL) was incubated
with each of the mycobacterial species (150 pL). Dilutions of each compound were prepared in
duplicate. For all synthesized compounds, final concentrations ranged from 300 pg/mL to 10 pg/mL.
All compounds were prepared in DMSO and subsequent dilutions were made in supplemented
Middlebrook broth. The plates were sealed with parafilm and were incubated at 37 °C overnight in the
case of M. smegmatis and M. absessus and for five days in the case of M. kansasii and M. avium
complex. Following incubation, a 10% addition of alamarBlue (AbD Serotec) was mixed into each
well and readings at 570 nm and 600 nm were taken, initially for background subtraction and
subsequently after 24 hour re-incubation. The background subtraction is necessary with strongly
coloured compounds which may interfere with the interpretation of any colour change. In
non-interfering compounds, a blue colour in the well was interpreted as an absence of growth, and
a pink colour was scored as growth. The MIC was initially defined as the lowest concentration which
prevented a visual colour change from blue to pink. The results are shown in Table 2.
4. 7. In vitro antifungal susceptibility testing
1 he broth microdilution test [69,70] was used for the assessment of in vitro antifungal activity of
the synthesized compounds against Candida albicans ATCC 44859 (CA), Candida tropicalis 156
(CT), Candida krusei ATCC 6258 (CK), Candida glabrata 20/1 (CG), Trichosporon asahii 1188
(TA), Aspergillus fumigatus 231 (AF), Absidia corymbifera 272 (AC), and Trichophyton
mentagrophytes 445 (TM). Fluconazole (FLU) was used as the standard of a clinically used
antimycotic drug. The procedure was performed with twofold dilution of the compounds in RPMI
1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-morpholinopropane-1-sulfonic acid (MOPS, Sigma, Germany). The final concentrations of the compounds ranged
from 500 to 0.975 pmol/L. Drug-free controls were included. The MIC was defined as an 80% or
greater (ICso) reduction of growth in comparison with the control. The values of MICs were
determined after 24 and 48 h of static incubation at 35 °C. For T. mentagrophytes, the final MICs were
determined after 72 and 120 h of incubation. The results are summarized in Table 3.
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Abstract: In this study, a series of fourteen ring-substituted 8-hydroxyquinoline
derivatives were prepared. The synthesis procedures are presented. The compounds were
analyzed using RP-HPLC to determine lipophilicity. They were tested for their activity
related to inhibition of photosynthetic electron transport (PET) in spinach {Spinacia
oleracea L.) chloroplasts. Primary in vitro screening of the synthesized compounds was
also performed against four mycobacterial strains and against eight fungal strains. Several
compounds showed biological activity comparable with or higher than the standards
isoniazid or fluconazole. For all the compounds, the relationships between the lipophilicity
and the chemical structure of the studied compounds are discussed.
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1. Introduction
A quinoline moiety is present in many classes of biologically-active compounds. A number of them
have been used clinically as antifungal, antibacterial and antiprotozoic drugs [1,2], as well as
antituberculotic agents [3-5]. Some quinoline-based compounds also show antineoplastic,
antiasthmatic and antiplatelet activity [6-11]. A series of compounds derived from 8-hydroxy quinoline
and styrylquinoline derivatives were recently synthesized as potential HIV-1 integrase inhibitors
[12-15]. These compounds showed a significant similarity to some novel antifungal agents, namely
homoallylamines. [16]. Our previous study dealing with 8-hydroxy quinoline and styrylquinoline
derivatives showed that they could also possess strong antifungal activity [17,18]. According to the
results reported recently, some new hydroxyquinoline derivatives also possess interesting herbicidal
activities [17,19-22]. In addition, some of the investigated quinoline derivatives also showed
antineoplastic activity [19,23].
Tuberculosis is a worldwide pandemic. About 1/3 of the world's population is infected with
Mycobacterium tuberculosis, and every year almost 2 million people die as a result [24]. I’he
Mycobacterium genus is composed of the M. tuberculosis complex and other species known as
nontuberculous mycobacteria (NTM). In recent decades, the decrease in the prevalence of tuberculosis
in developed countries has resulted in the increase in the proportion of diseases caused by NTM [25].
Among these species, the M. avium complex (MAC) has emerged as a major human pathogen, being a
common cause of disseminated disease and death in patients with HIV/AIDS [26].
Chronic pulmonary disease is the most common clinical manifestation among the diseases caused
by NTM, and the most common pathogens are the species belonging to the MAC, followed by
M. kansasii. The clinical characteristics of NTM-related pulmonary disease are, in many cases,
extremely similar to those of tuberculosis. Other clinical manifestations are caused principally by
M. fortuitum, M. smegmatis and M. abscessus due to peritoneal infection as a result of catheterization,
postsurgical infections, such as those following mammoplasty and heart transplant, as well as those
following invasive procedures [27]. The above mentioned non-tuberculous strains are sometimes
resistant to commonly used drugs (isoniazid, rifampicin, pyrazinamide) and other anti-tuberculous
drugs [24], therefore systematic development of new effective compounds is necessary. Similarly, the
discovery of new drugs for the treatment of systemic mycoses with novel modes of action due to the
rapid growth of the immunocompromised patient population and development of resistance to the
present azole therapies, and high toxicity of polyenes [28] is indispensable. It should be stressed that
hydroxyquinoline and its derivatives were introduced as antifungal or antimycobacterial agents in
clinical practice and novel compounds of this type are still investigated [3-5,29,30].
Over 50% of commercially available herbicides act by reversibly binding to photosystem II (PS II),
a membrane-protein complex in the thylakoid membranes which catalyses the oxidation of water and
the reduction of plastoquinone [31] and thereby inhibit photosynthesis [32-34]. Some organic
compounds, e.g., substituted benzanilides [35] or substituted anilides of 2,6-disubstituted pyridine-4-
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thiocarboxamides [36] or pyrazine-2-carboxylic acids [37] were found to interact with tyrosine
radieals Tyrz and Tyro which are situated in Di and D2 proteins on the donor side of PS II and due to
this interaction the photosynthetic electron transport is interrupted.
This is a follow-up paper to our previous articles [12-15,17-23] dealing with syntheses and
biological activities of ring-substituted quinoline derivatives. On the basis of formerly described
azanaphtalenes we tried to seareh for new modifications of quinoline moiety that can trigger
interesting biologieal aetivity.
Primary in vitro screening of the synthesized compounds was performed against four mycobacterial
strains and against eight fungal strains. The compounds were also tested for their photosynthesisinhibiting activity (the inhibition of photosynthetic electron transport) in spinach chloroplasts
{Spinacia oleracea L.). Relationships among the structure and in vitro antimicrobial activities or/and
inhibitory activity related to inhibition of photosynthetic electron transport (PET) in spinach
chloroplasts of the new compounds are discussed.
2. Results and Discussion
2.1. Chemistry
All studied compounds were prepared according to Scheme 1. Compounds 1-3 were obtained
according to a previously described proeedure [14]. Sulfonamides 4-7 were obtained from
8- hydroxyquinoline through chlorosulfonation and amination. Compound 8 was obtained from
commercially available 8-hydroxy-2-aminoquinoline by acylation in acetic anhydride. Styryquinolines
9- 14 were obtained from 5,7-dichloro-8-hydroxyquinaldine and the appropriate aldehyde in a two-step
reaction in acetic anhydride followed by pyridine/water.
Scheme 1. Synthesis of studied compounds.

4-7

Cl

Reagents and conditions: a) H2SO4/HNO3, Br2, AC2O; b) CISO3H, 0 °C; c) MeOH, amine;
d) aldehyde, AC2O, Py/H20.
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2.2. Lipophilicity

Many low molecular weight drugs cross biological membranes through passive transport, which
strongly depends on their lipophilicity. Lipophilicity is a property that has a major effect on
absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) properties as well as
pharmacological activity. Lipophilicity has been studied and applied as an important drug property for
decades [38].
Table 1. Comparison of the calculated lipophilicities (log /*/Clog P) with the determined
log k values.
R
OH

0.5695
0.1479
0.3786
0.3293
0.3373
0.3349
0.3902

log P/Clog P
ChemOffice
1.69/2.0836
0.37/-0.703
1.72/-0.004
0.61 / 1.43775
2.17/2.5697
3.17 / 3.83597
4.09/4.74397

logP
ACD/LogP
2.00 ±0.32
1.70 ±0.88
2.39 ±0.91
1.19±0.81
1.97 ±0.78
3.29 ±0.79
4.18 ±0.78

0.3583

1.33 /0.93375

0.52 ±0.73

Comp.

R

log A

1
2
3
4
5
6

5-NO2
5-SO3H-7-NO2
5-S03H-7-Br
5-SO2—

5-S02NHCH(CH3)2
5-S02NHC2H4Ph
5-S02NHC4H8Ph

7

8
0

Cl

^ R

OH

1.5854
1.5866
1.5858
1.5867
1.5864

log P/Clog P
ChemOffice
5.07/5.36425
5.07/5.36425
4.68 /4.69725
4.68 /4.69725
4.66/4.89345

logP
ACD/LogP
5.62 ±0.35
6.37 ±0.36
5.65 ±0.37
6.20 ±0.37
4.87 ±0.36

2.5760

8.88 /9.92051

10.50 ±0.39

Comp.

R

log A

9
10
11
12
13

2-OH
4-OH
2,4-OH
3,5-OH
2-OH-5-OAC
Cl

14

,ci

OH

Cl

Hydrophobicities (log /’/Clog P) of the compounds 1-14 were calculated using two commercially
available programs (ChemDraw Ultra 10.0 and ACD/LogP) and also measured by means of the
RP-HPLC determination of capacity factors k with subsequent calculation of log k. The procedure was
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performed under isocralic conditions with methanol as an organic modifier in the mobile phase using
an end-capped non-polar Cis stationary RP column. The ChemDraw program did not resolve various
lipophilicity values of individual positional isomers, that is, the same log P/Clog P data were
calculated for 9/10 and 11/12. The results are shown in Table 1 and illustrated in Figure 1.
Figure 1. Comparison of the computed log P/Clog P values using two programs with the
calculated log k values.

The results obtained with all the compounds show that the experimentally-determined
lipophilicities (log k) of compounds 1-14 are lower than those indicated by the calculated
log P/Clog P, as shown in Figure 1. The results indicate that experimentally-determined log k values
correlate relatively poorly with the calculated values. The correlation factors R yielded 0.83 for
ChemOffice log P; 0.86 for ACD/LogP and 0.55 for ChemOffice Clog P respectively.
These facts are probably caused by intramolecular interactions. As expected, compound 14 showed
the highest lipophilicity, while compound 2 exhibited the lowest. The presence of the sulfonic acid
moiety decreased the lipophilicity. Compound 6 showed less hydrophobicity compared with 5,
contrary to the lipophilicity results calculated by software. This observation has been made previously
[19]. Interesting results were obtained with subseries 9-13. Comparing the lipophilicity data log k of
both OH-monosubstituted isomers 9 and 10, it can be stated that 4-hydroxy derivative 10 possessed
higher hydrophobicity than 2-hydroxy isomer 9. This fact was predicted only by ACD/LogP. When
OH-disubstituted compounds were compared, it was found that strong intramolecular interactions play
a significant role. Hydrophobicity increased in the following order: 11 (2,4-OH) < 12 (3,5-OH). These
results were also predicted by ACD/LogP.
It can be assumed, that log k values specify lipophilicity within the individual series of studied
compounds. Calculated log P data (ChemDraw) of compounds 1-8 corresponded with experimentallydetermined log k, while for compounds 9-14 there was better agreement between the calculated log P
data (ACD/LogP) and experimentally-determined log k.
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2.3. Biological activities
The compounds under investigation could be divided into two groups based on their chemical
structure. Group 1 included compounds 1-8, and Group 2 compounds 9-14. The compounds showed a
wide range of biological activities and structure-activity relationships observations are interesting. All
the results are shown in Table 2 and Table 3.
Table 2. ICgo values related to PET inhibition in spinach chloroplasts in comparison with
3-(3,4-dichlorophenyl)-l,l-dimethylurea (DCMU) standard and in vitro antifungal activity
(ICgo) of compounds 1-10, 12 and 14 compared with fluconazole (FLU) standard.
(ND = not determined due to insufficient solubility of the compound).
MIC Ipmol/Ll
Comp.

PET reduction
IC50 [pmol/L]

CA"
24h
48h
>500
>500
>250
>250
0.77
1.95
125
500
125
250
125
125
>125
>125
15.60
62.50
>125
>125
125
>125
>125
>125
0.98
3.90

cr
24h
48h
>500
>500
>250
>250
1.95
3.90
500
500
250
250
125
125
>125
>125
31.25
31.25
>125
>125
125
>125
>125
>125
1.95
7.81

CK^
24h
48h
>500
>500
>250
>250
3.90
3.90
250
500
250
250
125
125
>125
>125
62.50
62.50
>125
>125
125
>125
>125
>125
0.98
1.95

CG^
24h
48h
>500
>500
>250
>250
1.95
3.90
500
500
125
250
125
125
>125
>125
31.25
62.50
>125
>125
125
>125
>125
>125
0.49
1.95

tb«

24h
48h
>500
>500
>250
>250
3.90
3.90
500
500
250
500
125
125
>125
>125
62.50
125
>125
>125
125
>125
>125
>125
3.90
15.62

AF^
24h
48h
>500
>500
>250
>250
0.77
1.95
500
500
250
250
125
125
>125
>125
62.50
62.50
125
125
125
125
125
125
3.90
15.62

AC*
24h
48h
>500
>500
>250
>250
7.80
7.80
125
250
125
125
125
125
>125
>125
62.50
62.50
62.50
125
31.25
62.50
62.50
62.50
15.62
31.25

TM*
72h
I20h
>500
>500
>250
>250
1.95
1.95
250
250
62.50
125
125
125
>125
>125
62.50
62.50
62.50
62.50
15.62
62.50
15.62
15.62
3.90
7.81

1

78.0

L

ND

\

33.5

4

ND

c

54.4

0

304

7

616

Q

0

306

Q

y

ND

10

660

12

341

14

334

DCMU

1.9

-

-

-

-

-

-

-

-

FLU

—

0.06
0.12

0.12
>125

3.91
15.62

0.98
3.91

0.24
0.48

>125
>125

>125
>125

1.95
3.91

according

to

The

MIC

determination

was

performed

" M27-A2 for yeasts (ICgo value) and ^ M3^-A for moulds (IC50 value).

the

CLSl

reference

protocol:
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2.3.1. Inhibition of photosynthetic electron transport (PET) in spinach chloroplasts
Quinoline derivatives 1-10, 12 and 14 showed a wide range of activity related to inhibition of
photosynthetic electron transport (PET) in spinach chloroplasts, see Table 2. Three compounds
showed moderate inhibitory IC50 values: 33.5 pmol/L (3), 54.4 pmol/L (5) and 78.0 pmol/L (1) while
the activity of all the other studied compounds was very low. PET inhibition by 2, 4 and 9 could not be
determined due to precipitation of the compounds during the experiments.
The highest PET inhibition was shown by compounds 3, 5 and 1 with suitable aqueous solubility as
well as lipophilicity. The sulfonic acid moiety contributed to enhanced aqueous solubility whereas
a 7-bromo moiety (compound 3) increased the lipophilicity. Herbicidal effects of organic compounds
with bromo or nitro substituents were observed previously [39]. Bulkiness and rigidity of the chain in
the R substituent play a liindamental role in the series of sulfonamides 4-7, in addition to lipophilicity
and water-solubility. The least lipophilic morpholine derivative 4 did not show any activity. On the
other hand, phenylbutyl substitution in compound 7 is probably too bulky for it to reach the site of
action in the photosynthetic electron transport chain and thus the inhibitory activity of this compound
is low. Within the sulfonamide series the isopropyl substituent was the most advantageous from the
aspect of effective PET inhibition and further lipophilicity increase caused reduction of inhibitory
activity. On the other hand, great differences in the activity of compounds characterized with rather
small differences in the lipophilicity (the log k values of compounds belonging to Group 1) indicate
that the position of substituents and their electronic Hammett's parameters o (especially electronwithdrawing effect) seem to be also important for biological activity. Lipophilicity of the discussed
compounds is only a secondary parameter influencing PET-inhibiting activity. In general. Group 2
compounds exhibited only slight inhibition of PET and IC50 values determined for three compounds do
not enable conclusions about structure-activity relationships.
2.3.2. In vitro antifungal susceptibility testing
Quinoline derivatives 1-10, 12 and 14 were tested for their in vitro antifungal activity. The results
are shown in Table 2. Two compounds 3 and 14 showed very high antifungal activity, comparable or
higher than the standard fluconazole.
Generally, Group 1 showed lower biological activity than Group 2, although compound 3
demonstrated high activity against all fungal strains. Compounds 1, 2, 4-7 did not show any antifungal
activity. Compound 8 showed only moderate activity especially against Candida albicans ATCC
44859.
Unfortunately due to general low activity, no thorough structure-activity relationships (SAR) can be
established. Nevertheless, an interesting relationship can be observed. According to the results
presented in Tables 1 and 2 it can be concluded that bulky substituents and low lipophilicity decreased
antifungal activity. A bromo moiety (compound 3) seems to be very important for high antifungal
effect, as was reported recently [17]. Contrary to all expectations [18], compounds with a nitro moiety
(/.e., 1, 2) did not show any activity. It can be concluded that relatively minor differences in
lipophilicity were correlated with major differences in the activity of compounds. This suggests that
for biological activity, the position of substituents and their electronic Hammett's parameters o seem to
be important. Similar observations were made with the PET-inhibiting activity.
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Compound 14 showed the highest antifungal activity within Group 2. The compounds 9-12 showed
only a moderate activity especially against Absidia corymbifera 272 and Trichophyton mentagrophytes
445. Contrary to all expectations [18], 9 (2-OH substitution) possessed less activity than 10 and 12
(4-OH or 3,5-OH respectively). This fact is probably caused by low solubility of 9. Lipophilicity is
probably an important parameter influencing the activity.
233. In vitro antimycobacterial evaluation
Six compounds within Group 2 9-14 were evaluated for their in vitro antimycobacterial activity
against four mycobacterial strains. The results are shown in Table 3. Compound 12 (3,5-OH) did not
exhibit any significant antimycobacterial activity and compounds 9-11, 13 showed only medium
and/or moderate activities. Nevertheless, compound 14 had an interesting MIC especially against
M. smegmatis, M. kansasii and M. absessus. This compound was more active than the standard
pyrazinamide (PZA) and in case of M smegmatis, its activity was comparable with the standard
isoniazid (INH).
Table 3. Antimycobacterial activity MIC/IC90 [pg/mLJ of compounds 9-14 in comparison
with the standards, pyrazinamide (PZA) and isoniazid (INH).
Comp.
9
10
11
12
13
14
PZA
INH

M. smegmatis
100
150
100
>100
100
40
>100
39

MIC/IC90 fpg/mL]
M. absessus
M. kansasii
>300
>300
>300
>300
>100
>100
>300
>300
>300
>300
40
130
>100
>100
<10
>100

M. avium complex
>300
>300
>100
>300
>300
>300
>100
<10

Due to medium and/or moderate activity of the majority of evaluated compounds, it is difficult to
determine simple structure-activity relationships. According to Tables 1 and 3, it can be concluded that
lipophilicity (log k) and other physico-chemical parameters only influence secondary characteristics of
the compounds.
3. Conclusions
A series of fourteen ring-substituted 8-hydroxyquinolines were prepared and characterized.
Compounds 1,3-14 are original new structures. All the prepared quinoline derivatives were analyzed
using a RP-HPLC method for the measurement of lipophilicity and their lipophilicity was determined.
The prepared compounds were tested for their antifungal and antimycobacterial activity and for their
activity related to the inhibition of photosynthetic electron transport (PET) in spinach chloroplasts
{Spinacia oleracea L.). 7-Bromo-8-hydroxyquinoline-5-sulfonic acid (3) and 5,7-dichloro-2-(2-{4-[2(5,7-dichloro-8-hydroxy-quinolin-2-yl)vinyl]phenyl}vinyl)quinolin-8-ol (14) possessed the highest in
vitro antifungal activity and 3 and 8-hydroxy quinoline-5-sulfonic acid isobutylamide (5) showed the
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highest PET-inhibiting activity. Compound 14 showed the highest antimycobacterial activity. In
general, compounds 3 and 14 showed the highest inhibitory effects within the series.
4. Experimental
4.1. General
All reagents were purchased from Aldrich. Kieselgel 60, 0.040-0.063 mm (Merck, Darmstadt,
Germany) was used for column chromatography. TEC experiments were performed on aluminabacked silica gel 40 F254 plates (Merck, Darmstadt, Germany). The plates were illuminated under UV
(254 nm) and evaluated in iodine vapour. The melting points were determined on Boetius PHMK 05
(VEB Kombinat Nagema, Radebeul, Germany) and are uncorrected. Elemental analyses (E.A.) were
earned out on an automatic Perkin-Elmer 240 microanalyser (Boston, MA, USA) for C, H, N and are
within 0.4% of theoretical values. The purity of the final compounds was checked by the HPLC
separation module Waters Alliance 2695 XE (Waters Corp., Milford, MA, USA). The detection
wavelength 210 nm was chosen. The peaks in the chromatogram of the solvent (blank) were deducted
from the peaks in the chromatogram of the sample solution. The purity of individual compounds was
determined from the area peaks in the chromatogram of the sample solution. UV spectra (A., nm) were
determined on a Waters Photodiode Array Detector 2996 (Waters Corp., Milford, MA, USA) in ca
dxlO'*^ mol methanolic solution and log c (the logarithm of molar absorption coefficient e) was
calculated for the absolute maximum >umax of individual target compounds. All ’H-NMR spectra were
recorded on a Bruker AM-500 (499.95 MHz for *H), and '^C-NMR spectra were recorded on a Bruker
AM-400 (100 MHz) instrument (Bruker BioSpin Corp., Germany). Chemicals shifts are reported in
ppm (5) with reference to internal Si(CH3)4, when diffused easily exchangeable signals are omitted.
4.2. Synthesis
5-Nitroquinolin-8-ol (1). Yield: 25% of a yellow crystalline compound; Mp. 179-180 °C; HPLC purity
98.09%; UV (nm), Wlog e: 398.4/3.67) [14].
8-Hydroxy-7-nitroqiiinoline-5-sulfonic acid (2). Yield: 54% of a bright yellow crystalline compound;
Mp. 265 °C; HPLC purity 97.97%; UV (nm), Wlog s: 427.9/3.71) [40].
7-Bromo-8-hydroxyquinoline-5-sulfonic acid (3). Yield: 25% of a beige crystalline compound; Mp.
280 °C; HPLC purity 98.32%; UV (nm), Wlog s: 264.2/3.69) [14].
5-(Morpholine-4-sulfonyl)quinolin-8-ol (4). 8-Hydroxyquinoline-5-sulfonyl chloride (2.4 g, 0.01 mol)
was dissolved in dry MeOH (30 mL) and heated to reflux. Then morpholine (1.75 mL, 0.02 mol) was
added dropwise. After 2 h of heating the resulted mixture was concentrated in vacuo and the resulting
brown oil put into dichloromethane (45 mL). The orange precipitate formed was filtered off and
recrystallized from MeOH. Yield 73% of a light yellow crystalline compound; Mp. 172 °C; E.A.
Calcd.: C 54.53%, H 5.23%, N 9.08%; found: C 54.26%, H 5.31%, N 9.27%; HPLC purity 97.89%;
UV (nm), >L,„ax/log e: 264.0/3.65; 'H-NMR (DMSO-i/6), 5: 2.52 (s, IH), 3.03 (t, J= 4.6 Hz, 4H), 3.70
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(t, J= 4.7 Hz, 4H), 6.95 (d, ./= 7.9 Hz, IH), 7.80 (d, J= 7.9 Hz, IH), 9.05 (d, J= 8.4 Hz, IH), 9.10 (d,
J=8.4 Hz, 2H).
8-Hydroxyquinoline-5-sulfonic acid isobutylamide (5). 8-Hydroxyquinoline-5-sulfonyl chloride (2.2 g,
0.01 mol) was dissolved in dry MeOH (30 mL) and heated to reflux. Then 2-butylamine (2.02 mL,
0.02 mol) was added dropwise. After 2 h of heating a yellow solid was precipitated from the reaction
mixture. After cooling the solid was filtered and crystallized from MeOH. Yield 50% of a yellow
crystalline compound; Mp. 151 °C; E.A. Calcd.; C 55.70%, H 5.75%, N 9.99%; found: C 55.67%,
H 5.63%, N 9.84%; HPLC purity 97.29%; UV (nm), Wlog s; 265.2/3.64; ‘H-NMR {DMSO-d(,), 5:
0.85 (t, J= 7.4 Hz, 3H), 1.05 (d,
6.4 Hz, IH), 1.50 (m, 2H), 2.50 (s, IH), 2.95 (m, IH), 6.95 (d,
8.0 Hz, IH), 7.80 (d, J= 7.9 Hz, IH), 9.05 (d, J= 7.6 Hz, IH), 9.10 (d, J= 7.3 Hz, 2H).
8-Hydroxyquinoline-5-sulfonic acid (2-phenylethyl)amide (6). Obtained in similar way to 4 from
8-hydroxyquinoline-5-sulfonyl chloride and phenylethylamine. Yield: 25% of a yellow crystalline
compound; Mp. 104 °C; E.A. Calcd.: C 62.18%, H 4.91%, N 8.53%; found: C 62.32%, H 4.86%,
N 8.71%. HPLC purity 97.37%; UV (nm), Wlog s: 265.5/3.68; ‘H-NMR (DMSO-r^), 5: 1.38 (d,
./= 6.7 Hz, 2H), 2.50 (t, J = 1.6 Hz, IH), 2.66 (s, IH), 6.90 (d, J = 7.8 Hz, IH), 7.30-7.41 (m, 2H),
7.72 (d,
8.0 Hz, 2H), 8.96 (d, J= 8.8 Hz, HI), 7.42-7.44 (m, 5H), 7.25 (d,
7.5 Hz, IH).
8-Hydroxyquinoline-5-sulfonic acid (4-phenylbutyl)amide (7). Obtained in similar way to 4 from
8-hydroxyquinoline-5-sulfonyl chloride and 4-phenylbuthylamine. Yield: 55% of a yellow crystalline
compound; Mp. 125 °C; E.A. Calcd: C 64.84%, H 5.99%, N 7.56%; found: C 65.02%, H 5.85%,
N 7.69%; HPLC purity 98.60%; UV (nm), Wlog c: 265.3/3.68; 'H-NMR (DMSO-de), 5: 1.44-1.58
(m, 2H), 2.49 (s, IH), 2.67 (t,
6.8 Hz, IH), 6.95 (d,
7.9 Hz, IH), 2.56 (t,
7.2 Hz, 2H), 7.18
(d, J= 6.8 Hz, IH), 7.24 (t, ./= 7.0 Hz, 5H), 7.54-7.58 (m, 2H), 7.82 (d, J = 7.8 Hz, IH), 9.06 (d,
J= 8.5 Hz, IH), 9.12 (d, J= 8.5 Hz, 2H).
2-Acetylaminoquinolin-8-yl acetate (8). 2-Amino-8-hydroxyquinoline (2.5 g, 0.01 mol) and acetic
anhydride (4 g, 3 mL, 0.04 mol) was mixed and heated in the microwave reactor at the boiling point
for 5 min, then evaporated until dryness. Crude product was recrystalized from EtOH and dried. Yield:
53% of a white crystalline compound; Mp. 120-126 °C; HPLC purity 99.69%; UV (nm), A.max/log s:
258.3/3.69; E.A. Calcd: C 63.93%, H 4.95%, N 11.47%; found: C 63.82%, H 4.56%, N 11.25%;
'H-NMR (DMSO-rf6), 8: 2.19 (s, 3H), 2.22 (s, 3H), 7.45 (m, 2H), 7.61 (d, J = 8.65Hz, IH), 7.8 (t,
7=9.5Hz, IH), 8.37 (d,J= 9.0Hz, IH), 10.5 (s, IH).
4.2.1. General method for synthesis of compounds 9-14.
To quinaldine (0.01 mol) in acetic anhydride (30 mL) an appropriate aldehyde (0.04 mol) was
added and resulting mixture was heated under reflux for 24 h. Then, the liquid was evaporated in
vacuo, pyridine (30 mL) and water (10 mL) were added and the mixture further heated for 3 h under
reflux. Then mixture was evaporated to dryness and solid was taken up in dichloromethane and
filtered. Crude product was recrystalized from EtOH and dried.
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5.7- Dichloro-2-[2-(2-hydroxyphenyl)vinyl]qumolin-8-ol (9). Yield 87% of a beige crystalline
compound; Mp. 141 °C; E.A. Calcd.: C 61.47%, H 3.34%, N 4.22%; found: C 61.87%, H 3.05%,
N 4,12%; HPLC purity 98.10%; UV (nm), X„„x/log e: 309.9/3.61; 'H-NMR (DMSO-rf6), 8: 6.88 (t,
J=1A Hz, IH, phenyl), 6.95 (A, J = 8.1 Hz, IH, phenyl), 7.20 (t,
7.7 Hz, IH, phenyl), 7.57 (d,
t/= 16.3 Hz, IH, vinyl), 7.61 (d, J = 7.7 Hz, IH, phenyl), 7.68 (s, IH, quinaldine), 7.93 (d, J = 8.8 Hz,
IH, quinaldine), 8.23 (d, J= 16.3 Hz, IH, vinyl), 8.39 (d, J = 8.8 Hz, IH, quinaldine), 10.08 (s, IH,
OH), 10.46 (bs, IH, OH); '^C-NMR (DMSO-*), 8: 116.01, 116.66, 119.63, 119.93, 122.19, 123.40,
123.94, 127.22, 127.84, 129.10, 130.56, 133.06, 133.55, 139.35, 149.11, 156.57, 156.74.
5.7- Dichloro-2-[2-(4-hydroxyphenyl)vmyl]quinolm-8-ol (10). Yield 86% of a beige crystalline
compound; Mp. 198 °C; E.A. Calcd.: C 61.47%, H 3.34%, N 4.22%; found: C 61.54%, H 3.32%,
N 4.28%; HPLC purity 98.52%; UV (nm), Wlog e: 309.9/3.58; ‘H-NMR (DMSO-t/6), 8: 6.85 (d,
J= 7.2 Hz, 2H, phenyl), 7.28 (d, J= 16.0 Hz, IH, vinyl), 7.56 (d, J= 7.3 Hz, 2H, phenyl), 7.69 (d,
J = \ J Hz, IH, quinaldine), 7.86 (dd, J= 2 Hz, J= 8.8 Hz, IH, quinaldine), 8.18 (d, ./= 16.1 Hz,
IH, vinyl), 8.40 (dd, J = 1.3 Hz, J = 8.8 Hz, IH, quinaldine), 9.84 (s, IH, OH), 10.30 (bs, IH, OH);
'^C-NMR (DMSO-rfs), 5: 115.17, 115.73, 119.02, 122.07, 123.19, 123.41, 126.41, 127.14, 128.97,
132.97, 136.53, 138.66, 148.36, 155.67, 158.52.
5.7- Dichloro-2-[2-(2,4-dihydroxyphenyl)vinyl]quinoliri-8-ol (11). Yield 83% of a beige crystalline
compound; Mp. 102-1030 °C; HPLC purity 98.96%; UV (nm), A.,nax/log e: 321.9/3.65 [41].
5.7- Dichloro-2-[2-(3,5-dihydroxyphenyl)vinylJquinolin-8-ol (12). Yield 93% of a beige crystalline
compound; Mp. 206 °C; HPLC purity 98.59%; UV (nm), %iax/log e: 314.5/3.68 [42].
5.7- Dichloro-2-[2-(2-hydroxy-5-acetoxyphenyl)vmyl]quinolin~8-ol (13). Yield 93% of a beige
crystalline compound; Mp. 205-206 °C; E.A. Calcd.: C 31.62%, H 1.59%, N 3.69%; found:
C 33.00%, H 2.35%, N 3.72%; HPLC purity 98.58%; UV (nm), X,„ax/log e: 345.1/3.63; 'H-NMR
(CDClj), 8: 2.34 (s, 3H, CHj), 7.22 (d,
16.4Hz, IH, vinyl), 7.85 (d,
16.4 Hz, IH, vinyl), 7.40 (s,
IH, quinaldine), 6.61 (d,
8.7 Hz, HI, quinaldine), 8.15 (d, J = 8.7 Hz, IH, quinaldine), 7.54 (d,
J = 8.8 Hz, IH, phenyl), 7.31 (d, J = 2.7 Hz, IH, phenyl), 6.81 (dd, J = 2.7 Hz, J = 8.7 Hz, IH,
phenyl); '’C-NMR (CDCI3), 8: 25.58, 115.27, 117.31, 119.97, 120.64, 121.21, 122.78, 123.24, 124.79,
127.43, 128.00, 129.01, 130.43, 133.97, 138.81, 147.84, 144,99, 152.21, 155.71, 177.45.
5,7-Dichloro-2-(2-{4-[2-(5,7-dichloro-8-hydroxyquinoUn-2-yl)vinyl]phenyl}vinyl)quinolm-8-ol (14).
Yield 69% of a dark brown crystalline compound; Mp. 300 °C; HPLC purity 98.68%; UV (nm),
Wlog s: 309.9/3.67 [42].
4.3. Lipophilicity determination by HPLC (capacity factor k/calcidated log k)
A Waters Alliance 2695 XE HPLC separation module and Waters Photodiode Array Detector 2996
(Waters Corp., Milford, MA, USA) were used. A Symmetry® Cig 5 pm, 4.6 x 250 mm. Part No.
WAT054275, (Waters Corp., Milford, MA, USA) chromatographic column was used. The HPLC
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separation process was monitored by Millennium32® Chromatography Manager Software, Waters
2004 (Waters Corp., Milford, MA, USA). A mixture of MeOH p.a. (55.0%) and H2O-HPLCMili-Q Grade (45.0%) was used as a mobile phase. The total flow of the column was 0.9 mL/min,
injection 30 pL, column temperature 30 °C and sample temperature 10 °C. The detection wavelength
210 nm was chosen. The KI methanolic solution was used for the dead time (to) determination.
Retention times (tR) were measured in minutes.
The capacity factors k were calculated using the Millennium32® Chromatography Manager
Software according to formula k = (tR - tD)/tD, where tR is the retention time of the solute, whereas to
denotes the dead time obtained via an unretained analyte. Log k, calculated from the capacity factor k,
is used as the lipophilicity index converted to log P scale. The log k values of the individual
compounds are shown in Table 1.
4.4. Lipophilicity calculations
Log P, i.e. the logarithm of the partition coefficient for /7-octanol/water, was calculated using the
programs CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, USA) and ACD/LogP ver.
1.0 (Advanced Chemistry Development Inc., Toronto, Canada). Clog P values (the logarithm of
^7-octanol/water partition coefficient based on established chemical interactions) were generated by
means of CS ChemOffice Ultra ver. 10.0 (CambridgeSoft, Cambridge, MA, USA) software. The
results are shown in Table 1.
4.5. In vitro antifungal susceptibility testing
The broth microdilution test [43-45] was used for the assessment of in vitro antifungal activity of
the synthesized compounds against Candida albicans ATCC 44859 (CA), Candida tropicalis 156
(CT), Candida krusei ATCC 6258 (CK), Candida glabrata 20/1 (CG), Trichosporon beigelii 1188
(TB), Aspergillus fumigatus 231 (AT), Absidia corymbifera 272 (AC), and Trichophyton
mentagrophytes 445 (TM). Fluconazole (FLU) was used as the standard of a clinically used
antimycotic drug. The procedure was performed with twofold dilution of the compounds in RPMI
1640 (Sevapharma a.s., Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-morpholinopropane-1-sulfonic acid (MOPS, Sigma, Germany). The final concentrations of the compounds ranged
from 500 to 0.975 pmol/L. Drug-free controls were included. The MIC determination was performed
according to the CLSI (formerly NCCLS) reference protocol M27-A2 for yeasts (ICso value) and
M38-A for moulds (IC50 value). ICso and IC50 were defined as an 80% resp. 50% or greater reduction
of growth in comparison with the control. The values of MICs were determined after 24 and 48 h of
static incubation at 35 °C. For T. mentagrophytes, the final MICs were determined after 72 and 120 h
of incubation. The results are summarized in Table 2.
4.6. Study of inhibition photosynthetic electron transport (PET) in spinach chloroplasts
Chloroplasts were prepared from spinach [Spinacia oleracea L.) according to Masarovicova and
Kralova [46]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was
determined spectrophotometrically (Genesys 6, Thermo Scientific, USA) using an artificial electron
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acceptor 2,6-dichlorophenol-indophenol (DCIPP) according to Kralova et al. [47] and the rate of
photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements
were carried out in phosphate buffer (0.02 mol/L, pH 7.2) containing suerose (0.4 mol/L), MgCb
(0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these experiments and
the samples were irradiated (~100 W/m^) from 10 cm distance with a halogen lamp (250 W) using
a 4 cm water filter to prevent warming of the samples (suspension temperature 22 °C). The studied
compounds were dissolved in DMSO due to their limited water solubility. The applied DMSO
concentration (up to 4%) did not affeet the photochemieal activity in spinach chloroplasts. The
inhibitor}' efficieney of the studied compounds was expressed by IC50 values, i.e., by molar
concentration of the compounds causing 50% decrease in the oxygen evolution rate relative to the
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-diehlorophenyl)-l,ldimethylurea, DCMU (Diurone®) was about 1.9 pmol/L [48]. The results are summarized in Table 2.
4.7. In vitro antimycobacterial evaluation
Clinical isolates of Mycobacterium avium complex CIT19/06, M kansasii CIT11/06, M. absessus
C1T21/06 and strain M. smegmatis MC2155 were grown in Middlebrook broth (MB), supplemented
with OADC supplement (Oleic, Albumin, Dextrose, Catalase, Becton Dickinson, U.K.). Identification
of these isolates was performed using biochemical and molecular protocols. At log phase growth, the
10 mL culture was centrifuged at 15,000 RPM for 20 minutes using a bench top centrifuge (Model CR
4-12 Jouan Inc U.K). Following the removal of the supernatant, the pellet was washed in fresh
Middlebrook 7H9GC broth and re-suspended in 10 ml of fresh supplemented MB. The turbidity was
adjusted to match McFarland standard No. 1 (3 x 10^ cfu) with MB broth. A further 1:20 dilution of
the culture was then performed in MB broth.
The antimicrobial susceptibility of all four mycobaeteria was investigated in 96 well plate format.
Here, 300 pL of sterile deionised water was added to all outer-perimeter wells of the plates to
minimize evaporation of the medium in the test wells during incubation. 100 pL of each dilution was
incubated with 100 pL of each of the mycobacterial species. Dilutions of each compound were
prepared in duplicate. For all synthesized compounds, final concentrations ranged from 300 pg/mL to
10 pg/mL. All compounds were prepared in DMSO and subsequent dilutions were made in
supplemented Middlebrook broth. The plates were sealed with parafilm and were incubated at 37 °C
overnight in the case of M. smegmatis and M. absessus and for 5 days in the case of M. kansasii and
M. avium complex. Following incubation, a 10% addition of alamarBlue (AbD Serotec) was mixed
into each well and readings at 570 nm and 600 nm were taken, initially for background subtraction and
subsequently after 24 hour re-incubation. The background subtraction is necessary with strongly
coloured compounds which may interfere with the interpretation of any colour change. In
non-interfering compounds, a blue colour in the well was interpreted as an absence of growth, and a
pink colour was scored as growth. The MIC was initially defined as the lowest concentration which
prevented a visual eolour change from blue to pink. The results are shown in Table 3.
The MIC for mycobacteria was defined as a 90% or greater (IC90) reduction of growth in
comparison with the control. The MIC/IC90 value is routinely and widely used in bacterial assays and
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is a standard detection limit according to the Clinical and Laboratory Standards Institute (CLSI,
w^ww.clsi.org/).
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